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1 Introduction
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1.1 General introduction
Approximately one person in five in the prosperous countries of the world dies of
cancer and besides heart disease, this disorder is the main cause of death in the Western
world.
In cancer, a mutation of a single healthy cell gives rise to selfish behavior of that cell.
This endangers the whole multicellular organism while in healthy organisms, all cells
collaborate and remain in their territories. When a mutated cell proliferates out of
control, it will give rise to a tumor (a neoplasm). As long as the neoplastic cells remain
clustered together and do not invade other tissue, the tumor is said to be benign
(harmless). A complete cure can be achieved by removing the tumor surgically or by
killing the tumor cells by irradiation. Neoplastic cells are said to be malignant if they
have the ability to invade other tissue. Additionally, malignant cells can break loose to
eventually enter the bloodstream to be transported to distant sites in the body and form
a secondary tumor. This process is called metastazation and makes the disease
especially hard to eradicate as the tumor cells remain no longer localized. A complete
cure can no longer be effected by local therapies such as surgery or irradiation and a
systemic therapy such as chemotherapy is required to treat patients with a malignant
tumor.
1.2 Cancer chemotherapy
During World War I, mustard gas (sulfur mustard,
chart 1.1) was used as an offensive weapon. Besides
the use in chemical warfare, it was recognized that
sulfur mustard had an effect on rapidly dividing
cells of the gastrointestinal tract and on the blood
forming organs. In the early literature [1] it is de-
scribed that sulfur mustard could stop the develop-
ment of chemically induced tumors in animals. After
these experiments, however, the question rose
whether this agent could eradicate the tumor before
death of the patient. In order to find more selective
anti-tumor agents, derivatives of sulfur mustard
were synthesized and evaluated for their anti-tumor
activity.  Nitrogen  mustard  (chart 1.1)  was the  first
S N
Me
N
sulfur mustard nitrogen mustard
aniline mustard
N
P
OO NH
cyclophosphamide
Cl Cl Cl Cl
ClClClCl
Chart 1.1   Mustard compounds.
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anti-cancer agent introduced into a clinical trial in 1942 [2].  Analogs  of this  compound
sharing the  same mechanism of action (alkylation of DNA) but differing in toxicity and
pharmacokinetics appeared soon thereafter (see chart 1.1). The discovery of the anti-
tumor activity of these alkylating agents resulted in research for other effective drugs in
cancer treatment which led to the development of a wide variety of anti-cancer agents.
These drugs are divided into classes based on their mechanism of action or on their
origin [3]. The most important classes are i. the aforementioned alkylating agents (chart
1.1); ii. the platinum based anti-cancer drugs (chart 1.2) making DNA intrastrand cross-
linkings (for example cisplatin and carboplatin); iii. the anti-metabolites (for example 5-
fluorouracil and methotrexate, chart 1.2), interfering with DNA synthesis; iv. the natural
products such as the vinca alkaloids vinblastine and vincristine and semisynthetic
derivatives of epipodophyllotoxins for example etoposide (chart 1.2) (all affecting
tubulin functions), and v. the anti-tumor antibiotics (for example mitomycin C chart 1.2
and the anthracyclines, chart 1.3). The more recently discovered drug taxol (chart 1.2)
and its semi-synthetic analogs are claimed to possess an unique mechanism of action
involving cell microtubules [4].
The anthracyclines
This thesis deals with prodrugs of anthracyclines, in view of this, more detailed
information concerning the anti-tumor activity of the most important anthracyclines is
given.
HN
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NH3
NH3
Cl
Cl
cisplatin
5-fluorouracil
O
O
O
O
O
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OMeMeO
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CO2H
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AcO
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BzOHO
O
O
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Chart 1.2   Anti-tumor compounds.
The anthracycline anti-tumor antibiotics [5] belong to the class of compounds with the
widest spectrum of activity in human cancers. The cytotoxic activity of these drugs is
ascribed to a number of parallel mechanisms of action. These include i. intercalation of
the anthracyclinone aglycon moiety between adjacent base pairs in the DNA double
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helix causing inhibition of DNA, RNA and protein synthesis; ii. stabilization of the
topoisomerase II-DNA complex resulting in DNA strand breaks; iii. modification of cell
membrane functions; iv. free radical mediated alkylation of DNA, and v. generation of
free radicals (e.g. superoxide O2-·) which cause DNA damage. The use of anthracyclines
is attended by serious toxic side-effects such as myelosupression, mucositis and
cumulative and irreversible cardiotoxicity.
2
3
4
1
5
12
6
11
7
8
9
10
O
OR1
HO
HO
13
O
14
OH
O
1'
O5'
4'
3' 2'
NH2HO
O
OOMe
HO
HO
O
OH
O
O
NH2
HO
OH
R2
daunorubicin: R1 = -OMe, R2 = -H
doxorubicin: R1 = -OMe, R2 = -OH
idarubicin: R1 = -H, R2 = -H
epirubicin
anthracyclinone
aglycon
daunosamine
sugar
Chart 1.3   Major anthracyclines.
The first discovered anthracyclines were isolated from various strains of streptomyces
and from these, doxorubicin (chart 1.3), discovered in the 1960s, is the most commonly
prescribed agent in the treatment of cancer [6]. Daunorubicin, discovered prior to
doxorubicin, is almost exclusively used to treat leukaemia because it enters cells very
readily. Apart from doxorubicin and daunorubicin two other derivatives (idarubicin
and 4'-epirubicin, see chart 1.3) are used worldwide although much less frequently than
doxorubicin. Idarubicin can be administered orally (all other anthracyclines are
administered intravenously) and is much more active than daunorubicin but it has not
replaced doxorubicin and daunorubicin because of its limited bioavailability after oral
administration. Epirubicin is more active against different tumors than daunorubicin
and doxorubicin and possesses a reduced cardiotoxicity. This compound is rapidly
metabolized as a glucuronide [7] and it is becoming used more in the clinic. Major side
effects of anthracyclines, however, are myelosuppression and a dose related cumulative
and irreversible cardiotoxicity [8] which limits the use of these drugs. An other problem
associated with the use of anthracyclines (and other anti-tumor drugs) is the
development of multidrug resistance (MDR). In MDR, upon treatment with a single
drug, cancer cells acquire resistance to more than one drug by the activation of a
cellular excretion system, the P-glycoprotein pump [9]. Resistant cells survive and
proliferate leading to a resistant cell clone. Because of the severe side effects of all
conventional anti-cancer agents, patients are treated multiple times with a limited dose.
This increases the incidence of the developing MDR. When a more selective agent
would be employed, a higher dose can be given which diminishes the chance of
development of MDR.
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Despite efforts of numerous research groups and the synthesis and evaluation of anti-
tumor activity of more than 2000 anthracycline analogs, a drug with a higher
therapeutic index than doxorubicin has not been developed and doxorubicin remains a
major cytostatic agent [10].
1.3 Selective chemotherapy
The insufficient selectivity of conventional cancer chemotherapeutic agents arises from
the lack of distinction between tumor and normal cells. Most of the available anti-tumor
drugs are specifically toxic to proliferating cells and therefore tumor cells are slightly
more sensitive to cytostatics compared with normal cells. Nevertheless therapeutic
indices of anti-cancer drugs are too low resulting in unacceptable damage to healthy
tissue upon chemo treatment.
A variety of approaches to improve the effectiveness and tumor cell selectivity of anti-
cancer agents is under development in an increasing number of research groups. In this
context the majority of the research teams utilize antibodies to direct cytotoxicity to
tumor tissue. To target cytotoxicity to neoplastic cells, tumor cell-specific antibodies are
equipped with for example i. drugs [11], ii. radioisotopes[ 12], iii. cytotoxins[ 13], iv.
liposomes carrying drugs[ 14], v. enzymes[ 15] or vi. genes expressing enzymes[ 16].
Because of the limited number of antigens present on a tumor cell surface it is often
impossible to deliver cytotoxic concentrations of a drug at the tumor site. Apart from
this, the number of drug molecules that can be bound to an antibody without loss of
antibody binding capacity is limited[17] , setting a maximum to the number of drug
molecules targeted to the tumor. Alternatively, only a limited dose of an antibody-
radioisotope conjugate can be given to a patient because of radiation of the conjugate to
normal tissue prior to localization. Because of this, only the most radiosensitive tumors
can be treated. In another strategy, when an enzyme which generates toxicity is
targeted to a tumor, a much larger effect can be expected because of the catalytic nature
of the system. Cytotoxicity generated by an enzyme targeted to a tumor was first
demonstrated in 1973[ 18]. In this study, glucose oxidase was covalently bound to an
antibody and generated H2O2 from glucose. Disappointingly, very little cytotoxicity
was obtained.
A more promising approach is to use a relatively non-toxic prodrug that is selectively
activated at the tumor site by a targeted enzyme. This approach was independently
introduced by the group of Bagshawe[ 19] in London and by the group of Senter[ 20] in
Seattle and is denoted as Antibody Directed Enzyme Prodrug Therapy, ADEPT. An
other approach of directing an enzyme to a tumor in order to activate a prodrug is
GDEPT[16] : Gene Directed Enzyme Prodrug Therapy. In this strategy a gene encoding
for an enzyme is targeted to cancer cells. This enzyme is chosen to convert a prodrug to
the parent drug. A difference of this method compared to ADEPT is that the enzyme
remains located inside the cell and an immune respons of the host is not expected.
Therefore, in contrast to ADEPT, a prodrug in GDEPT must be able to penetrate cells in
order to be activated by the matching enzyme which is expressed intracellularly.
Alternatively, when a retrovirus is used to deliver the gene encoding for an enzyme
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which is able to convert a prodrug to the parent drug, the concept is called Virus
Directed Enzyme Prodrug Therapy, VDEPT[ 21].
In this thesis the synthesis and evaluation of prodrugs of anthracyclines designed for
use in ADEPT is described. The ADEPT concept has been extensively reviewed in the
last few years[22] . Therefore only a concise summary of it will be given in this chapter,
especially focusing on the prodrugs used in ADEPT.
1.4 Antibody Directed Enzyme Prodrug Therapy (ADEPT)
1.4.1 General
The ADEPT[ 23] approach of treating cancer (see figure 1.1) builds on the discovery that
tumors have specific antigens on their cell surface. In this anti-cancer therapy a
monoclonal antibody (mAb) which is specific for tumor antigens, carries an enzyme to
the tumor site (step 1). After the mAb-enzyme conjugate has been localized at the tumor
site and non-tumor associated conjugate has cleared from plasma and other tissue, a
relatively non-toxic prodrug is administered which is converted to the parent cytotoxic
drug by the targeted enzyme (step 2).
Because of the catalytic nature of the ADEPT system, a higher local concentration of the
drug at the tumor site can be obtained compared to chemotherapy using a mAb-drug
conjugate. The lower toxicity of a prodrug used in ADEPT compared to the parent drug
itself allows administration of a higher dose of the prodrug compared to conventional
chemotherapy. Consequently, higher concentrations of the drug at the tumor site can be
achieved.
Although only a limited number of cancer cells express an antigen on their cell surface,
this is not expected to be critical for ADEPT. When the active drug is generated by the
mAb-enzyme conjugate bound to an antigen positive tumor cell, it can diffuse through
the tumor mass and enter a tumor cell which does not express the antigen. This is
referred to as the bystander effect[ 24], see figure 1.1. The main problems associated with
the ADEPT approach of treating cancer are: i. development of host antibodies against
the mAb-enzyme conjugate, ii. too slow clearance of the non-tumor-associated mAb-
enzyme conjugate from the circulation (a number of strategies has been developed to
accelerate clearance of the conjugate after tumor localization[ 25]) and iii. cross-reactivity
of mAb-enzyme with normal tissue as most tumor antigens are not exclusively tumor-
specific. A first clinical experience with an ADEPT system employing a nitrogen
mustard prodrug and a mAb-carboxypeptidase G2 conjugate was reported recently by
the group of Bagshawe[33c, d] (see section 1.4.3) and gave a strong impetus to the
development of the ADEPT approach of treating cancer.
A recent development in the field of ADEPT is the use of humanized catalytic
antibodies to activate a specific prodrug. The rationale behind this strategy is that such
a humanized catalytic antibody (also called abzyme) is highly specific for a certain
substrate and is non-immunogenic. This approach is called ADAPT: Antibody Directed
Abzyme Prodrug Therapy[ 26].
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step 1
step 2
mAb
enzyme
enzyme
tumor
cell
tumor
cell
tumor
cell
tumor
cell
enzyme tumor
cell
tumor
cell
prodrug
prodrug drug
antigen-
negative cell
antigen
mAb
mAb
Figure 1.1   The concept of ADEPT.
1.4.2 mAb-Enzyme conjugates in ADEPT
Enzyme
A number of prerequisites must be met for the enzyme in the mAb-enzyme conjugate to
be optimal for use in ADEPT. Among these are: i. optimal pH for enzyme action should
be close to that of tumor extracellular fluid, ii. preferably no requirement for a cofactor,
iii. low level of enzyme in plasma and iv. high specificity of the enzyme for the prodrug.
Most ADEPT systems described in the literature utilize an enzyme of non-human
origin. These enzymes were chosen because of the absence of a human homolog
resulting in minimal aselective prodrug activation. Therefore, non-human enzymes
enable a highly tumor-selectivity ADEPT system. A general disadvantage of the use of
such non-human enzymes is the development of host antibodies that restricts the use of
the mAb-enzyme conjugate. In the first clinical trial described in the literature [33] the
development of host antibodies was anticipated with the administration of an
immunosuppressive agent.
Alternatively, the use of an enzyme of human origin does not lead to immunogenicity
against the mAb-enzyme conjugate but can lead to aselective prodrug activation by
endogenous enzymes. This results in a higher toxicity of the ADEPT system for non-
target tissue.
Monoclonal antibody-enzyme conjugate
Important characteristics for a mAb-enzyme conjugate are: i. high specificity for a
tumor associated antigen, ii. no internalization into the tumor cell, iii. stability under
physiological conditions, iv. rapid clearance from the circulation and v. penetrability
into the tumor mass.
Most of the mAb-enzyme conjugates used in ADEPT have been prepared by a
conventional coupling reaction of mAb and enzyme. Alternatively, using DNA
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recombinant technology, a DNA fragment encoding for both the mAb and enzyme can
be prepared and transcription of this fragment results in a fusion protein possessing
both the mAb binding potency and the enzyme activity. Bosslet et al. have referred to
the use of a fusion protein in ADEPT as FMPA; Fusion protein Mediated Prodrug
Activation[ 27] This technique facilitates the preparation of a mAb-enzyme conjugate to
some extent which is required for extensive clinical trials of ADEPT.
1.4.3 Prodrugs in ADEPT
A prodrug in ADEPT must fulfil a number of conditions to be applicable. Important
characteristics for a prodrug are: i. reduced toxicity compared to the parent drug, ii.
stability in serum, iii. efficient enzymatic activation only by the targeted enzymes, and
iv. low cellular uptake. In the literature, a large number of prodrugs designed for use in
ADEPT are described. The major obstacles, however, for the use of most of the
prodrugs in ADEPT are: i. too slow activation rate by the matching enzyme[ 28], ii.
premature prodrug activation by endogenous enzymes[ 29] and iii. too high toxicity of
the prodrug[ 30].
Initially, prodrugs were reported which were constructed according to alternative A in
scheme 1.1. According to this design, a substrate group for a given enzyme is coupled
directly to a cytotoxic drug. Upon contact of the prodrug with the matching enzyme,
the drug is generated. The group which is a substrate for the enzyme is referred to as
the specifier group. A problem encountered in this type of prodrug is a too slow
enzymatic activation rate. In most cases, this was attributed to steric hindrance of the
prodrug on the enzymatic scission reaction.
SPACER
DRUG
SPECIFIER
enzyme
SPACER
DRUG
spontaneous
DRUG
pro-
moiety
SPECIFIER
enzymeDRUG
DRUGA
B
Scheme 1.1   Prodrugs with and without spacer group.
A possible way to improve the rate of activation of a prodrug is the incorporation of a
self-eliminating (immolative) spacer moiety between the drug and the specifier group.
In this design (alternative B, scheme 1.1), after enzymatic hydrolysis of the specifier
group, elimination of the spacer from the spacer-drug molecule is promoted and the
free drug is generated. The spacer plus connected specifier is referred to as the pro-
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moiety. The use of such a three-component prodrug system enables optimization of
enzymatic activation characteristics merely by structural variation of the spacer.
Examples of spacer-containing prodrugs are given in scheme 1.3.
The first example of an ADEPT system was described by Bagshawe and co-workers in
1987[ 31]. In this system a mAb-carboxypeptidase G2 conjugate was used to activate
prodrug 1 (chart 1.4) releasing a nitrogen mustard drug and glutamic acid. Originally,
the mAb-enzyme conjugate was intended to be used without prodrug because it was
believed to kill cancer cells via folate deprivation[ 32].The combination of prodrug 1 and
the mAb-carboxypeptidase G2 conjugate is the first ADEPT system that advanced into
human clinical trials[33] . The group of Bagshawe and Springer has devoted a great deal
of research to the application[ 34] and optimization[ 35] of prodrug 1 in ADEPT. A major
limitation of this anti-cancer therapy, however, is the development of antibodies against
the bacterial carboxypeptidase G2 enzyme so that immunosuppression using
cyclosporin was necessary.
N
O
N
H
CO2H
CO2H
mAb-carboxypeptidase G2
1
2
O
O
O
O
O
OO
O
O
OMeMeO
HO
HO
P
O
ONaNaO
mAb-alkaline
phosphatase
MeO2SO
Cl
Chart 1.4   Early ADEPT prodrugs.
Other early reports[ 36] by Senter and co-workers at Bristol-Myers Squibb on an ADEPT
system describe the use of a mAb-alkaline phosphatase (AP) conjugate. In this system,
initially etoposide phosphate 2[ 37] (chart 1.4) was used as a prodrug. Other phosphates
of anti-cancer drugs studied as prodrug in combination with a mAb-AP conjugate
include mitomycin C[ 38], hydroxyaniline mustard[ 39], daunorubicin[ 40], doxo-
rubicin[36c] and taxol (with [ 41] and without[ 42] spacer). A serious restriction of the use
of AP activated prodrugs, however, is the abundance of phosphatase enzymes in
human serum and tissue, resulting in non-specific prodrug activation.
Because comprehensive reviews treating prodrugs which are developed in the context
of the ADEPT concept have emerged in the literature[22] (especially refs. 22b and 22g),
only some representative examples of prodrug/mAb-enzyme system will be given in
this section.
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b -Lactamase activated prodrugs
b -Lactamase enzymes are a defence mechanism of bacteria against b -lactam antibiotics.
These enzymes are readily available and highly selective, and have no human homolog.
To prepare b -lactamase activated prodrugs, a wide variety of anti-cancer agents have
been coupled to the cephalosporin group and are activated according to scheme 1.2.
X = 
R = 
S
Ph
N
X
HO2C
N
H
DRUG
CO2H
O
R
mAb-b -Lactamase
S S
O
+
-
+
N
XN
H
CO2H
O
R
O
DRUG
Scheme 1.2   Prodrugs activated by b -lactamase.
Drugs used in this context include methotrexate[ 43], 5-fluorouracil[43], vinblastine
analogs[ 44], doxorubicin[ 45], taxol (with spacer)[ 46], nitrogen mustard drugs[ 47],
mitomycin C[ 48] and carboplatin analogs[49]  (for the structures of these drugs, see
section 1.2).
Penicillin V and G Amidase
Penicillin V amidase is a bacterial enzyme selective for p-hydroxyphenoxy acetyl
containing substrates whereas penicillin G amidase hydrolyses phenylacetamides (chart
1.5). Penicillin V amidase activated prodrugs[ 50] were prepared from doxorubicin and
melphalan (a nitrogen mustard derivative). Penicillin G amidase activated prodrugs[ 51]
were prepared from doxorubicin, melphalan and palytoxin[ 52] (one of the most potent
cytotoxins known).
DRUG-NH
O
O
O H
DRUG-NH
O
penicillin V amidase penicillin G amidase
Chart 1.5   Penicillin amidase based prodrugs.
Other enzymes frequently used in the context of ADEPT include i. nitroreductase, ii.
carboxypeptidase A and B, and iii. cytosine deaminase.
Glycosidases
b -Glucuronidase and a -galactosidase are human intracellular enzymes present in the
circulation in only minor concentrations. These enzymes were chosen for the use in
ADEPT because their low immunogeneticity and because b -glucuronide and a -
galactoside derivatives of drugs are much more polar than the drug molecule
themselves. Because of this property such glycosyl based prodrugs can hardly enter
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cells and hence will have a reduced cytotoxicity. In a recent paper the role of human
b -glucuronidase in drug targeting has been reviewed[ 53] A variety of b -glucuronide
containing prodrugs have been prepared from drugs. These include p-hydroxyaniline
mustard (with [54] and without[ 55] spacer) and epirubicin[ 56]. Spaced[ 57] and non-
spaced[ 58] b -glucuronide and a -galactoside based prodrugs have been prepared from
both daunorubicin and doxorubicin. In the literature, these anthracycline prodrugs
have been extensively evaluated[ 59] for their application in ADEPT.
Observations made by Connors et al. already in 1966[ 60] pointed out that certain tumor
cells contain high levels of b -glucuronidase. In a more recent paper of Bosslet et al.[ 61] it
has been demonstrated that b -glucuronidase is liberated especially from necrotic tumor
areas. It was suggested in both articles that this endogenous b -glucuronidase can
activate a b -glucuronide containing prodrug. This approach is referred to as mono-
therapy. For a more detailed background, see section 6.4.3.
Spacer containing prodrugs
Me
Me
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Me
Me
O OH
O
AcO
H
BzOHO
O
O
AcO
BzNH
Ph
O
alkaline 
phosphatase
Me
Me
O
Me
Me
O OH
O
AcO
H
BzOHO
O
O
AcO
BzNH
Ph
O
OH
TAXOL MeMe
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O
+
O
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OOMe
HO
HO
O
OH
O
O
NH
OO
HO
HO
NaO 2C
HO
HO
O
O
O
OOMe
HO
HO
O
OH
O
O
NH
OH
HO
:
b -glucuronidase
OH
OH
NO 2
NO 2
DOXORUBICIN
+
CO 2+
3
4
PO32-O
. .
Scheme 1.3   Spacer containing prodrugs.
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As was mentioned earlier, a possible way to improve the rate of activation of a prodrug
is the incorporation of an immolative spacer group between the drug and the specifier
group (see alternative B, scheme 1.1). After enzymatic hydrolysis of the specifier group,
elimination of the spacer from the spacer-drug molecule is promoted and the free drug
is generated. To date, most prodrugs designed for use in ADEPT contain a spacer
moiety between specifier and drug to facilitate activation. Examples are given in
scheme 1.3. The majority of spacer types used for prodrug preparation eliminate by i.
intramolecular cyclization (e.g. taxol prodrug 3 [41]) or ii. 1,6-elimination (e.g.
doxorubicin prodrug 4[59]).
1.5 Aim of research and outline of this thesis
Upto now a number of ADEPT systems has been developed and described in the
literature which all had some drawbacks. Among these are immunogenicity of the
mAb-enzyme conjugate, a low prodrug activation rate and a too high prodrug toxicity.
The aim of the research presented in this thesis is the design and chemical synthesis of
prodrugs of anthracycline anti-tumor agents which are optimal for use in the ADEPT
approach of treating cancer.
In chapter 1, the background of cancer chemotherapy is described and a concise
overview of selective chemotherapy according to the Antibody Directed Enzyme
Prodrug Therapy (ADEPT) approach is given.
Chapter 2 describes preliminary research with the objective to select the most
advantageous ADEPT system. Prodrugs of daunorubicin were prepared containing a
phosphate, sulfate, b -glucuronide, b -glucoside or b -galactoside specifier group. From
these the b -glucuronide containing prodrug/human b -glucuronidase combination was
found the most promising system for use in ADEPT.
In chapter 3, b -glucuronide-based prodrugs of daunorubicin containing a spacer group
between drug and b -glucuronyl carbamate specifier in order to facilitate prodrug
activation are outlined. The spacer group in these prodrugs was designed to eliminate
by an intramolecular cyclization reaction after hydrolysis of the b -glucuronyl group by
b -glucuronidase.
In chapter 4, b -glucuronide-based prodrugs of anthracyclines containing a spacer
designed to eliminate by an 1,6-elimination process are discribed. The spacer group of
these prodrugs was substituted with a chlorine, bromine or alkyl group in order to
affect prodrug pharmacokinetics. In the final sections of chapters 3 and 4, an evaluation
of the synthesized prodrugs for use in ADEPT is presented.
In chapter 5, new synthetic methods for the stereoselective preparation of b -glucuronyl
carbamates is described. These tools were developed for the synthesis of b -glucuronyl
carbamate containing prodrugs.
In Chapter 6, an overview is given of the results obtained in both ADEPT and
monotherapy experiments using the most promising prodrug which was developed in
the course of the research described in this thesis.
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2 The Selection of a PolarSpecifier / Enzyme CombinationFor Use in ADEPT [1]
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2.1 Introduction
Ideal prodrugs are pharmacologically inactive substances which are transformed into
active drugs exclusively on the location were they actually exert their effect. This
implies that the prodrug should not be activated by the same or other mechanisms at
distant sites, leading to undesired side-effects. An additional prerequisite for making
the use of a prodrug advantageous in comparison with the the parent drug, is an easy
clearance from the bloodstream of a patient so that non-specific chemical or enzymatic
prodrug activation is minimized. The inactivation of a cytotoxic drug exerting its action
within the cell can be achieved by coupling it to a polar moiety, resulting in a poor cell-
membrane penetration of the thus obtained polar drug derivative. As a consequence the
derivative will exhibit a reduced cytotoxicity. Moreover, when the polar group is
attached to the drug via a functional group which is important for the antitumor
activity, the cytotoxicity of the prodrug will be reduced further. Activation of these
relatively non-toxic prodrugs at the tumor site can be effected by targeted enzymes
according to the ADEPT principle (Antibody Directed Prodrug Therapy, see Ch. 1).
A priori the enzyme of choice for an ADEPT system is of human origin to prevent the
development of host antibodies to the monoclonal antibody-enzyme (mAb-enzyme)
conjugate. Furthermore, plasma levels of the candidate enzyme must be low precluding
non-specific prodrug activation. From the prodrug characteristics described in the
literature and reviewed in chapter 1, rates of enzyme-mediated activation of a prodrug
into a drug as well as prodrug toxicities are critical parameters for an effective
application of ADEPT to cancer treatment. To enable the selection of the most
promising ADEPT-system, polar prodrugs from daunorubicin, employing phosphate-,
sulfate-, glucuronide-, glucoside- and galactoside-specifiers were synthesized and
subjected to a series of cytotoxicity- and enzyme hydrolysis assays. Hydrolysis rates
were studied using alkaline phosphatase, aryl sulfatase, b -glucuronidase and b -
galactosidase [44].
2.2 Target compounds
2.2.1 Phosphates and sulfates
Early ADEPT systems described in the literature involved drug-phosphates that were
cleaved by mAb-alkaline phosphatase conjugates (mAb-AP). The first phosphorylated
drug was etoposide phosphate 1 [2, 3] (chart 2.1). Others include phenol mustard
phosphate 2 [4] and doxorubicin phosphate 3 [5]. Etoposide phosphate was much less
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toxic compared to etoposide and was readily converted by mAb-AP. Significant levels
of antitumor activity have been obtained in vitro and in vivo using 1 in combination with
a mAb-AP and this provided the first evidence that the combination of a prodrug
derived from a clinically approved anticancer drug and a mAb-enzyme conjugate is
able to kill antigen-positive tumor cells in vivo. Phosphorylated mustard drug 2
displayed similar effects, whereas no further evaluation of doxorubicin phosphate 3
was published, except its rapid conversion into free doxorubicin. A disadvantage of
using phosphorylated prodrugs is premature prodrug activation by endogenous
phosphatases ubiquitous in biological systems. In 1994 [6], the NDA filed etoposide
phosphate 1 which is a water-soluble clinically active prodrug of etoposide. This
phosphate 1 is activated by phosphatases present in serum without pretreating a
patient with a mAb-AP. Using 1 instead of etoposide, no enhanced tumor-selectivity
was found but solubility problems were solved. To study the enzymatic activation of
daunorubicin phosphates as a function of the position of the phosphate group,
daunorubicin-phosphates DAU-P1 and DAU-P2 (Chart 2.2) were designed and
prepared.
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Chart 2.1   Drug-phosphates described in the literature.
Sulfatation is a well-known detoxification mechanism in many organisms, thus,
anticancer drug-sulfates are conceivable candidates for prodrugs in ADEPT. The
exclusive example in this context, described in the literature, is etoposide sulfate (sulfate
analog of 1). This compound could not be hydrolyzed by a variety of arylsulfatases
until a Japanese group reported the isolation of an arylsulfatase from soil samples
which was indeed capable of hydrolyzing etoposide sulfate [7]. apparently, no further
research has been devoted to etoposide sulfate as a prodrug in ADEPT. In this study,
daunorubicin sulfates DAU-S1 and DAU-S2 (chart 2.2) were synthesized to investigate
their potential in selective chemotherapy when used in combination with mAb-aryl
sulfatase conjugates.
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Chart 2.2   Target compounds; daunorubicin phosphates and sulfates.
2.2.2 b -D-Glucuronides, b -D-glucosides and b -D-galactosides
b -Glucuronidase, b -glucosidase and b -galactosidase are human intracellular enzymes
present in the circulation in only minor concentrations [8]. As for sulfates,
b -D-glucuronides are formed in the body in the context of a detoxification process and
therefore a drug- b -D-glucuronide seems a likely candidate to function as a prodrug in
ADEPT. In the literature the synthesis and use in ADEPT of several drug- b -
D-glucuronides have been described. Among these are the prodrugs of anthracyclines
epirubicin 4'-O-b -D-glucuronide 4 [9] (chart 2.3) and doxorubicin 14-O-b -D-glucuronide
5 [10]. At clinically achievable concentrations of both enzyme and prodrug at pH = 6.8,
both epirubicin glucuronide 4 and doxorubicin glucuronide 5 are activated very slowly
by human b -glucuronidase [11].
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Chart 2.3   b -D-Glucuronide containing prodrugs.
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Preliminary studies showed that O- b -D-glucuronyl carbamates 7 (chart 2.4) are fairly
good substrates for b -glucuronidase. Enzymatic hydrolysis of O-b -D-glucuronyl
carbamates has not emerged in the literature. It was found that model compound 8
(chart 2.4) is readily hydrolyzed by b -glucuronidase to give the unstable N-phenyl
carbamic acid (9) which instantaneously decomposes to CO2 and aniline. The
hydrolysis rate of 8 is comparable to that of 4-nitrophenyl-O-b -D-glucuronide (6, R = -p-
nitrophenol) which is a very good substrate for b -glucuronidase.
From this comparison it appears that O- b -D-glucuronyl carbamates 7 are better substrates for
b -glucuronidase than alkyl- and aryl-O-b -D-glucuronides 6. In this perspective, it is conceivable
that a b -D-glucuronyl carbamate group can be used as a specifier in prodrugs of anthracyclines
when coupled to the 3'-amino group of the anthracycline.
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Chart 2.4   Hydrolysis of O-b -D-glucuronyl carbamates.
The prodrugs that are designed on this basis are presented in chart 2.5. The polar
glucuronyl group is attached to the drug via the 3'-amino group which is important for
the anthracycline antitumor activity and accordingly the cytotoxicity of the prodrug
will be minimized. In addition to N-3'-daunorubicinyl O-b -D-glucuronyl carbamate
DAU-GA1, the corresponding -O-b -D-glucosyl and -O- b -D-galactosyl analogs DAU-
GsA1 and DAU-GlA1, respectively, were designed and synthesized and their
application in ADEPT was investigated. These novel glycosylated prodrugs are
designed to be activated as indicated in chart 2.5. All glycosylated prodrugs in this
thesis are named using the nomenclature system shown in chart 2.5.
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Chart 2.5   Target compounds; N-3'-daunorubicinyl O- b -glycosyl carbamates and activation pathway to free drug.
2.3 Synthesis of daunorubicin-N-phosphate and -sulfate
The synthesis of daunorubicin-N-phosphate and -N-sulfate was readily accomplished.
Making use of the much larger nucleophilicity of the 3'-amino group of daunorubicin,
protection of the hydroxyl group in the molecule was not necessary. Daunorubicin-N-
phosphate DAU-P1 (scheme 2.1) was obtained in 40% overall yield after reaction of
daunorubicin hydrochloride DAU-HCl with the bis-[2-(methylsulfonyl)ethyl]-protected
(MSE) phosphochloridate 1 0  [12], immediately followed by deprotection of the
20 Chapter 2
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
phosphate group of product 11 and purification on a reversed phase C18- column. The
cyclic phosphate 12 was isolated as a major side product from the phosphorylation
reaction.
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Scheme 2.1   Synthesis of daunorubicin-N-phosphate.
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Scheme 2.2   Synthesis of daunorubicin-N-sulfate.
Daunorubicin-N-sulfate DAU-S1 was readily obtained in 71% yield by refluxing
daunorubicin-HCl with sulfur trioxide-triethylamine complex in chloroform [13],
followed by conversion of the resulting triethyl ammonium salt into the sodium salt
using sodium bicarbonate (scheme 2.2). The phosphamide DAU-P1 and sulfamide
DAU-S1 are highly soluble in water and displayed no detectable decomposition in
aqueous solution.
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2.4 Synthesis of daunorubicin-4'-O-phosphate and -sulfate
For the preparation of daunorubicin-4'-O-phosphate and -sulfate, the 3'-amino group
needs to be protected. Leaving the amino group unprotected during phosphorylation
and sulfatation, led to DAU-P1 and DAU-S1, respectively (section 2.3). Traditionally,
the  trifluoroacetyl  (TFA)  group  is  used  in  anthracycline  chemistry  to protect the 3'-
amino group [14]. The TFA group was used in the
synthesis of DAU-P2 but removal of the TFA group
from phosphate 13 without hydrolysis of the 4'-O-
phosphate group was impossible. Therefore, a new
protective group strategy is required for the synthesis of
the DAU-P2 and DAU-S2. It was suggested that using
the -C(O)OMSE moiety to protect the 3'-amino group
[15], along with the bis-MSE protected phosphorylating
agent 10 (scheme 2.1), simultaneous deprotection of both
the amino- and phosphate-groups is possible. When
applied to the synthesis of D A U - P 2, protection
of the 3'-amino group employing O-MSE N-succinimidyl
O
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H O
H O
O
O H
O
O
N HO
P
O-O
NaO
13
O
CF3
carbonate 14 [15] prior to phosphorylation of daunorubicin at the 4'-hydroxyl  position,
resulted in N-3'-daunorubicinyl O-MSE-carbamate 15 (scheme 2.3). This protected
intermediate 15, however, appeared to be inert to phosphorylation at the 4'-hydroxyl
group using phosphorochloridate 10.
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Scheme 2.3   Synthesis of daunorubicin-4'-O-phosphate.
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However, phosphitylation employing phosphoroamidite 16 [16] in situ followed by m-
CPBA mediated oxidation of the phosphorus atom, yielded the desired tris-MSE-
protected intermediate 17. Simultaneous removal of all three MSE groups afforded
daunorubicin-4'-O-phosphate DAU-P2 in 74% overall yield. Because of the extremely
fast (<1 min) b -eliminative deprotection process [17], no alkaline hydrolysis of the
phosphate ester takes place.
Daunorubicin-4'-O-sulfate DAU-S2 was prepared analogously in an overall yield of
51% by sulfatation of the 4'-hydroxyl group of 15 with sulfur trioxide-pyridine complex
[18] followed by deprotection of the 3'-amino group of sulfate 18 (scheme 2.4).
Daunorubicin phosphate DAU-P2 was appreciably soluble in water, whereas the
sulfate DAU-S2 dissolved moderately in water and partly precipitated on standing.
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Scheme 2.4   Synthesis of daunorubicin-4'-O-sulfate.
2.5 Synthesis of N-3'-daunorubicinyl O- b -D-glycosyl 
carbamates
2.5.1 Introduction on O- b -D-glycosyl carbamates
In the proceeding sections of this chapter and in the following chapters, mainly
O-b -D-glucuronyl carbamates and to a minor extent, O-b -D-glucosides and O-b -D-galac-
tosides will be encountered (chart 2.6). Glucuronides are glucosides, oxidized at the
C(6)-OH position and galactosides differ from glucosides in the stereochemistry at C(4).
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Chart 2.6   Carbohydrates in this thesis.
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In the last decade, numerous sugar coupling procedures for the synthesis of glycosides
20 have been published. In scheme 2.5, which only represents the b -D-glucose- and
b -D-galactose- series,
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Scheme 2.5   Sugar coupling reactions.
these coupling reactions are exemplified by the classical Koenigs-Knorr methodology
[19] (route A) and by the acetimidate coupling method (route B) more recently
developed by Schmidt and co-workers [20]. Several other methods have been described
whereby the glycosyl donor is activated prior to reaction with an aglycon alcohol 19
(depicted in general route C). For the synthesis of O- b -glycosyl carbamates 22, all these
methods cannot be applied because the required carbamic acids 21 are insufficiently
stable compounds. Methods for preparing O-b -D-glycosyl carbamates are very scarce in
the literature [21]. New ways for obtaining O-b -D-glycosyl carbamates are shown in
route D and E (scheme 2.6). In a two step procedure (route D), the 1-hydroxyl group of
a 2,3,4,6-tetra-protected D-glycosyl donor 23 is first activated as an active carbonate 25
by reaction with chloroformate 24. In step 2, the active carbonate 25 is condensed with
an amine to afford carbamates 22. The a/ b  selectivity of the reaction of anomerically
unprotected sugar 23 with 24 is governed by the anomeric effect favoring the formation
of the a -isomer. The diastereomeric product mixture of 22-a/b  is then separated and the
desired b -anomer can be obtained as a minor product, if at all.
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Scheme 2.6   Synthesis of O-b -D-glycosyl carbamates.
The synthesis of O- b -D-glycosyl carbamates by the addition of the 1-hydroxy group of a
D-glycosyl donor to an isocyanate (route E), however, is preferred because of its
superior b -diastereoselectivity. This isocyanate addition reaction generally leads to very
high, and in some cases to exclusive b -diastereoselectivities. Solvent and catalyst are of
profound influence on both the yield and the diastereoselectivity of the reaction. This
has been outlined in detail in section 5.1 [22].
Limitations following route E are imposed by substituents in isocyanate 26 because
active hydrogen functional groups in -R need to be protected to avoid reaction with the
isocyanate group.
2.5.2 Synthesis of N-3'-daunorubicinyl O-b -D-glucuronyl carbamate DAU-GA1
For the synthesis of glucuronides [23] of anthracyclines, an appropriately 2,3,4,6-tetra-
protected D-glucuronic acid possessing a free 1-hydroxyl group is required. In the
literature, methyl 2,3,4-tri-O-acetyl D-glucuronate 27 and benzyl 2,3,4-tri-O-benzyl
D-glucuronate 28 are almost exclusively used for D-glucuronic acid conjugation
reactions (scheme 2.7). The allyl-type protected and 2,2,2-trichloroethyl-type protected
D-glucuronic acids 29 [24] and 30 [25], respectively, have to be synthesized in nine-step
procedures each and therefore, the easier accessible D-glucuronyl donors 27 and 28 are
preferred. Compound 27 is readily synthesized from D-(+)-glucurono-3,6-lactone 31 [26]
using literature methods [27] for selective hydrolysis of the 1-OAc group while
additional acetate groups are retained. It was found that the ammonium carbonate
mediated 1-OAc hydrolysis [28] is superior to other methods. Compound 28 is obtained
from D-(+)-glucose (32) from which the C(6) is oxidized to the carboxylic acid according
to literature procedures [29].
Selection of ADEPT System 25
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
AllO2C
O
O
O
O
O H
BnO2C
BnO
BnO
BnO
O
O H
MeO2C
AcO
AcO
AcO
O
O H
O
AllO
O
AllO
O
OAll
O2C
O
O
O
O
O H
O
O
O
O
O
O
CCl3
Cl3C
Cl3C
Cl3C
27 28 29 30
MeO2C
AcO
AcO
AcO
O
OAc
MeO2C
H O
H O
H O
O
O H
O
O
O
O H
O HH O
BnO2C
BnO
BnO
BnO
O
OAll
BnO
BnO
BnO
O
OAll
H O
H O
H O
H O
O
OAll
TrtO
H O
H O
H O
O
O H
H O
i
ii
iii
iv, v
vi, vii
viii, ix
x
MeONa, MeOH
Ac2O, pyridine(NH4)2CO3, DMF
AllOH, HCl
TrtCl, pyridine
BnBr, NaH, Bu4NI, DMF, 65 ° C
HCl, acetone
CrO3, H2SO4, acetone
BnOH, DCC, DMAP, MeCN
Pd(PPh3)4, morpholine, THF
31 32
i:
ii:
iii:
iv:
v:
vi:
vii:
viii:
ix:
x:
Scheme 2.7   Synthesis of 2,3,4,6-tetra protected D-glucuronates.
Benzyl 2,3,4-tri-O-benzyl D-glucuronate (28 , scheme 2.7) was initially used as a
D-glucuronyl donor in the synthesis of DAU-GA1. Route D (scheme 2.6) was preferred
over route E because transformation of the 3'-amino group of daunorubicin to an
isocyanate would require protection of the 4'-, 6-, 9- and 11-hydroxyl groups present
elsewhere in the molecule. Therefore, 28 was transformed to an active carbonate using
N-succinimidyl chloroformate 33 [30] which then was further transformed to the tetra-
benzyl protected target molecule 35 (scheme 2.8). The diastereoselectivity of the
chloroformate addition reaction and the subsequent reaction of the thus obtained active
carbonate with daunorubicin is in favor of the a -anomer in accordance with the
anomeric effect and resulted in 35 a/b   = 7/2. This is similar to the a/b  ratio of reactions
of 28 with acid chlorides as described by Keglevic and coworkers [31]. The anomeric
hydroxyl group of 28 is predominantly in the a -configuration as confirmed by proton
NMR; the exact a/ b  balance could not be ascertained because of overlap of signals of
other protons with the 1-H doublet of 28 b . 1-H of 28 a  showed a clear doublet with an
integral of almost one proton at d = 5.19 ppm (J = 3.4 Hz) [32]. This observation is
opposed to the suggested b -configuration of this compound made by Pravdic and
Keglevic in 1965 [29a] deduced from optical rotation data.
The 35 a / b   anomeric pair was separated by circular chromatography and attempts to
hydrogenolyze the four benzyl protective groups of the pure b -anomer were
undertaken. All attempts to deprotect 35 intended to obtain DAU-GA1 failed, including
classical hydrogenolysis using palladium on charcoal, palladium on Ba2SO4, catalytic
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transfer hydrogenation using cyclohexene [33] and Pd/C, 1,4-cyclohexadiene [34] and
Pd/C, and cyclohexene and Pd(OH)2/C [35]. In all cases scission of the benzylic ether on
C(7) occurred and when a prolonged reaction time was used, reduction of the
benzoquinone moiety was observed as well. It is clear that benzyl protection is not
compatible with anthracycline chemistry.
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Scheme 2.8   First attempt to synthesize DAU-GA1.
Next methyl 2,3,4-tri-O -
acetyl D-glucuronate 27 was
prepared and used as a
D-glucuronyl donor. Analo-
gously to the all-benzyl pro-
tected D-glucuronate 28,
compound 27 was activated
using 33 and the resulting
mixed carbonate 37  was
reacted with daunorubicin to
furnish 38 (scheme 2.9). Very
small amounts of the b -
anomer were detected. The
almost exclusive a -diastereo-
selectivity of the reaction
was found to be independent
of the solvent used for the
reaction.   In  solution,  hemi-
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Scheme 2.9   Second attempt to synthesize DAU-GA1.
acetal 27 is an equilibrium between the a -and b -form of the free anomeric hydroxyl
group via the open aldehyde 27(open) as depicted in scheme 2.10. For 27, the a/b  ratio in
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different solvents is about 5/1, as was determined by proton NMR (see table 5.4 in
section 5.1). This is explained by the anomeric effect stating that an electronegative
substituent at C(1) of a tetrahydropyranyl ring is preferred in the axial position [36].
When a tertiary amine base was added to a solution of 27 the equilibrium shifted almost
completely to the a -anomer, as was determined by proton NMR. On this basis it is
understandable that the reaction of 27 with chloroformate 33 catalyzed by pyridine is
almost exclusively a -diastereoselective. When the reactions of D-glucuronyl donors 27
and 28 with chloroformate 33 are compared ( a / b  = 7/2 and 99/1, respectively), 27
results in higher a -selectivities than 28. This can be attributed to an enhanced anomeric
effect in 27, caused by the presence of the electron-withdrawing acetyl protection
groups, in comparison with the more neutral benzyl ether groups in 28.
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Scheme 2.10   Mutarotation.
It was argued that the desired b -product could be obtained when 27 (a /b  = 5/1, scheme
2.9) is transformed into the b -OH anomer. A subsequent reaction of the b -anomer of 27
with chloroformate 33 would lead to the b -anomer of 37 (scheme 2.9). A reaction with
daunorubicin will then lead to the desired b -product. In this context it is relevant to
note that in steroid chemistry it is known that N,N-diethyl trimethylsilyl amine (39b,
table 2.1) is able to silylate equatorial hydroxyl groups selectively in the presence of
axial hydroxyl functions [37]. Analogously to this, it was reasoned that from the
equilibrium of 27 a/ b , only the equatorial 1-b -OH group will be silylated. Once the
silylated b -anomer is formed, it can be hydrolyzed and the resulting 1-b -OH anomer
should be converted to the desired b -product in a rapid reaction to minimize anomeri-
zation of the 1-b -OH anomer to the 1- a -OH anomer.
NSi NSi O
MeO2C
AcO
AcO
AcO
O
OH27
reaction
condition
MeO2C
AcO
AcO
AcO
O
O Si
39a-c
40
ClSi
imidazole
+
39a
39b 39c
reaction a /b -ratio of 40 using silylating reagent
conditions 39a 39b 39c
CHCl3, 20ºC 99/1 53/47 13/87
THF, 20ºC 99/1 10/90 15/85
CHCl3, 0ºC 9/91
THF, 0ºC 1/99
Table 2.1   a / b -Ratio of the silylation reaction of 27 with 39a-c to 40.
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To find optimal conditions for the formation of O- b -trimethylsilyl D-glucuronic acid 40
(see scheme of table 2.1), silylating agents 39a-c were investigated under a number of
different reaction conditions (table 2.1) [38]. Using the least reactive reagent N,N-diethyl
trimethylsilyl amine (39b) in THF at 0ºC, highest b -diastereoselectivities were obtained.
In the mid sixties it was already observed that the 1- b -OH anomer of 27 is more
nucleophilic than the 1- a -OH isomer [39]. Thus, by taking into account the Curtin-
Hammett principle, D-glucuronic acid 40 was silylated almost exclusively in the
b -anomeric form, despite the preponderance of the 1-a -OH of 27 in solution.
Following this strategy, O- b -trimethylsilyl D-glucuronate 40 [40] was converted into the
active carbonate 37b   with zinc chloride [41] and chloroformate 33 (scheme 2.11).
Subsequent coupling of 37 b  to daunorubicin yielded the protected prodrug 38 b   in 90%
b -diastereoselectivity and 38% overall yield. Simultaneous removal of all four protective
groups of the D-glucuronide moiety in 38b   was conveniently achieved in 93% yield in a
one step procedure with LiOH in MeOH/H2O at 0ºC furnishing DAU-GA1.
MeO2CAcO
AcO
AcO
O
OH
N O
O
O
O
Cl
MeO2CAcO
AcO
AcO
O
O
O O
O
O N
27
33
a/b  = 5/1
N Si
THF, 0 ° C
MeO2C
AcO
AcO
AcO
O
O Si
ZnCl2, MeCN
O
OOMe
HO
HO
O
OH
O
O
NHHO
OO
OHOHO
NaO2C
HO
O
OOMe
HO
HO
O
OH
O
O
NHHO
OO
OAcOAcO
MeO2C
AcO
 DMF, i-Pr2NEt
1)
 LiOH
2)
 cation exchange
3) NaHCO3, H2O
MeOH/H2O, 0° C
DAU-GA1
a/b  = 1/99
39
40
37b
38b
DAU-HCl
Scheme 2.11   Synthesis of DAU-GA1.
2.5.3 Synthesis of N-3'-daunorubicinyl O-b -D-glucosyl and O- b -D-galactosyl 
carbamates DAU-GsA1 and -GlA1, respectively
For the synthesis of the D-glucose- and D-galactose- analogs of DAU-GA1, 2,3,4,6-tetra-
O-acetyl protected D-glucose [42] and D -galactose [43] were used because the acetyl
Selection of ADEPT System 29
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
groups proved to be easily removable without affecting the daunorubicin part of the
molecule, see section 2.5.2. N-3'-Daunorubicinyl O- b -D-glucosyl carbamate DAU-GsA1
(scheme 2.12) was conveniently prepared in 60% overall yield by reaction of the
anomerically pure D-glucose tetraacetate-1-b -OH 41, which selectively crystallized from
the anomeric mixture of 41 a/b , with chloroformate 33 followed by deprotection of the
resulting intermediate 43. Reaction of the pure anomer 41 with chloroformate 33 is
faster than anomerization of the 1- b -OH group to an 1- a -OH, as only about 10% of the
a -isomer of 43 was detected by proton NMR.
AcO
AcO
AcO
O
THF, pyr.
N O
O
O
O
Cl AcOAcO
AcO
O
O
O O
O
O N41 33
a/b  = 0/100
O
OOMe
HO
HO
O
OH
O
O
NHHO
OO
OHOHO
HO
O
OOMe
HO
HO
O
OH
O
O
NHHO
OO
OAcOAcO
AcO
 DMF, i-Pr2NEt
1)
 LiOH
2)
 cation exchange
MeOH/H2O, 0° C
DAU-GsA1
42
43
DAU-HCl
AcO AcO
AcO HO
OH
Scheme 2.12   Synthesis of DAU-GsA1.
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Scheme 2.13   Synthesis of DAU-GlA1.
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It was not possible to prepare D-galactosyl prodrug DAU-GlA1 analogously to the
D-glucosyl prodrug because 2,3,4,6-tetra-O-acetyl D-galactose (44 a/ b  ) could not be
crystallized. The protected D-galactosyl prodrug 45 (scheme 2.13), however, was
prepared using a novel glycosyl-carbonyl transfer reaction which is outlined in section
5.2. Deprotection of 45 was readily accomplished with LiOH.
2.6 Evaluation of the synthesized prodrugs for application in 
ADEPT
2.6.1 Cytotoxicities
Table 2.2 shows a highly decreased cytotoxicity for the sulfate prodrugs, especially the
N-derivative DAU-S1 which is 1,600 - 230,000 times less toxic than daunorubicin. On
the other hand, the phosphate prodrugs DAU-P1 and -P2 exhibit the same or a slightly
diminished cytotoxicity on the cell lines compared to daunorubicin. This can be
explained by the presence of endogenous phosphatase enzymes in the culture medium.
Furthermore, the 4'-O-sulfate prodrug DAU-S2 shows a higher residual activity when
compared to the N-sulfate analog. This can probably be ascribed to the unoccupied
3'-amino group which is present in the 4'-O-sulfate derivative.
The cytotoxicities of the b -D-glucosyl- and b -D-galactosyl-based prodrugs DAU-GsA1
and DAU-GlA1, respectively, (table 2.3) are not as strongly reduced as the
b -D-glucuronyl-based prodrug DAU-GA1 which is at least 2,000 times less toxic than
the parent drug. The difference in cytotoxicity between the b -D-glucuronyl prodrug on
one hand and b -D-glucosyl and b -D-galactosyl based prodrugs on the other hand, can
probably be explained by their large difference in polarity and hence difference in
cellular uptake.
–––––––––––––––––––– IC50 ( m M) –––––––––––––––––––– Activation
Compound A204 MCF-7 T24 WiDr IgR-37 t1/2  (min)
DAU 3 2 2 7 11
DAU-P1 17 370 2 10 96 n.d.†
DAU-P2 17 89 3 58 45 n.d.†
DAU-S1 4,900 10,400 >180,000 >1,600,000 >1,600,000 ¥
DAU-S2 1,300 870 5,500 >1,600,000 3,000 ¥
† not determined
Table 2.2   Cytotoxicities and enzymatic activation rates of phosphate and sulfate prodrugs.
2.6.2 Enzymatic prodrug activation rates
For the determination of the activation half-lives, the prodrugs were incubated with
aryl sulfatase, human b -glucuronidase or bovine liver b -galactosidase [44], respectively,
see table 2.2 and 2.3. In the cytotoxicity assays (table 2.2), the phosphate prodrugs were
almost as toxic as daunorubicin. It was concluded that these prodrugs undergo
premature activation by endogenous enzymes and are of no interest for ADEPT.
Therefore, the enzymatic hydrolysis half-lives of the phosphate prodrugs were not
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determined. Whereas the novel daunorubicin phosphate prodrugs were hydrolyzed
rapidly by endogenous enzymes, the daunorubicin sulfates were not activated to the
parent drug by the aryl sulfatase used.
––––––––––––––––––––––––– IC50 ( m M) ––––––––––––––––––––––––– Activation
Compound OVCAR-3 MCF-7 WiDr EVSAT IGROV M-19 A-498 t1/2  (min)
DAU 0.1 2 7 2 18 2 3
DAU-GA1 100 11,200 39,500 13,500 36,900 15,800 12,100 8,200 †
DAU-GsA1
DAU-GlA1 6
125 370 280 520 200 250 >5,000 ‡
>5,000 ‡
† human b -glucuronidase, ‡ bovine liver b -galactosidase [44]
Table 2.3   Cytotoxicities and enzymatic activation rates of b -D-glycosyl prodrugs.
The b -glycosyl-based prodrugs DAU-GA1, -GsA1  and -GlA1 (table 2.3) were
hydrolyzed at a rate which must be considered too low to be applicable in ADEPT. It
was shown in the literature [11a, 45] that prodrugs having an enzymatic hydrolysis rate
comparable to those of the aforementioned three b -glycosyl prodrugs are less suitable to
be used in ADEPT.
These results indicate that prodrugs consisting of a b -D-glucuronyl-carbamate moiety
are potential candidates for application in ADEPT if enzymatic activation can be
accelerated. The relatively low cytotoxicity of DAU-GA1 compared to daunorubicin
(table 2.3) and the facile hydrolysis of model compound N-phenyl O-b -D-glucuronyl
carbamate (8, chart 2.4) makes the b -D-glucuronyl carbamate group an interesting
specifier to be used in prodrug development. The research presented in the following
chapters focuses on the synthetic approaches to and evaluation of b -D-glucuronyl
carbamate-based prodrugs possessing an immolative spacer entity between drug and
b -D-glucuronyl carbamate specifier to facilitate enzymatic prodrug activation.
2.7 Experimental part
2.7.1 Biological evaluation
Cytotoxicities
The cytotoxicities of the daunorubicin-phosphate and -sulfate analogs (table 2.2) were
evaluated using a panel of 5 human tumor cell lines consisting of rhabdomyosarcoma
cells (A-204), mammary carcinoma cells (MCF-7), bladder carcinoma cells (T-24),
melanoma cells (IgR-37) and colon carcinoma cells (WiDr). For the b -D-glycosyl
prodrugs (table 2.3), a panel consisting of MCF-7 and WiDr Cells, mammary carcinoma
cells (EVSAT), ovarian carcinoma cells (IGROV), melanoma cells (M-19) and renal
cancer cells (A-498) was used [46]. IC50 values were calculated from a dose-response
curve which was obtained from cell-kill values at 12 different concentrations performed
twice for each drug.
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Enzymatic prodrug activation rates
The enzymatic activation rates of the b -D-glucuronyl-containing prodrugs were
determined by incubation of 100 m M of prodrug in 0.1% BSA/PBS at pH = 6.8 [47] with
0.03 U/mL human b -glucuronidase at 37ºC. The b -D-glucose and b -D-galactose based
prodrugs were incubated with 0.3 U/mL bovine liver b -galactosidase [44] and the
daunorubicin-sulfates were incubated with 1 m g/mL aryl sulfatase under the same
conditions as the b -D-glucuronides. Samples were prepared and analyzed on reversed
phase SiO2-C18 HPLC as described [11b].
2.7.2 Chemistry
General
Daunorubicin hydrochloride DAU-HCl was a generous gift from Pharmachemie BV
Haarlem. 2-(Methylsulfonyl)ethyl alcohol was kindly provided by Prof. G.I. Tesser.
Chromatotron model 7924-T Harrison Research (Palo Alto, California, USA) equipped
with plates (thickness 2 mm, diameter 8.5 cm) made form Merck silicagel 60 PF254
which contains gypsum (art. 7749) was used when circular chromatography is
indicated. Reversed phase chromatography was performed with a liquid chro-
matography pump LC-410 (Kontron) using a pre-packed column (24 cm, diameter 11
mm) containing octadecylsilane (40-63 m m) (Merck, Darmstadt). Prior to use the RP-C18
column was equilibrated with demineralized water. 1H NMR spectra at 400 MHz were
obtained on a Bruker AM-400. Chemical shifts are expressed in ppm downfield from
internal standard Me4Si, the 31P NMR spectra were recorded at 162 MHz using
(MeO)3PO as external standard on a Bruker AM-400. Abbreviations are used as follows:
2-(methylsulfonyl)ethyl-: MSE-. All solvents were dried before use. MeCN, CH2Cl2 and
Et3N were dried by distillation over CaH2, CHCl3 and pyridine by distillation over
CaCl2 and THF by distillation over LiAlH4 or over sodium. i-Pr2NEt was dried over
KOH pellets. In all cases demineralized H2O was used.
Synthesis of daunorubicin-N-phosphate disodium salt (DAU-P1).
Daunorubicin-N-(bis[2-(methylsulfonyl)ethyl] phosphate) (11). To a stirred suspension of 340 mg (0.60 mmol)
of DAU-HCl and 0.84 mL (10 equiv.) of Et3N cooled to -40 ºC was added dropwise a solution of 238 mg
of bis[MSE]-phosphorochloridate 10 (1.2 equiv.) in MeCN. After 2 h, TLC (CH2Cl2/EtOH, 10/1) indicated
completion of the reaction. After evaporation of the MeCN and the Et3N under reduced pressure, the red
residue was dissolved in CHCl3 washed with 20 mL portions of saturated aqueous NaHCO3 (3x), H2O
(2x) and brine and dried over Na2SO4. After evaporation of the CHCl3, the unstable 11 which formed
cyclic phosphate 12 upon standing, was immediately deprotected.
Daunorubicin-N-phosphate disodium salt (DAU-P1). Compound 11 obtained as above was dissolved in 40.0
mL of dioxane/MeOH 14/5 and 3.0 mL of 4 N NaOH (20 equiv.) in 12.0 mL of dioxane/MeOH 14/5. The
resulting deep blue solution was quenched after 30 sec. until the blue colour had disappeared using
solutions of 2 N and 0.1 N HCl successively. After this, the red solution was poured into 100 mL of an
aqueous 0.1 M phosphate buffer pH = 7.5. The aqueous solution was diluted to ca. 400 mL with H2O and
washed with CHCl3 (6x). The aqueous layer was concentrated under reduced pressure to ca. 250 mL and
applied to a RP-C18 pre-packed column. The column was eluted with H2O (250 mL) to remove the
inorganic salts. Elution of the product from the column using 20 mL of MeCN/H2O 1/1, evaporation of
MeCN and lyophilizing the H2O yielded 154 mg, 40% of pure DAU-P1 as a red fluffy solid, mp 210-
230ºC. Anal.: calc. (found) for C27H28NO13PNa2.4,5 H2O: C: 44.27 (44.28), H: 5.09 (5.09), N: 1.91 (1.96). MS
(FAB+) m/z = 688 ([M(with P(O)O2Na2)+H+2 H2O]+), 666 ([M(with P(O)O2NaH)+H+2 H2O]+), 644 ([M(with
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P(O)O2H2)+H+2 H2O]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.12 (d, 3H, 5'-Me, J = 6.2 Hz), 1.54 (bd,
1H, 2'eq-H, J = 9.8 Hz), 1.77 (bt, 1H, 2'ax-H, J = 12.3 Hz), 2.15 (bd, 1H, 8ax-H, J = 13.3), 2.20 (bd, 1H, 8eq-H, J
= 11.2 Hz), 2.24 (s, 3H, 9-C(O)Me), 2.91 (d, 1H, 10eq-H, J = 16.2 Hz), 3.01 (d, 1H, 10ax-H, J = 17.8 Hz), 3.10-
3.55 (m, 2H, 3',4'-H), 3.97 (s, 3H, 4-OMe), 4.03 (q, 1H, 5'-H, J = 6.7 Hz), 4.96 (bs, 1H, 7-H), 5.18 (bs, 1H, 1'-
H), 5.48 (bs, 1H, 3'-NH-), 7.60 (bs, 1H, 3-H), 7.79 (bs, 2H, 1,2-H). Due to the presence of H2O in the
(CD3)2SO, signals of -OH groups were not present in the spectrum. 31P-NMR (162 MHz, proton-
decoupled, (CD3)2SO) d  (ppm) = 8.11.
Synthesis of daunorubicin-N-sulfate sodium salt (DAU-S1).
0.23 mL Et3N (4 equiv.) and 152 mg (2 equiv.) of Et3N-SO3 salt in 8.0 mL of dry CHCl3 were added to 237
mg (0.420 mmol) of daunorubicin. After stirring the reaction mixture at ambient temperature overnight,
another 2 equiv. of the Et3N-SO3 reagent were added and reaction was stirred at reflux temperature.
After 1 h, ca. 90% of the starting material had disappeared (RP-C18 TLC, MeCN/H2O 1/1) and the
suspension was taken to dryness. To remove the unreacted daunorubicin, the red residue was dissolved
in 100 mL of H2O containing 2 mL of saturated aqueous NaHCO3 and was washed with three portions of
50 mL CHCl3. The aqueous solution of DAU-S1 was purified on a RP-C18 column as described for DAU-
P1. The thus obtained triethylammonium salt of the sulfate was converted to the sodium salt by eluting
an aqueous solution of the product over a column containing cation exchange material (Na+ form). The
product fraction was lyophilized to furnish 188 mg, 71% of pure DAU-S1 as a red fluffy solid, mp 188-
191ºC. Anal.: calc. (found) for C27H28NO13SNa.3 H2O: C: 47.44 (47.09), H: 5.01 (4.97), N: 2.05 (2.36), S: 4.69
(4.40). MS (FAB+) m/z = 652 ([M+Na]+), 630 ([M+H]+). 1H-NMR (400 MHz, CDCl3) of Et3N+H salt d  (ppm)
= 1.13 (d, 3H, 5'-Me, J = 6.1 Hz), 1.25-1.35 (m, 15H, Et3N+H), 1.82 (dt, 1H, 2'ax-H, J = 12.5 Hz J = 4.5 Hz),
1.86 (dd, 1H, 2'eq-H, J = 13.4 Hz J = 3.8 Hz), 2.07 (dd, 1H, 8ax-H, J = 14.8 Hz J = 4.1 Hz), 2.35 (d, 1H, 8eq-H, J
= 14.8 Hz), 2.41 (s, 3H, 9-C(O)Me), 2.97 (d, 1H, 10ax-H, J = 18.8 Hz), 3.00-3.15 (m, 2H, 3'-NH- 4'-OH), 3.20
(dd, 1H, 10eq-H, J = 18.9 Hz J = 1.6 Hz), 3.63 (bd, 1H, 4'-H, J = 6.4 Hz), 3.85 (bs, 1H, 3'-H), 4.07 (s, 3H, 4-
OMe), 4.15 (q, 1H, 5'-H, J = 6.8 Hz), 4.71 (s, 1H, 9-OH), 5.28 (d, 1H, 7-H, J = 1.8 Hz), 5.52 (d, 1H, 1'-H, J =
3.5 Hz), 7.39 (d, 1H, 3-H, J = 8.4 Hz), 7.78 (t, 1H, 2-H, J = 8.1 Hz), 8.03 (d, 1H, 1-H, J = 7.5 Hz), 13.29 (s, 1H,
11-OH), 13.95 (s, 1H, 6-OH).
Synthesis of N-3'-daunorubicinyl O-(2-(methylsulfonyl)ethyl) carbamate (15).
To a stirred suspension of 100 mg (0.177 mmol) of DAU-HCl and (61 m L, 2.0 equiv.) of i-Pr2NEt in 10 mL
of DMF, 52 mg (1.1 equiv.) of MSE 1-hydroxysuccinimidyl carbonate 14 was added. After 0.5 h of
stirring, reaction was complete and the mixture was diluted with 150 mL of EtOAc and washed
successively with aqueous 0.5 N KHSO4 (2x), H2O, saturated aqueous NaHCO3 (2x), H2O and brine. The
organic fraction was dried over Na2SO4 and taken to dryness. The crude product was purified in two
runs by circular chromatography using respectively CH2Cl2/EtOH 10/1 and 20/1 as the eluent. The
product fraction was evaporated, the red residue was sonicated in i-Pr2O and filtered of to yield 104 mg,
87% of 15 as an orange powder, mp 155ºC. Anal.: calc. (found) for C31H35NO14S.1 H2O: C: 53.75 (53.52),
H: 5.36 (5.17), N: 2.01 (2.04), S: 4.61 (4.60). MS (FAB+) m/z = 700 ([M+Na]+), 778 ([M+H]+). 1H-NMR (400
MHz, CDCl3) d  (ppm) = 1.30 (d, 3H, 5'-Me, J = 6.8 Hz), 1.78 (dd, 1H, 2'ax-H, J = 12.9 Hz J = 4.0 Hz), 1.90
(dd, 1H, 2'eq-H, J = 13.1 J = 4.8), 2.12 (dd, 1H, 8ax-H, J = 14.8, J = 4.1 Hz), 2.31 (d, 1H, 8eq-H, J = 14.8 Hz),
2.42 (s, 3H, 9-C(O)Me), 2.92 (d, 1H, 10ax-H, J = 18.6), 2.94 (s, 3H, -SO2Me), 3.20-3.35 (m, 3H, 10eq-H,
-CH2SO2Me), 3.67 (bs, 1H, 4'-H), 3.88 (bs, 1H, 3'-H), 4.07 (s, 3H, 4-OMe), 4.21 (q, 1H, 5'-H J = 6.6 Hz), 4.44
(s, 1H, 9-OH), 4.45-4.50 (m, 2H, -CH2CH2SO2Me), 5.23 (d, 1H, 3'-NH-, J = 8.8 Hz), 5.26 (d, 1H, 7-H, J = 1.8
Hz), 5.50 (d, 1H, 1'-H, J = 3.5 Hz), 7.39 (d, 1H, 3-H, J = 8.4 Hz), 7.78 (t, 1H, 2-H, J = 8.0 Hz), 8.03 (d, 1H, 1-
H, J = 7.6 Hz), 13.27 (s, 1H, 11-OH), 13.99 (s, 1H, 6-OH).
Synthesis of daunorubicin-4’-O-phosphate (DAU-P2).
Daunorubicin-N-(carbonyl-oxy-2-(methylsulfonyl)ethyl) -4'-O-(bis[2-(methylsulfonyl)ethyl] phosphate) (17). 150
mg (0.222 mmol) of the 3'-amino protected daunorubicin 15, 167 mg (2.0 equiv.) of phosphitilating
reagent 16 and 17 mg (1.1 equiv.) of 1-H-tetrazole were dissolved in CH2Cl2 under an argon atmosphere
and heated to reflux. Conversion of the starting material to daunorubicin-4'-phosphite was monitored by
TLC (SiO2, CH2Cl2/EtOH 10/1). After 30 min, additional portions of 0.1 equiv. of both phosphite and
tetrazole were added. After 1 h, almost all of the starting material had disappeared. The reaction mixture
was cooled to -67 ºC and m-CPBA (115 mg, 3.0 equiv.), dissolved in 10 mL CH2Cl2 was added. The
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phosphite was easily oxidized to the protected phosphate 17. The reaction mixture was diluted with 150
mL of CH2Cl2 and washed with 10% aqueous Na2SO3 (4x 50 mL), saturated aqueous NaHCO3 (2x), H2O
(2x) and brine successively. The organic layer was dried with Na2SO4 and the solvent was evaporated.
Daunorubicin-4’-O-phosphate (DAU-P2). The 17 obtained as above was dissolved in 20 mL of dioxane
/MeOH 14/5 and 1.66 mL of 4 N aqueous NaOH (10 equiv. per protective group) in 11.7 mL of
dioxane/MeOH 14/5 was added in one portion while vigorously stirring the mixture. After 1 min, the
resulting deep blue solution was quenched with an aqueous 1.0 N AcOH solution until the blue colour
turned red and poured into 100 mL of a 0.1 N aqueous phosphate buffer pH = 7.0. The resulting aqueous
solution of DAU-P2 was purified on a reversed phase column as described for DAU-P1 to obtain 104 mg,
74% of DAU-P2 as a red fluffy solid, mp >350ºC. Anal.: calc. (found) for C27H29NO13PNa.4 H2O: C: 46.23
(46.51), H: 5.32 (5.09), N: 2.00 (2.06). MS (FAB+) m/z = 644 ([M(with P(O)O2H2)+H+2 H2O]+), 630 ([M(with
P(O)O2NaH)+H]+), 608 ([M(with P(O)O2H2)+H]+). In the NMR-spectrum, signals were strongly broadened [49].
1H-NMR (400 MHz, (D2O) d  (ppm) = 1.21 (d, 3H, 5'-Me, J = 6.5 Hz), 1.80-1.90 (m, 2H, 2'ax-H 2'eq-H), 2.00-
2.15 (m, 2H, 8ax-H 8eq-H), 2.33 (s, 3H, 9-C(O)Me), 2.44 (bd, 1H, 10ax-H, J = 17.2), 2.68 (bd, 1H, 10ax-H, J =
17.2 Hz), 2.91 (d, 1H, 10eq-H, J = 16.2 Hz), 3.60-3.65 (m, 1H, 3'-H), 3.69 (s, 3H, 4-OMe), 4.16 (bd, 1H, 5'-H, J
= 7.5 Hz), 4.40-4.65 (m, 3H, 7-H 4'-H 3'-NH3+), 5.30 (bs, 1H, 1'-H), 7.11 (bs, 2H, 1,3-H), 7.39 (bs, 1H, 2-H).
Due to the presence of H2O, signals of -OH groups were not present in the spectrum. 31P-NMR (162 MHz,
proton-decoupled, (D2O) d  (ppm) = 4.35.
Synthesis of daunorubicin-4’-O-sulfate (DAU-S2).
Daunorubicin-N-carbonyl-oxy-2-(methylsulfonyl)ethyl -4'-O-sulfate (18). 0.2 mL of ClSO3H was added to 10
mL of dry pyridine under a stream argon. 2.0 mL of this 0.3 mmol/mL pyr-SO3 solution was transferred
to a solution of 184 mg (0.272 mmol) of 15 in 10 mL dry pyridine. After 2 h, an additional portion of 2.0
mL of the sulfate reagent was added. Progress of the reaction was monitored on TLC (RP-C1 8
MeCN/H2O 1/1). When almost all of the starting material had disappeared (ca. 2 h), 1.0 mL of a
saturated aqueous NaHCO3 solution in 100 mL of H2O were added. The solution was washed with
CHCl3 and purified as described for DAU-P1.
Daunorubicin-4’-O-sulfate (DAU-S2). The protected sulfate 18 was dissolved in 7.0 mL of dioxane/MeOH
14/5. 0.6 mL of 4 N aqueous NaOH (10 equiv.) in 4.4 mL of dioxane/MeOH 14/5 was added in one
portion. After vigorously stirring for 1 min, the mixture was quenched until the blue colour turned red
with a 2.0 N aqueous AcOH solution, and poured into 100 mL of a 0.1 N aqueous phosphate buffer pH =
7.5. The aqueous solution was washed with CHCl3 and purified using a reversed phase column as
described for DAU-P1. Lyophilisation of the product fraction from the RP-C18 column afforded 85 mg,
51% of DAU-S2 as a red fluffy solid, mp >350ºC. Anal.: calc. (found [48]) for C27H29NO13S.4 H2O: C: 47.72
(47.26), H: 5.49 (4.70), N: 2.06 (2.10), S: 4.72 (5.13). MS (FAB+) m/z = 630 ([M+Na]+), 608 ([M+H]+). Due to
the poor solubility of the sulfate during work-up, a considerable amount of the product was lost. In the
NMR-spectrum, signals were broadened [49]. 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.17 (d, 3H, 5'-Me,
J = 6.0 Hz), 1.69 (bs, 1H, 2'ax-H), 1.82 (bs, 1H, 2'eq-H), 2.05-2.15 (m, 2H, 8ax-H 8eq-H), 2.26 (s, 3H, 9-
C(O)Me), 2.89 (d, 1H, 10ax-H, J = 19.6 Hz), 2.94 (d, 1H, 10eq-H, J = 19.6 Hz), 3.97 (s, 3H, 4-OMe), 4.20 (bs,
1H,4'-H), 4.24 (d, 1H, 5'-H, J = 6.0 Hz), 4.95 (bs, 1H, 7-H), 5.28 (bs, 1H, 1'-H), 5.41 (bs, – 1H, 3'-NH3+), 7.62
(bs, 1H, 3-H), 7.89 (bs, 2H, 1,2-H). Due to the presence of H2O in the (CD3)2SO, signals of -OH groups
were not present in the spectrum. The 3'-H signal was overlapped by H2O signal [50].
Synthesis of N-3'-daunorubicinyl O- b -D-glucuronyl carbamate (DAU-GA1).
Diastereoselective formation of 1-O- b -trimethylsilyl methyl 2,3,4-tri-O-acetyl D-glucuronic acid (40). To a
solution of 100 mg (299 mmol) of the anomerically unprotected D-glucuronic acid 27 in 2.0 mL of THF
was added 114 m L (2.0 equiv.) of N,N-diethyl trimethylsilyl amine (39b) at 0 ºC under an argon
atmosphere. After stirring the reaction mixture for 48 h at 0 ºC, the starting material had disappeared
(TLC, SiO2, Et2O). After removal of the THF, diethyl amine and excess silylating reagent under reduced
pressure, 40 was obtained in 90% yield (determined by 1H-NMR). 1H-NMR spectrum according to
literature [40]. the unstable 1-O-b -trimethylsilyl D-glucuronide was immediately used in the next reaction.
Using different silylating reagents and reaction conditions (see table 2.1), the anomeric composition of the
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silylated product was evaluated using the integrated signals of 5-H from both anomers in the 100 MHz
1H-NMR spectrum in CDCl3 ( d  5-Ha  = 4.45 ppm, d  5-H b  = 3.99 ppm).
N-3'-Daunorubicinyl O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (38 b ). To 1-O- b -trimethylsilyl
D-glucuronide 40 obtained as described above in 5 mL of MeCN, 64 mg (1,2 equiv.) of chloroformate 33
and 10 mg (0.25 equiv.) of anhydrous ZnCl2 were added. When most of 40 had disappeared, 48 m L (2.0
equiv.) of pyridine were added. After 0.5 h, 254 mg (1.5 equiv.) of DAU-HCl and 156 m L (3.0 equiv.) of i-
Pr2NEt were added. The reaction mixture was diluted with 200 mL of CH2Cl2 and washed with a 5%
aqueous solution of KHSO4 (3x), H2O and saturated aqueous NaHCO3 (2x), and with brine successively.
The organic layer was dried over Na2SO4 and evaporated. The crude 38 b  was purified by circular
chromatography in three successive sessions using CH2Cl2/EtOH 10/1, 20/1 and 30/1 respectively.
Evaporation of the product fractions, sonification of the residue in i-Pr2O and filtration yielded 115 mg
(48%) of 38 b  , mp 160-162ºC. Anal.: calc. (found) for C41H45NO21.1 H2O: C: 54.37 (54.67), H: 5.23 (5.34), N:
1.55 (1.50). 1H-NMR (400 MHz, CDCl3) d  (ppm) = 1.29 (d, 1H, 5'-Me, J = 6.6 Hz), 1.76 (dt, 1H, 2'ax-H, J =
13.2 Hz J = 4.0 Hz), 1.89 (dd, 1H, 2'eq-H, J = 13.4 Hz J = 4.8 Hz), 1.99 (s, 6H, 2 -OAc), 2.01 (s, 3H, -OAc),
2.10 (dd, 1H, 8ax-H, J = 14.8 Hz J = 4.1 Hz), 2.28 (d, 1H, 8eq-H, J = 14.8 Hz), 2.39 (s, 3H, 9-C(O)Me), 2.46 (s,
1H, 4'-OH), 2.93 (d, 1H, 10ax-H, J = 18.9 Hz), 3.23 (d, 1H, 10eq-H, J = 19.1 Hz), 3.64 (bd, 1H, 4'-H, J = 6.4
Hz), 3.68 (s, 3H, -CO2Me), 3.87 (bs, 1H, 3'-H), 4.07 (s, 3H, 4-OMe), 4.08 (d, 1H, Gluc5-H, J = 9.9 Hz), 4.19
(q, 1H, 5'-H, J = 6.4 Hz), 4.42 (s, 1H, 9-OH), 5.08 (t, 1H, Gluc2-H, J = 8.7 Hz), 5.16 (t, 1H, Gluc4-H, J = 9.6
Hz), 5.20-5.30 (m, 1H, 7-H), 5.27 (t, 1H, Gluc3-H, J = 9.3 Hz), 5.37 (d, 1H, 3'-NH-, J = 8.6 Hz), 5.48 (d, 1H,
1'-H, J = 3.5 Hz), 5.62 (d, 1H, Gluc1-H, J = 8.0 Hz), 7.38 (d, 1H, 3-H, J = 8.4 Hz), 7.77 (t, 1H, 2-H, J = 8.0
Hz), 8.03 (d, 1H, 1-H, J = 7.7 Hz), 13.26 (s, 1H, 11-OH), 13.97 (s, 1H, 6-OH).
N-3'-Daunorubicinyl O- b -D-glucuronyl carbamate (DAU-GA1). 42 mg of 38 b  (47.4 m mol) was dissolved in
1.90 mL of a 0.25 N solution of LiOH in MeOH/H2O 3/1 (10 equiv.). The resulting deep blue solution
was stirred at 0 ºC under an argon atmosphere while the course of the reaction was monitored on TLC
(RP-C18 MeCN/H2O 1/1). After 20 min, the reaction mixture was diluted with 50 mL of H2O and the
LiOH solution was neutralized with ca 1 g of amberlite cation exchange material (H+ form) whereupon
the blue mixture turned to red. After the amberlite had been removed by filtration, 0.5 mL of saturated
aqueous NaHCO3 was added. The prodrug was purified on a reversed phase column as described for
DAU-P1 to afforded 34 mg, 93% of DAU-GA1, mp 178ºC. Anal.: calc. (found) for C34H36NO18Na.4 H2O:
C: 48.52 (48.08), H: 5.27 (4.87), N: 1.66 (1.75). MS (FAB+) m/z = 792 ([M+Na]+), 770 ([M+H]+). 1H-NMR (400
MHz, (CD3)2SO) d  (ppm) = 1.12 (d, 3H, 5'-Me, J = 6.4 Hz), 1.54 (dd, 1H, 2'eq-H, J = 11.6 Hz J = 3.4 Hz), 1.84
(dt, 1H, 2'ax-H, J = 11.5 Hz J = 3.4 Hz), 2.08 (dd, 1H, 8ax-H, J = 13.7 Hz J = 5.3 Hz), 2.20 (bd, 1H, 8eq-H, J =
11.2 Hz), 2.25 (s, 3H, 9-C(O)Me), 2.90 (d, 1H, 10eq-H, J = 18.2 Hz), 2.96 (d, 1H, 10ax-H, J = 18.2 Hz), 3.00-
3.45 (m, 5H, 4'-H Gluc2,3,4,5-H), 3.72 (m, 1H, 3'-H), 3.96 (s, 3H, 4-OMe), 4.16 (q, 1H, 5'-H, J = 6.6 Hz), 4.76
(d, 1H, -OH), 4.90 (t, 1H, 7-H, J = 4.4 Hz), 5.00 (s, 1H, -OH), 5.05 (s, 1H, -OH), 5.09 (d, 1H, Gluc1-H, J = 8.1
Hz), 5.21 (s, 1H, 1'-H), 5.55 (s, 1H, 9-OH), 5.77 (s, 1H, -OH), 6.11 (s, 1H, -OH), 6.93 (d, 1H, 3'-NH-, J = 8.0
Hz), 7.60 (dd, 1H, 3-H, J = 6.3 Hz J = 3.3 Hz), 7.80-7.90 (m, 2H, 1,2-H), 13.23 (s, 1H, 11-OH), 14.01 (s, 1H, 6-
OH).
Synthesis of N-3'-daunorubicin O-b -D-glucosyl carbamate (DAU-GsA1).
N-3'-Daunorubicinyl O- b -(2,3,4,6-tetra-O-acetyl D-glucosyl) carbamate (43). To a solution of 126 mg (4 equiv.)
of chloroformate 33 and 115 m L (8 equiv.) of pyridine in 15 mL of THF was added 62 mg (0.178 mmol) of
2,3,4,6-tetra-O-acetyl b -D-glucose 41. The mixture was stirred for 2 h and 120 mg (1.2 equiv.) of DAU-HCl
and 74 m L (2.4 equiv.) of i-Pr2NEt in 5 mL of DMF were added. After 2 h, the reaction mixture was
worked up as described for 38b  to obtain 96 mg, 60% of 43 as amorphous red crystals, mp 152-155ºC. 1H-
NMR (400 MHz, CDCl3) d  (ppm) = 1.28 (d, 3H, 5'-Me, J = 6.6 Hz), 1.70-1.95 (m, 3H, 2'eq-H 2'ax-H 4'-OH),
1.99, 2.00, 2.02 and 2.03 (4s, 12H, 4 -OAc), 2.10 (dd, 1H, 8ax-H, J = 14.8 Hz J = 3.8 Hz), 2.30 (d, 1H, 8eq-H, J
= 14.8 Hz), 2.38 (s, 3H, 9-C(O)Me), 2.90 (d, 1H, 10ax-H, J = 18.8 Hz), 3.22 (d, 1H, 10eq-H, J = 18.8 Hz), 3.63
(bs, 1H, 4'-H), 3.75-3.85 (m, 2H, 3'-H Gluc5-H), 4.06 (s, 3H, 4-OMe), 4.05 (d, 1H, Gluc6-HaHb-, J = 11.6 Hz),
4.21 (q, 1H, 5'-H, J = 6.5 Hz), 4.24 (dd, 1H, Gluc6-HaHb-, J = 11.4 Hz J = 4.3 Hz), 4.46 (s, 1H, 9-OH), 5.05-
5.35 (m, 5H, 7-H 3'-NH- Gluc2,3,4-H), 5.46 (d, 1H, 1'-H, J = 3.3 Hz), 5.60 (d, 1H, Gluc1-H, J = 8.0 Hz), 7.37
(d, 1H, 3-H, J = 8.6 Hz), 7.78 (t, 1H, 2-H, J = 8.0 Hz), 8.01 (d, 1H, 1-H, J = 7.5 Hz), 13.28 (s, 1H, 11-OH),
13.98 (s, 1H, 6-OH).
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N-3'-Daunorubicinyl O- b -D-glucosyl carbamate (DAU-GsA1). 32 mg (0.035 mmol) of 43 was dissolved in
2.84 mL (10 equiv.) of a 0.125 N solution of LiOH in MeOH/H2O 3/1 and stirred under an argon
atmosphere at 0ºC. After 10 min, deprotection was complete as judged by TLC (RP-C18 MeCN/H2O 1/1)
and 10 mL of H2O and 1 g of amberlite cation exchange material (H+ form) were added. After the deep
blue solution had turned red, the amberlite was filtered off, the residue was washed with THF and the
filtrate was concentrated under reduced pressure. After that, 2 mL of MeCN were added and the solution
was transferred to a RP-C18 column. The column was washed with 200 mL of MeCN/H2O 1/5 and the
product was eluted with MeCN/H2O 1/1, MeCN was evaporated and the aqueous solution was
lyophilized to yield 25 mg, 97% of  DAU-GsA1 as a red fluffy solid, mp 163-170ºC. Anal.: calc. (found) for
C34H39NO17.3 H2O: C: 51.84 (51.36), H: 5.76 (5.52), N: 1.78 (2.42). MS (FAB+) m/z = 756 ([M+Na]+), 734
([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.13 (d, 3H, 5'-Me, J = 6.4 Hz), 1.45 (dd, 1H, 2'eq-H, J =
11.8 Hz J = 4.0 Hz), 1.87 (dt, 1H, 2'ax-H, J = 11.6 Hz J = 4.8 Hz), 2.05 (dd, 1H, 8ax-H, J = 14.2 Hz J = 5.7 Hz),
2.20 (d, 1H, 8eq-H, J = 14.2 Hz), 2.26 (s, 3H, 9-C(O)Me), 2.90 (s, 2H, Gluc6-H2), 3.00-3.80 (m, 8H, 10eq-H
10ax-H 3',4'-H, Gluc2,3,4,5-H), 3.96 (s, 3H, 4-OMe), 4.17 (q, 1H, 5'-H, J = 6.6 Hz), 4.46 (s, 1H, -OH), 4.69 (s,
1H, -OH), 4.90 (s, 1H, 7-H), 5.08 (s, 1H, -OH),  5.15 (d, 1H, Gluc1-H, J = 8.1 Hz), 5.21 (s, 1H, 1'-H), 5.49 (s,
1H, 9-OH), 6.92 (d, 1H, 3'-NH-, J = 7.8 Hz), 7.62 (t, 1H, 3-H, J = 4.6 Hz), 7.80-7.85 (m, 2H, 1,2-H), 13.25 (s,
1H, 11-OH), 14.07 (s, 1H, 6-OH).
Synthesis of N-3'-daunorubicinyl O- b -D-galactosyl carbamate (DAU-GlA1).
N-3'-Daunorubicinyl O-b -(2,3,4,6-tetra-O-acetyl D-galactosyl) carbamate (45).
This compound was prepared in a three step reaction sequence from 44 according to the method
described in section 5.2 (scheme 5.6, section 5.2, compound 37b).
N-3'-Daunorubicinyl O- b -D-galactosyl carbamate (DAU-GlA1). 56 mg (0.062 mmol) of 45 was dissolved in
3.0 mL (6 equiv.) of a 0.125 N solution of LiOH in MeOH/H2O 3/1 and stirred under an argon
atmosphere at 0ºC. After 10 min, deprotection was complete as judged by TLC (RP-C18 MeCN/H2O 1/1)
and the reaction mixture was processed as described for DAU-GsA1 to yield 36 mg, 79% of DAU-GlA1
as a red fluffy solid, mp 163-170ºC. Anal.: calc. (found) for C34H39NO17.3 H2O: C: 51.84 (52.13), H: 5.76
(5.30), N: 1.78 (2.09). MS (FAB+) m/z = 756 ([M+Na]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.12 (d,
3H, 5'-Me, J = 6.4 Hz), 1.46 (dd, 1H, 2'eq-H, J = 12.3 Hz J = 4.0 Hz), 1.84 (dd, 1H, 2'ax-H, J = 13.2 Hz J = 3.8
Hz), 2.08 (dd, 1H, 8ax-H, J = 14.2 Hz J = 5.3 Hz), 2.18 (d, 1H, 8eq-H, J = 11.1 Hz), 2.25 (s, 3H, 9-C(O)Me),
2.93 (s, 2H, Gal6-H2), 2.85-3.80 (m, 8H, 10eq-H 10ax-H, 3',4'-H, Gal2,3,4,5-H), 3.96 (s, 3H, 4-OMe), 4.17 (q,
1H, 5'-H, J = 6.6 Hz), 4.42 (d, 1H, -OH, J = 3.1 Hz), 4.53 (bs, 1H, -OH), 5.71 (d, 1H, -OH, J = 5.4 Hz), 4.75-
4.95 (m, 3H, 7-H 2 -OH), 5.11 (d, 1H, Gal1-H, J = 7.9 Hz), 5.21 (d, 1H, 1'-H, J = 2.0 Hz), 5.51 (s, 1H, 9-OH),
6.89 (d, 1H, 3'-NH-, J = 8.0 Hz), 7.61 (t, 1H, 3-H, J = 7.6 Hz), 7.85-7.90 (m, 2H, 1,2-H), 13.24 (s, 1H, 11-OH),
14.00 (s, 1H, 6-OH).
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3 Daunorubicin-Spacer-b -D-GlucuronylCarbamates as Prodrugs [1]Spacer Elimination by Ring-closure
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3.1 Introduction
Important prerequisites of a prodrug to be applicable in ADEPT are i. low toxicity
compared to the parent drug, ii. stability in plasma, iii. ready activation by the matching
mAb-enzyme conjugate (for a more comprehensive overview of important prodrug
characteristics, see chapter 1). As was concluded in chapter 2, among the prodrugs
containing a phosphate- sulfate- b -D-glucosyl carbamate- or b -galactosyl- carbamate
specifier, those having a b -D-glucuronyl carbamate specifier are promising for the use
in ADEPT. In this respect, N-3'-daunorubicinyl O- b -D-glucuronyl carbamate DAU-GA1
(chart 2.5) displayed a strongly reduced cytotoxicity compared to daunorubicin and
was stable in serum. Although DAU-GA1 was activated to the parent drug by
b -glucuronidase, the rate was too low to fulfil the requirements for effective use in
ADEPT. One possible way to improve the rate of hydrolysis of the b -D-glucuronyl
specifier is the incorporation of a spacer moiety between daunorubicin and the
b -D-glucuronyl carbamate specifier group. A general representation of prodrugs in
which the pro-moiety consists of a spacer and a specifier is given in scheme 3.1.
According to this scheme, after enzymatic hydrolysis of the specifier group of the intact
prodrug 1, elimination of the spacer from the spacer-drug molecule 2 is promoted and
the free drug is generated. The use of such a three-component prodrug system enables
optimization of enzymatic activation characteristics merely by structural variation of
the spacer.
SPACER
DRUG
SPECIFIER
ENZYMATIC
SPACER
DRUG
SPONTANEOUS
DRUG
pro-moiety
1
2
Scheme 3.1   Spacer containing prodrugs.
In the literature, two major types of self-eliminating (immolative) spacers are
investigated. In this chapter, prodrugs containing a spacer which is eliminated by ring
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closure are described. Chapter 4 deals with prodrugs having a spacer eliminated by a
1,6-elimination process.
An example of a prodrug containing a self-eliminating spacer is depicted in scheme 3.2.
The specifier of compound 3 [2] is a cephalosporin derivative which is hydrolyzed by
b -lactamase and upon this enzymatic triggering step, the resulting taxol-g -aminobutyric
acid 5 reverts to free taxol in a half-life time of approximately 6 hours at pH = 7.4 and
25ºC. Earlier, taxol derivative 5 was prepared [3] which was found to be an unstable
compound because of the intramolecular displacement reaction depicted in scheme 3.2.
NH
O
Taxol
O
Cephem
b -lactamase
NH
O
Taxol
O
HO
H2N
O
Taxol: NH
O
Taxol
3 4
5
+
CO2
Scheme 3.2   Taxol prodrug 3 with immolative cyclization spacer.
3.2 Target compounds
3.2.1 General structure
The designed cycloeliminative spacer containing target molecules I are all based on the
b -D-glucuronyl carbamate element (scheme 3.3). Compared to a b -D-glucuronyl ether
group, the b -D-glucuronyl carbamate entity is expected to be more prone to hydrolysis
O
NH
O
SPACER
O
OOMe
HO
HO
O
OH
O
O
NHHO
OOO
HO
HO
NaO2C
HO
b -glucuronidase
NH
O
SPACER
:
O
OOMe
HO
HO
O
OH
O
O
NHHO
NH2
- CO2
S
P
A
C
E R
O
OOMe
HO
HO
O
OH
O
O
NH2HO
I
DAU
II
III
Scheme 3.3   General representation of target compounds and their activation pathway to the free drug.
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than a conventional O-b -D-glucuronyl group (Indication for this supposition is given in
chapter 2 by comparing rates of enzymatic hydrolysis of compounds in 7 {R = -p-
nitrophenyl} and 8 chart 2.4). Moreover, after cleavage of the b -D-glucuronyl group of
compounds I and loss of a molecule of CO2, a primary amino group on spacer-drug
molecule II is generated. This amine function may trigger the cycloelimination of the
spacer. Prodrugs are designed in such a manner that elimination of the spacer of II
should be a spontaneous process. The generation of the free drug from prodrugs I are
dependent on: i. rate of enzymatic hydrolysis of the b -D-glucuronyl group, and ii. rate
of the intramolecular cyclization reaction of the spacer entity leading to expulsion of
daunorubicin. Loss of CO2 from II will be instantaneous. Both the rates of the enzyme-
mediated b -D-glucuronyl scission and that of the immolative spacer elimination are a
function of the nature of the spacer. The enzyme-dependent factor is relatively
unpredictable since the steric environment of the active site of human b -glucuronidase
is not known.
3.2.2 Selection of the cyclisable spacer
The propensity of g - and d -amino and -hydroxy amides to undergo intramolecular
cyclization is well documented in the literature [4] .(see scheme in table 3.1). This
concept has found application in the fields of synthetic peptide chemistry [5] and
protective group chemistry [6] as well as in prodrug design [7]. The kinetics and
mechanism of cyclization of the above mentioned compounds have been studied in
detail [8]. An excerpt of rates of ring-closure reactions of various hydroxy- and amino-
amides is given in table 3.1.
O
XH
X
O
NH
H2N R
S
P
A
C
ER
+
SPACER
:
X = -O-, -NH-
R
Reference Compound Cyclization t1/2  (min) Conditions
[7a] O
H
N
OMe
OH
R1
R1
R2
(R1, R2 = -H) 27.103
(R1 = -Me, R2 = -H) 630
(R1, R2 = -Me) 65.4
pH = 7.5, 30ºC
pH = 7.5, 30ºC
pH = 7.5, 30ºC
[7d]
O
H
N
NH2 OMe
R R (R = -H, -H) 260
(R = -H, -Me) 16
(R = -Me, -Me) 0.07
(R = -Me, -Me) 72
pH = 2.4, 37ºC
pH = 2.4, 37ºC
pH = 2.4, 37ºC
pH = 6.8, 37ºC
Table 3.1   Cyclization half-lives of some hydroxy- and amino-amides.
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Cohen and co-workers published an extensive series of papers [9] describing the
influence of substituents on rate constants of intramolecular cyclization reactions of
hydroxy- and amino- esters, amides and acids. The designation "Stereopopulation
Control" was introduced by these investigators to refer to the influence of the
preorganization of a molecule on the cyclization rate.
As can be concluded from the data in table 3.1, rates of cyclization are markedly
enhanced by methyl substitution at proper positions. In this context, prodrugs GB1-10
(chart 3.1) are chosen to study glucuronide hydrolysis and the cyclization of the spacer
leading to lactam III and the free drug daunorubicin (scheme 3.3). All glycosylated
prodrugs in this thesis are named using the nomenclature system described in chart 3.1.
It should be noted that the rate of cyclization of amino amides is relatively insensitive to
the electronic environment of the leaving amine [5a, 7d, 8a] in the amido group.
Therefore, it was expected that the poor leaving ability of the 3'-N-daunorubicinyl
group would not impede the intramolecular eliminative cyclization reaction. The
mechanism of the cyclization reaction is treated in more detail in section 3.4.
O
SPACER
O
OOMe
HO
HO
O
OH
O
O
NHHO
OOO
HO
HO
NaO2C
HO
NH
Me
Me Me
Me
SPACER
=
1 2 3 4
5 6
Me
Me
Me
Me
DAU-GB1 - 10
Me
Me
7
8 9 10
spacer number
...-.. .. ..
drug
specifier spacer type
spacer number
anthracycline: DAU = daunorubicin
DOX = doxorubicin (Ch. 4)
IDA = idarubicin (Ch. 4)
specifier: G = b -D-glucuronyl carbamate
Gs = b -D-glucosyl carbamate (Ch. 4)
Gl = b -D-galactosyl carbamate (Ch. 4)
spacer type: A = -CO2 spacer (Ch.1) or spacer expulsion by 1,4- or 1,6-elimination (Ch. 4) 
B = spacer expulsion by cyclization (Ch.3)
spacer number: numbering of prodrugs of the same type
(for example 
"DAU-GB1")
nomenclature of glycosylated prodrugs:
Chart 3.1   Target compounds.
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3.3 Synthesis of daunorubicin-3'-N-[spacer]-O- b -D-glucuronyl
carbamates
3.3.1 Strategy of the synthesis
Considering the multiple functionalities present in daunorubicin, its ease of oxidation
and especially the vulnerability of the glycosidic bond connecting the daunorubicinone
aglycon and daunosamine sugar (see chart 1.3), the synthesis of target compounds
GB1-6 requires a subtle approach. Preferably, daunorubicin is involved in the synthesis
sequence in one of the final reaction steps. For the preparation of a large number of
target compounds by merely variation of the starting material, a versatile synthesis
with a broad scope is needed.
O
SPACER
NH2-HCl
PG O
O
SPACER
PG O
OOO
AcO
AcO
MeO2C
AcO
N HO
SPACER
PG O
H O O
O
SPACER
PG O
N
C
O
route A
route B
OAcOAcO
MeO2C
AcO OH
6
7
8
9
10
pg = protecting group
Scheme 3.4   General synthetic pathways leading to pro-moiety 10.
Key compound 10 can be prepared via routes A and B (scheme 3.4) by the introduction
of a b -D-glucuronyl carbamate group to the spacer via the addition of anomerically
unprotected glucuronic acid 9 to spacer isocyanate 8. As outlined in section 5.1, this
isocyanate addition reaction generally leads to very high b -diastereoselectivities and
was elaborated during our studies toward the synthesis of b -D-glucuronyl carbamate
based prodrugs [10]. At first glance, easy access to a large number of prodrugs can be
attained using route A in which spacer isocyanate 8 is formed from spacer amine 6.
Because of the desired lactamization potential, however, a serious drawback of the use
of g - and d -amino esters 6 is their tendency to cyclize prematurely, expelling the
protecting group (pg) on the carboxylic acid function. Moreover, only a few g - and d -
amino acids from which 8 can be prepared are commercially available. Nevertheless,
initially prodrug DAU-GB1 was prepared starting from a g -amino butyric acid ester
following route A.
Route B, wherein the synthesis starts from spacer g - and d -dicarboxylic acid monoesters
7 offers a number of advantages over route A. The b -D-glucuronyl carbamate fragment
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can be introduced very conveniently without untimely cyclization of the spacer making
use of the Curtius rearrangement to transform a carboxylic acid group into an
isocyanate group (scheme 3.5).
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MeO2C
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N H
H O O
N
C
O
OAcOAcO
MeO2C
AcO OH
16
9
17
N3P
OPh
OPh
O
11
65 - 100ºC
12
PhMe,Et3N
R
R R
O O
R
P
OPhO
PhO
N3 O
R
+
N O
R
NN
+
N2
N3-
O-P
OPh
OPh
O13 14
15
-
Scheme 3.5   Modified Curtius reaction.
The rearrangement of acyl azides to isocyanates can be employed in the synthesis of
prodrugs to generate isocyanates 16 from carboxylic acids 11. Using diphenylphospho-
ryl azide 12 [11], spacer acyl azides 14  [12] were formed from carboxylic acids 11 via
mixed phosphorus anhydrides 13 [13]. Upon heating acyl azides 14 rearranged to
isocyanates 16 according to the mechanism depicted in 15. Diphenyl phosphoryl azide
12 appeared an invaluable reagent for the convenient one-pot preparation of acyl azides
directly from carboxylic acids. After the isocyanates had been formed, the mixture was
cooled to ambient temperature and anomerically unprotected glucuronate 9 was added.
Following this scheme, b -D-glucuronyl carbamates 17 can be obtained in a one-pot
procedure from acids 1 1  in good to excellent yields in more than 95%
b -diastereoselectivity. For further details concerning the addition reaction of 9 and
other anomerically unprotected glycosyl donors to isocyanates, see section 5.1.
When applied to the preparation of prodrugs, dicarboxylic acid monoesters 19 (scheme
3.6) are processed in the modified Curtius reaction. These acids 19 are readily accessible
from a variety of commercially available g - and d -anhydrides 18 and dicarboxylic acids
so that the synthetic procedure depicted in scheme 3.6, is a versatile method giving
access to a large number of target compounds.
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  for  complete structure of prodrugs, see chart 3.1
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Scheme 3.6   Synthesis of prodrugs GB1 - 10.
3.3.2 Preparation of dicarboxylic acid monoesters
Carboxylic acid esters 19 (scheme 3.6) for prodrugs DAU-GB2 - 4 are readily prepared
by ring opening of the respective commercially available cyclic anhydrides 18. In case
of the unsymmetrical anhydride 28  (scheme 3.7), ring opening resulted in the
predominant formation of g -dimethyl  glutaric acid allyl esters 29. The a -dimethyl
isomer 30 was formed to a much smaller extent. It was not possible to determined the
ratio of the isomeric products using 1H-NMR because of overlap of signals [14]. The
mixture could not be separated and was used as such in subsequent reaction steps.
Later on in the synthesis of DAU-GB3, however, when the corresponding pro-moieties
48b/49b were coupled to daunorubicin, both isomeric coupling products 48c and 49c
(scheme 3.9) could be separated.
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Scheme 3.7   Preparation of starting material for prodrugs DAU-GB1-4.
Homophthalic anhydride 33 (scheme 3.8) is a versatile starting material for the
synthesis of prodrugs DAU-GB5 - 10 (presented in chart 3.1). This unsymmetrical
anhydride was opened regioselectively with allyl alcohol affording monoallyl ester 34,
which is the starting material for prodrug DAU-GB5 (chart 3.1), in a high yield.
Because of its efficient and smooth removal, the allyl group was chosen to protect one
of the carboxylic acid units of the spacer moiety. Kunz and co-workers have developed
a number of methods to unmask allyl-type protected alcohol- amine-, and carboxylic
acid functional groups [15]. This methodology is suitable for syntheses in the field of
carbohydrate chemistry. The other isomer having the allyl group on the aromatic acid
was not detected in this reaction. The preference for opening of the anhydride at the
phenylacetic acid side of the molecule is attributed to the facts that the benzoic acid
fragment is a better leaving group than the phenylacetic acid part and that in case of
attack of a nucleophile on the aromatic acid carbonyl, this would lead to a tetrahedral
intermediate in which the conjugation of the carbonyl with the aromatic ring is no
longer present.
The starting material for DAU-GB8 (chart 3.1), tert.-butyl ester 36, was easily prepared
from 34 via diester 35 (scheme 3.8). Examples of selectively demasking a tert.-butyl
esters in the presence of carbohydrate acetal functionalities are described in the
literature [16].
Spaced Prodrugs I Spacer Elimination by Ring-closure 47
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
O
O
O O
OH
O O
O
O
O O
O
O
O O
Me
O
O
O OH
O
O
O O
Si
O
O
O O
Me
Me
Si
O
O
O OH
Me
Me
Si
37 35
O
O-
O O
40
38
41
Me
Me
39
42
33
O
O
O
Me Me
HO
O
OH
O O
Me
O
O
O OH
45
34 36
Me
44
ii
i
iiiiv
v
iiivi
v
iiivii
AllOH, DMAP
isobutene, H2SO4, CH2Cl2
Pd(PPh3)4, morpholine, THF
2-(TMS)ethanol, DCC, DMAP, CH2Cl2
NaH, MeI, 18-crown-6, DMF, 0 -> 20 ° C
TBAF, THF
CF3CO2H, CH2Cl2
v
O
O
O O
Me
Me
X
43
i:
ii:
iii:
iv:
v:
vi:
vii:
Scheme 3.8   Preparation of starting material for prodrugs DAU-GB5 - 10.
For the synthesis of prodrugs containing additional methyl groups in the spacer, bis-
protected homophthalic acid 35 was methylated at the benzylic position using sodium
hydride and methyl iodide. Despite variation of reaction temperature and -time and
addition of a crown ether, the dimethylated product 42 could not be obtained. Probably
due to steric hindrance of the bulky tert.-butyl group, only the monomethyl derivative
43 was obtained in all cases. Removal of the tert.-butyl group of 43 afforded 44, being
the starting material for prodrug DAU-GB6. Removal of the allyl group of 43 led to 45
which is the starting material for DAU-GB9.
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To study whether the tert.-butyl group actually impeded bis-methylation of the
benzylic carbon atom of 35, the carboxylic acid group of 34 was protected with a
sterically less demanding group. For this purpose, the 2-trimethylsilylethyl ester 37 was
prepared. This functionalized ethyl ester can be unmasked selectively with fluoride
ions in the presence of other esters groups in a b -elimination reaction to give ethylene,
trimethylsilyl fluoride and the carboxylate salt [17]. Furthermore, the ester is unaffected
under the reaction conditions required for methylation. In contrast to 35 ,
bismethylation of 37 was feasable and led to 38. Removal of the 2-trimethylsilyl ethyl
group with TBAF, however, did not lead to the desired product 39 (starting material for
DAU-GB7), but instead anhydride 41 was obtained instead almost quantitatively. A
likely mechanism for this reaction is cyclization by intramolecular attack of the
carboxylate anion on the adjacent allyl ester whereby both methyl groups facilitate ring
closure by pushing the phenylacetic acid ester towards the benzoic acid fragment
(stereopopulation control). Attempts to open a ,a -dimethyl homophthalic anhydride 41
with allylalcohol analogously to the unsubstituted homophthalic acid 33 failed.
Removal of the allyl group of 38 led to 40, the starting dicarboxylic acid monoester for
the synthesis of prodrug DAU-GB10.
3.3.3 One-pot synthesis of b -D-glucuronyl carbamate pro-moieties from spacer 
carboxylic acids and further reactions to prodrugs
As outlined in scheme 3.6, a one-pot modified Curtius reaction of dicarboxylic acid
monoesters with general structure 19 and the subsequent reaction with glucuronyl
donor 9 led to protected pro-moieties of general structure 21. In the specific cases
(scheme 3.9), glutaric acid derivatives 27 and the mixture 29/30 cleanly gave protected
pro-moieties 47a and 48a/49a, respectively. Protected pro-moiety 46a was obtained by
the addition reaction of glucuronyl donor 9 to the isocyanate obtained from amine
hydrochloride 25 and phosgene. The allyl-protected carboxylic acid groups of 46a - 50a
are demasked almost quantitatively using Pd(0) to transfer the allyl group to
morpholine [15] that is used in five-fold excess, yielding 46b - 50b. To obtain the
protected prodrugs 46c - 49c, the carboxylic acid groups of the corresponding pro-
moieties 46b - 49b were coupled to daunorubicin. A number of different methods and
reagents were examined for this amide coupling reaction such as DCC, DCC/N-
hydroxy succinimide, N,N'-disuccinimidyl carbonate (DSC) [18], N,N-bis[2-oxo-3-oxazo-
lidinyl]phosphorodiamidic chloride (BOP-Cl, compound 53 scheme 3.9) [19], O-(benzo-
triazol-1-yl)-N,N,N',N'-tetramethyl uronium tetrafluoroborate (TBTU) [20] and diphenyl
phosphoryl azide (DPPA) [11a]. The (benzotriazol-1-yloxy)tris(dimethylamino)phos-
phonium hexafluorophosphate reagent [21] (BOP, compound 63 scheme 3.11), however,
gave the best results. Analogously to the final deprotection step in the synthesis of
DAU-GA1 (scheme 2.11), target compounds DAU-GB1 - 3 were obtained after LiOH-
mediated hydrolysis of the four protective groups of the b -D-glucuronyl entity.
Additionally, DAU-GB11 was obtained after deprotection of the isomeric side product
49c obtained in the synthesis of DAU-GB3.
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Scheme 3.9   Preparation of prodrugs DAU-GB1 - 3.
Surprisingly, when it was attempted to couple 50b to daunorubicin using the BOP
coupling reagent (compound 63 scheme 3.10), the expected protected prodrug 50c
containing the biphenyl spacer was not obtained (scheme 3.9). Variation of reaction
temperature and use of other peptide coupling reagents for this condensation reaction
always produced the protected precursor of DAU-GA1, compound 52 (i.e. 38 b  in
scheme 2.11) in high yield. Together with this compound, the cyclized biphenyl spacer,
viz phenanthridinone 51, was formed. Apparently, cyclization of the biphenyl spacer is
very facile and target prodrug DAU-GB4 was not obtained because of this premature
spacer elimination. It is of interest to note that this novel glycosyl-carbonyl transfer
reaction offers the alternative possibility to prepare b -D-glycosyl carbamates from
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primary or secondary amines which can not be transformed into isocyanates to make
b -D-glycosyl carbamates. This new chemistry is further outlined in section 5.2.
To avoid premature cyclization of the -GB4 spacer, methylation of the spacer nitrogen
atom was considered to prevent intramolecular attack of this nitrogen atom on the
adjacent ester (for a mechanism of the cyclization reaction, see section 5.2, scheme 5.7).
When the N-biphenyl O-b -D-glucuronyl carbamate 50a was treated with silver oxide
and methyl iodide in DMF [22] (scheme 3.10), the nitrogen atom was methylated and
yielded the N-methyl derivative 54a. Removal of the allyl group using Pd(0) /
morpholine and subsequent coupling of the resulting acid 54b to daunorubicin using
BOP, resulted in the desired coupling product 54c. Using the N-methyl analog of the
-GB4 pro-moiety to prepare the corresponding prodrug, no spacer elimination took
place as was the case for the conversion of 50b into 52 (in scheme 3.9). Deprotection of
54c resulted in the N-methylated prodrug DAU-Me-GB4.
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Scheme 3.10   Synthesis of N-methyl DAU-GB4.
Analogously to the syntheses of prodrugs DAU-GB1 -3 (scheme 3.9), homophthalic
acid monoesters 34 , 36  and 45 (depicted in scheme 3.8) were processed to obtain
prodrugs DAU-GB5, -GB8 and -GB9, respectively (scheme 3.11). Using trifluoroacetic
acid and carefully excluding moisture, the tert.-butyl group of 56b and 60b was easily
removed whilst the carbohydrate acetal linkage was left unaffected[16]. When
demasking the allyl ester of 57 (obtained from mono a -methylated acid 44, depicted in
scheme 3.8), only glucuronic acid 9 and amino acid 59 were isolated. The fragmentation
of free carboxylic acid 58  is probably due to acid-catalyzed hydrolysis of the
b -D-glucuronyl carbamate by the carboxylic acid during work-up. Similarly to this,
demasking of allyl ester 55a to 55c led to decomposition products, but sufficient intact
pro-moiety was isolated and could be coupled to daunorubicin [23].
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Scheme 3.11   Preparation of prodrugs DAU-GB5, -GB8 and -GB9.
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When a ,a -dimethyl homophthalic acid derivative 40 was processed in the modified
Curtius reaction following the usual procedure (see general procedure #2 in the
experimental section), no reaction was observed. When the reaction mixture was heated
to 95ºC after glucuronyl donor 9 had been added, exclusively cyclization product 62
was obtained in 39% yield after column chromatography as was established by
1H-NMR and mass-spectrometry. This premature cyclization reaction demonstrates
that the geminal methyl groups on the spacer indeed facilitate the intramolecular
cyclization.
3.4 Evaluation of the synthesized prodrugs for application in 
ADEPT [24]
3.4.1 Enzymatic activation rates
The synthesized prodrugs were designed to be activated to daunorubicin in a two step
process, according to scheme 3.12, viz. step i. Hydrolysis of the b -D-glucuronyl
carbamate specifier by b -glucuronidase and step ii. self elimination of the spacer by ring
closure. Spacers were incorporated between drug and specifier to facilitate enzymatic
hydrolysis.
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NH
OOO
HO
HO
NaO2C
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+
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Me Me
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5
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 pH = 6.8, 37 ° C.
* For structure, see scheme 3.10.
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?
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Scheme 3.12   Hydrolysis of prodrugs. Table 3.2   b -Glucuronidase mediated hydrolysis
of prodrugs to drug-spacer molecules.
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The structure of the spacer influences both step i. and ii.. Because detailed information
concerning the active site of human b -glucuronidase is not known, construction of a
spacer to achieve optimal hydrolysis rates on rational grounds is not possible. In
contrast to this "black box" situation of step i. (scheme 3.12), the cyclization reaction of
step 2 is much better understood. As described in section 3.2.2, the intramolecular
cyclization reaction is accelerated by stereopopulation control of the spacer. Under
physiological conditions, a proper preorganization of the spacer is a prerequisite for a
favorable elimination rate. Therefore, prodrugs were designed containing spacers with
increasing cyclization tendency according to stereopopulation control. Disappointingly,
the synthesis of three of the designed prodrugs, DAU-GB6, 7 and 10 (see chart 3.1)
could not be accomplished. Prodrugs DAU-GB7 and -10 were expected to have high
cyclization rates on account of stereopopulation control.
Concerning the mechanism of spacer elimination, the rate-determining step in the intra-
molecular aminolysis of amides is a general-acid-catalyzed formation of tetrahedral
intermediate 65 (scheme 3.13) [5a, 7d,  8a]. The electronic nature of the leaving amine was
reported to have a minor effect on the rate constant because breakdown of the
tetrahedral intermediate 66 occurs after the rate-determining step [5a, 7d, 8a]. Therefore,
in case of the present prodrugs, it was expected that the poor leaving ability of
3'-N-daunorubicinyl group would not impede the intramolecular cyclization reaction.
O
NH R
NH2..
H A
O
NH R
NH2
+
slow
O
NH2 R
NH
+
H H
fast
O
H2N R
NH
+
rate determining step,
general acid catalyzed
64 65 66 67
Scheme 3.13   Cyclization of amino amides.
For the determination of the enzymatic activation rates, prodrugs were incubated with
human b -glucuronidase at pH = 6.8 [25]. Compared to DAU-GA1 (Ch. 2), which was
activated very slowly by b -glucuronidase (t1/2 = 8200 min, see table 2.3), all the present
prodrugs were hydrolyzed more easily (table 3.2). The incorporation of a spacer
between drug and specifier proved to accelerate enzyme hydrolysis rates. Disappoin-
tingly, all prodrugs, except DAU-Me-GB4, were not converted to daunorubicin upon
hydrolysis by b -glucuronidase but to the corresponding drug-spacer molecule (scheme
3.12). The desired elimination of the spacer by ring closure did not take place and
daunorubicin was not recovered. When DAU-Me-GB4 , was incubated with
b -glucuronidase, daunorubicin was formed but the activation half-life was too slow to
be of interest for application in ADEPT (t1/2 >5000 min).
although the present prodrugs were not activated to produce daunorubicin, the rates of
the enzymatic hydrolysis of some prodrugs were remarkable. Compound DAU-GB8
was hydrolyzed smoothly (see table 3.2), about 1600 times faster than DAU-GA1. A
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striking difference in hydrolysis rates was observed for prodrugs containing additional
methyl groups on the aliphatics spacer when compared to DAU-GB1. Hydrolysis rates
of these prodrugs (DAU-GB2, -GB3 and -GB11) were increased. On the other hand,
prodrug DAU-GB9, having an additional methyl group on the benzylic position of the
spacer compared to DAU-GB8, was hydrolyzed very slowly (t1/2 >1000 min), also
spacer elimination did not take place. In this case the additional methyl group retarded
the hydrolysis more than 200-fold (table 3.2). In this light, prodrug DAU-GB10 (its
synthesis could not be accoplished) containing two additional methyl groups compared
to DAU-GB8 (chart 3.1), is expected to be hydrolyzed by b -glucuronidase very slowly.
It is therefore concluded that stereopopulation control does not seem a conceivable
strategy to realize immolative spacer cyclization, because stereopopulation control has
an opposing effect on the initial enzymatic hydrolysis step.
3.4.2 Cytotoxicities
The in vitro cytotoxicities of all prodrugs [24] were determined on OVCAR-3 cells and
compared to the toxicity of daunorubicin. the prodrugs were 20 to 100-fold less toxic
than daunorubicin. Because the prodrugs of the present chapter were not activated to
produce daunorubicin, exact data of prodrug cytotoxicities were not collected.
3.5 Alternative approach to spacer cycloelimination
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-
Scheme 3.14   Intramolecularly catalyzed spacer cyclization.
In scheme 3.14, a possibility is presented to accomplish spacer elimination of prodrug
DAU-GB8, which was hydrolyzed very fast by b -glucuronidase to the corresponding
drug-spacer molecule (t1/2 = 5 min, scheme 3.12 and table 3.2). As mentioned earlier,
drug-spacer molecule 68, obtained from DAU-GB8 after b -glucuronide hydrolysis, did
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not convert to daunorubicin and the corresponding lactam. The inability of 68 to
undergo spontaneous cycloelimination may be attributed to a low reactivity of the
amide function in this substrate to nucleophylic attack. It is now proposed to stabilize
the initial sp3 intermediate during the intramolecular aminolysis through anchimeric
assistance. This can, in principle, be realized by the introduction of a hydroxyl group in
the ortho-position to the amide carboxyl function, as in 69 (scheme 3.14). The intramole-
cular aminolysis should then proceed via the stabilized sp3 intermediates 71 and 72 to
eventually give cycloelimination as shown in scheme 3.14. In the literature, the
proposed anchimeric assistance of an ortho-hydroxy group has been demonstrated for
the intramolecular aminolysis of an ester, whereby this hydroxyl function served as an
intramolecular general acid catalyst [26].
OHO
HO
OHO
OO
O
OHO
Si
NH
OO
OAcOAcO
MeO2C
AcO
OO
O
Si
OHO
PMBO
OHO
OHO
X
NH
OO
OAcOAcO
MeO2C
AcO
OHNH
O
NH
OO
OAcOAcO
MeO2C
AcO
daunorubicin-3'-
Cl
Si
Cl
i
iv
iv
OHO
O
O
viiX
X
vi
1)
3)
73
76
78
77
O P N3
OPh
OPh
79a 80
AcCl
OAcOAcO
MeO2C
AcO OH
2)
 60 - 100 ° C
iv:
Et3N
9
vi: H2, Pd/C
i:
imidazole
ii:
iii:
vii: coupling to daunorubicin
79b
a: X = -OPMB
b: X = -OH
OHO
HO
OO
ii
iii
AllOH, DMAP
 
2) Pd(PPh3)4, morpholine
1)
v
v: 1) PMBOH, DCC, DMAP
2) Pd(PPh3)4, morpholine
74
75
PMB = 
OMe
Scheme 3.15   Attempts to prepare prodrug 69 (scheme 3.14).
Disappointingly, however, attempts to prepare prodrug 69 failed (scheme 3.15). For the
purpose outlied above, 6-hydroxy homophthalic acid (73), prepared according to
literature procedures [27], was converted to the anhydride 74 which was opened with
allylalcohol to give allylester 75. This compound was bis-protected with the di-tert.-
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butylsilene group and the allyl ester was removed to give compound 76. A modified
Curtius reaction of 76, however, did not give the desired b -D-glucuronyl carbamate
product 77. Loss of the silyl protecting group and subsequent side product formation
was observed. It was then decided to prepare prodrug 69 from acid 73 analogous to the
synthesis of DAU-GB8 from 36 (scheme 3.8 and 3.11) but using a p-methoxybenzoyl
protecting group instead of a tert.-butyl protecting group. Modified Curtius reaction of
78 led to the b -D-glucuronyl carbamate 79a. After removal of the p-methoxybenzyl
group of 79a, however, it was not possible to couple the resulting acid 79b to dauno-
rubicin using the BOP coupling reagent and as a consequence compound 80 was not
obtained. Other coupling reactions have sofar not been tried. In spite of the
disappointing results, compound 69 remains an interesting candidate as a prodrug.
3.6 Experimental part
3.6.1 Biological evaluation
Cytotoxicities
The cytotoxicities of the prodrugs were determined as described in section 4.5.1.
Prodrug activation half-lives
The enzymatic activation rates of the prodrugs were determined by incubation of 100
m M of prodrug in 0.1% BSA/PBS at pH = 6.8 with 0.03 U/mL human b -glucuronidase
at 37ºC. Samples were prepared and analyzed on reversed phase SiO2-C18 HPLC as
described [24].
3.6.2 Chemistry
General
Daunorubicin hydrochloride DAU-HCl was a generous gift from PharmaChemie BV
Haarlem. Chromatotron model 7924-T Harrison Research (Palo Alto, California, USA)
equipped with plates (thickness 2 mm, diameter 8.5 cm) made form Merck silicagel 60
PF254 which contains gypsum (art. 7749) was used when circular chromatography is
indicated. Reversed phase chromatography was performed with a liquid
chromatography pump LC-410 (Kontron) using a pre-packed column (24 cm, diameter
11 mm) containing octadecylsilane (40-63 m m) (Merck, Darmstadt). Prior to use the RP-
C18 column was equilibrated with demineralized water. 1H NMR spectra at 400 MHz
were obtained on a Bruker AM-400 spectrometer, spectra at 100 MHz on a Bruker AM-
100 spectrometer. Chemical shifts are expressed in ppm downfield from internal
standard Me4Si. All solvents were dried before use: Et3N, CH2Cl2 and PhMe were dried
by distillation over CaH2, pyridine by distillation over CaCl2 and THF by distillation
over LiAlH4 or sodium. i-Pr2NEt was dried over KOH pellets. In all cases demineral-
ized H2O was used. Allyl alcohol was dried by distillation over Mg/I2.
General Procedure #1: Opening of cyclic anhydrides with AllOH (scheme 3.7 and 3.8).
The commercially available anhydrides were dissolved in AllOH (2.0 g anhydride in 10-15 mL AllOH)
and ca. 10 mol% DMAP was added and the reaction was stirred overnight. After that, the AllOH was
removed by evaporation under reduced pressure and the residue was dissolved in Et2O and washed
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successively with 100 mL portions of 0.5 N aqueous NaHSO4 and brine. The organic fraction was dried
over Na2SO4 and concentrated to dryness. Traces of allyl alcohol were removed by azeotropic distillation
with n-Hex to obtain the respective dicarboxylic acid monoesters in > 80% yield as colorless liquids.
General procedure #2: Modified Curtius procedure for conversion of carboxylic acids to 
b -D-glucuronyl carbamates (scheme 3.9 and 3.11).
500 mg of dicarboxylic acid mono ester prepared as described above was stirred overnight with 1.1
equiv. of (PhO)2P(O)N3 and 1.1 equiv. of Et3N in 15 mL of dry PhMe under an argon atmosphere at room
temperature. The reaction mixture was subsequently heated until gas evolution was observed, occurring
between 65-100ºC depending on the actual substrate. heating was continued for 2 h. In case of aromatic
or benzylic isocyanates, the reaction mixture was allowed to cool to ambient temperature and for
aliphatic isocyanates the reaction mixture was cooled down to 60ºC. 0.5-0.75 equiv. [28] of the
anomerically unprotected glucuronate 9 were added. The reaction mixture was stirred until 9 had almost
disappeared on TLC (SiO2, Et2O). After that, the reaction mixture was diluted with 100 mL of Et2O and
successively washed with 200 mL portions of aqueous 0.5 N KHSO4, saturated aqueous NaHCO3 (3x)
and brine. The organic layer was dried over Na2SO4 and evaporated. The residual material was purified
by column chromatography (SiO2, Et2O/n-Hex 4/1) to yield the respective 1-O-b -D-glucuronyl
carbamates in good to excellent yield and in 95-100% b -diastereoselectivity.
General procedure #3: Demasking of allyl esters using Pd(0) (scheme 3.8 to 3.11).
300 mg of allyl ester was dissolved in 25 mL of dry THF and 5 equiv. of morpholine were added. During
30 min, argon was bubbled through the solution to remove oxygen. After that, a catalytic amount of
Pd(PPh3)4 was added and the mixture was stirred for 20 min under an argon atmosphere. Completion of
the deprotection was checked by TLC (SiO2, Et2O) and when necessary, an additional small amount of
the Pd(0) complex was added. After all starting material had disappeared, 100 mL of an aqueous 5%
KHSO4 solution was added. The aqueous solution was washed with two 100 mL portions of Et2O, the
organic extract was washed with brine, dried over Na2SO4 and evaporated. To remove the Pd complex,
the residue was dissolved in either n-Hex, i-Pr2O or Et2O depending on the polarity of the product, and
the precipitated orange-brown Pd complex was filtered of. The solvent was removed to furnish the free
carboxylic acid in (near) quantitative yield. 1H-NMR spectra are not given because they are similar to the
respective allyl ester precursors except for the absence of the allyl protons. Coupling of the thus obtained
pro-moieties to daunorubicin was executed without delay to minimize decomposition of the pro-moiety.
General procedure #4: Demasking of tert.-butyl esters using CF3CO2H (scheme 3.8 and 3.11).
100 mg of tert.-butyl ester was dissolved in 2.0 mL of CH2Cl2 under an argon atmosphere and 300 m L of
CF3CO2H was added. After 1 h, the solvents were evaporated and traces of CF3CO2H were removed
under high vacuum to yield the free carboxylic acids in near quantitative yield. 1H-NMR spectra are not
given because they are similar to the respective tert.-butyl ester precursors except for the absence of the
tert.-butyl protons. Coupling of the thus obtained pro-moieties to daunorubicin was executed without
delay to minimize decomposition of the pro-moiety.
General procedure #5: Coupling of the pro-moiety-CO2H group to the 3'-NH2 function of 
daunorubicin using BOP-Cl or BOP (scheme 3.9 and 3.11).
BOP-Cl coupling
100 mg of pro-moiety-CO2H 47b or 48b/49b and 2.5 equiv. of i-Pr2NEt were dissolved in CH2Cl2 and
cooled to 0ºC. 1.2 equiv. of BOP-Cl 53 (scheme 3.9) were added. The mixture was allowed to warm to
ambient temperature and was stirred for 1 h and 1.5 equiv. of DAU-HCl and 3 equiv. of i-Pr2NEt were
added. The coupling reaction was stirred overnight and worked-up as described below.
BOP coupling
100 mg of pro-moiety-CO2H 55c, 56c or 60c, 1.1 equiv. of BOP 63 (scheme 3.11), 3 equiv. of i-Pr2NEt and
1.1 equiv. of DAU-HCl were stirred under an argon atmosphere at ambient temperature for 15-120 min,
the course of the coupling reaction was monitored on TLC (SiO2, CH2Cl2/EtOH 10/1). After that, the
reaction mixture was diluted with 150 mL of CH2Cl2 and washed successively with 200 mL portions of
aqueous 0.5 N KHSO4 (3x), saturated aqueous NaHCO3 and brine. The organic layer was dried over
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Na2SO4 and evaporated. The resulting red residue was purified by means of circular chromatography
using a chromatotron supplied with a 2 mm thick silica plate and mixtures of CH2Cl2/EtOH 10/1 (first
run) and 20/1 or 30/1 (successive runs) until the protected prodrug was a single spot on TLC (SiO2,
CH2Cl2/EtOH 20/1). After evaporation of the eluent, the product was sonicated in i-Pr2O and collected
by filtration to yield the protected prodrug as red powder.
General procedure #6: Deprotection of the b -D-glucuronyl specifier in the protected prodrugs 
(scheme 3.9 and 3.11).
To the protected prodrug were added 6 equiv. of a 0.10 N LiOH solution in MeOH/H2O/THF 2.5/1/0.5.
the resulting deep blue solution was stirred at 0ºC under an argon atmosphere and progress of the
deprotection reaction was continuously monitored by reversed phase TLC (SiO2-C18, MeCN/H2O 1/1).
After 15-90 min of deprotection, the reaction mixture was diluted to ca. twice the volume with H2O and
neutralized by adding ca. 2 g of amberlite cation exchange material (H+ form) per 100 mg of protected
prodrug, 25 vol% of THF were added. This was stirred until the deep blue solution turned red. The
amberlite material was removed by filtration and ca. 10 equiv. of NaHCO3 were added to convert the
glucuronyl carboxylic acid to the sodium salt. The MeOH and THF suspended in the water layer were
removed by evaporation and the red aqueous product solution was transferred it to a reversed phase
column packed with RP-C18 material. To remove the excess of NaCO3, the column was eluted with ca. 300
mL of H2O. The product stayed on the column. The column was then washed with MeCN/H2O 1/4 to
elute the product and the MeCN was removed by evaporation. In cases where the prodrug was not a
single spot on TLC, the aqueous solution was again transferred to the reversed phase column and
purified once more by eluting a MeCN/H2O mixture in a ratio of 1/4 to 1/10. The MeCN was removed
by evaporation and freeze drying of the aqueous product solution afforded the prodrug as red fluffy
solid.
General procedure #7: a -methylation of homophthalic acid diesters 37 and 35 (scheme 3.8).
500 mg of 37 or 35 was dissolved in 10 mL of DMF and 10 equiv. of MeI and 0.1 equiv. of 18-crown-6
were added and the mixture was cooled to 0ºC. 4 equiv. of NaH were added and the reaction mixture
was stirred for 3 days at ambient temperature under an argon atmosphere. After that, the mixture was
diluted with ca. 100 mL of n-Hex and washed with 100 mL portions of a 5% aqueous solution of KHSO4,
H2O, saturated aqueous NaHCO3 and brine. The solution was dried over Na2SO4 and evaporated. The
crude diester was purified by flash-column chromatography (SiO2, Et2O/n-Hex 1/6) to yield 38 or 43,
respectively, as slightly yellow oils.
____________
Synthesis of N-g -(daunorubicin-3'-N-butyryl) O-b -D-glucuronyl carbamate sodium salt (DAU-
GB1).
g -Amino butyric acid allyl ester (25). 7.5 g of 24 was dissolved in 75 mL of AllOH and cooled to 0ºC. 40 mL
(2.9 equiv.) of SOCl2 were added slowly using a dropping funnel. The reaction was stirred overnight at
ambient temperature. After this, the reaction mixture was filtered to remove solid material and the
filtrate was evaporated. AllOH was removed by azeotropic distillation with n-Hex. The 13.7 g thus
obtained brown oil of impure 25 was used without further purification.
g -Isocyanato butyric acid allyl ester. 13.7 g of impure 25 was dissolved in 75 mL of PhMe. During 2.5 h, the
solution was heated to reflux while bubbling phosgene through. After this, argon was bubbled through
and stirring was continued for 1 h. The reaction mixture was concentrated by evaporation under reduced
pressure and  distilled to give the isocyanate, 8.2 g 67% from 24, as a colorless oil, bp 82ºC (2 mm Hg). 1H-
NMR (100 MHz, CDCl3) d  (ppm) = 1.93 (k, 2H, -CH2CH2CH2-, J = 6.5 Hz), 2.46 (t, 2H, -CH2CH2CO2-, J =
7.0 Hz), 3.41 (t, 2H, -CH2CH2NCO, J = 6.5 Hz), 4.59 (dt, 2H, -OCH2CH=, J = 1.2 Hz J = 5.6 Hz), 5.15-5.45
(m, 1H, =CH2), 5.70-6.15 (m, 1H, -CH=).
N-g -(Butyric acid allyl ester) O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (46a). 63 m L Of the latter
isocyanate was dissolved in 5 mL of PhMe and 104 mg (0.8 equiv.) of 9 and a catalytic amount of Et3N
were added. The reaction was stirred overnight at 50ºC and worked up as described according to general
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procedure #2 to obtain 139 mg of 46a in 74% yield and 95% b -diastereoselectivity as a colorless oil, 1H-
NMR (100 MHz, CDCl3) d  (ppm) = 1.70-1.90 (m, 2H, -CH2CH2CH2-), 2.01 (s, 9H, 3 -OAc), 2.36 (t, 2H,
-CH2CH2CO2-, J = 7.4 Hz), 3.20 (dd, 2H, -CH2CH2NH-, J = 6.7 Hz J = 12.9 Hz), 3.69 (s, 3H, -CO2Me), 4.17
(d, 1H, Gluc5-H, J = 9.3 Hz), 4.54 (dt, 2H, -OCH2CH=, J = 1.4 Hz J = 5.6 Hz), 5.05-6.10 (m, 6H, =CH2 -CH=
-NH- Gluc2,3,4-H), 5.69 (d, 1H, Gluc1-H, J = 7.6 Hz).
N-g -(Daunorubicin-3'-N-butyryl) O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (46c). The allyl ester
of 46a was removed according to general procedure #3 furnishing 46b  which was coupled to
daunorubicin without delay. 70 mg (0.172 mmol) of 46b  and 24 mg (1.2 equiv.) of N-hydroxy succinimide
were dissolved in 11 mL of MeCN and cooled to 0ºC. 37 mg (1.05 equiv.) of DCC and a catalytic amount
of DMAP were added. The reaction was stirred at 0ºC for 1 h and additionally for 1 h at ambient
temperature. After this the mixture was filtered and evaporated. The crude active ester thus obtained
was dissolved in 10 mL of DMF and 104 mg (1.05 equiv.) of DAU-HCl and 77 m L (2.5 equiv.) of i-Pr2NEt
dissolved in 5 mL of DMF were added. The reaction was stirred overnight and worked-up according to
general procedure #5 to obtain 46c in 71%, mp 90-95ºC, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.30 (d,
3H, 5'-Me, J = 6.4 Hz), 1.65-2.25 (m, 6H, 2'ax-H 2'eq-H 8ax-H -CH2CH2CH2- 4'-OH), 2.02, 2.03 and 2.04 (3s,
9H, 3 -OAc), 2.32 (d, 1H, 8eq-H, J = 14.7 Hz), 2.42 (s, 3H, 9-C(O)Me), 2.80-3.00 (m, 2H, -CH2CH2C(O)-), 2.88
(d, 1H, 10ax-H, J = 18.8 Hz), 3.10-3.35 (m, 2H, -CH2CH2NH-), 3.20 (d, 1H, 10eq-H, J = 18.6 Hz), 3.69 (s, 1H,
4'-H), 3.74 (s, 3H, C(O)OMe), 4.05 (s, 3H, 4-OMe), 4.10-4.25 (m, 3H,Gluc5-H 5'-H 3'-H), 4.52 (s, 1H, 9-OH),
5.10 (t, 1H, Gluc2-H, J = 8.5 Hz), 5.15-5.40 (m, 3H, Gluc3,4-H 7-H), 5.49 (d, 1H, 1'-H, J = 3.0 Hz), 5.63, t,
1H, -CH2NH-, J = 5.9 Hz), 5.68 (d, 1H, Gluc1-H, J = 7.9 Hz), 6.22 (d, 1H, 3'-NH-, J = 8.4 Hz), 7.36 (d, 1H, 3-
H, J = 8.5 Hz), 7.76 (t, 1H, 2-H, J = 8.1 Hz), 8.00 (d, 1H, 1-H, J = 7.7 Hz), 13.23 (s, 1H, 11-OH), 13.96 (s, 1H,
6-OH).
N-g -(Daunorubicin-3'-N-butyryl) O-b -D-glucuronyl carbamate sodium salt (DAU-GB1) from 46c according to
general procedure #6 in 98%, mp 188ºC (dec.), elem. anal.: calc. (found) for C48H43N2O19Na.6 H2O: C:
47.40 (47.02), H: 5.76 (5.18), N: 2.91 (3.05). MS (FAB+) m/z = 856 ([M+1+H]+), 855 ([M+H]+). 1H-NMR (100
MHz, (CD3)2SO) d  (ppm) = 1.11 (d, 3H, 5'-Me, J = 6.4 Hz), 1.30 (m, 3H, 2'eq-H -CH2CH2CH2-), 1.82 (td, 1H,
2'ax-H, J = 12.1 Hz J = 3.6 Hz), 1.90-2.20 (m, 4H, -CH2CH2C(O)- 8ax-H 8eq-H), 2.25 (s, 3H, 9-C(O)Me), 2.95
(d, 1H, 10eq-H, J = 9.8 Hz), 3.00-3.10 (m, 2H, -CH2CH2NH-), 3.16 (d, 1H, 10ax-H, J = 9.8 Hz), 3.20-3.50 (m,
4H, 4'-H Gluc2,3,4-H), 3.97 (s, 3H, 4-OMe), 4.15 (q, 1H, 5'-H, J = 6.6 Hz), 4.94 (bs, 1H, 7-H), 5.02 and 5.07
(2s, 2H, 2 -OH), 5.12 (d, 1H, Gluc1-H, J = 8.1 Hz), 5.21 (bs, 1H, 1'-H), 5.53 (s, 1H, 9-OH), 7.25 (t, 1H,
-CH2CH2NH-, J = 5.9 Hz), 6.63 (bs, 2H, 3-H 3'-NH-), 7.85-7.90 (m, 2H, 1-H 2-H), 13.27 (s, 1H, 11-OH),
14.04 (s, 1H, 6-OH).
Synthesis of N-g -[daunorubicin-3'-N-(3,3-dimethyl)butyryl] O-b -D-glucuronyl carbamate 
sodium salt (DAU-GB2).
3,3-Dimethyl glutaric acid mono allyl ester (27) from 26 in 78% according to general procedure #1, 1H-NMR
(100 MHz, CDCl3) d  (ppm) = 1.15 (s, 6H, 2 -Me), 2.49 (s, 4H, 2 -CH2-), 5.58 (dt, 2H, -OCH2-, J = 6.0 Hz J =
1.2 Hz), 5.15-5.45 (m, 2H, =CH2), 5.70-6.15 (m, 1H, -CH=), 11.51 (bs, 1H, -CO2H).
N-g -[(3,3-Dimethyl)butyric acid allyl ester] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (47a) from
27  according to general procedure #2 as a white foam, mp 30-33ºC in 82% yield and 98% b -
diastereoselectivity, 1H-NMR (100 mHz, CDCl3) d  (ppm) = 1.00 (s, 6H, -C(Me)2-), 2.03 (s, 9H, 3 -OAc), 2.25
(s, 2H, -C(Me)2CH2CO2-), 3.13 (d, 2H, -C(Me)2CH2NH-, J = 6.7 Hz), 3.74 (s, 3H, -CO2Me), 4.16 (d, 1H,
Gluc5-H, J = 9.8 Hz), 4.57 (d, 2H, -OCH2CH=, J = 5.9 Hz), 5.10-5.95 (m, 6H, =CH2 -CH= -NH- Gluc2,3,4-
H), 5.72 (d, 1H, Gluc1-H, J = 8.1 Hz).
N-g -[(3,3-Dimethyl)butyric acid] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (4 7 b ) from 47a
according to general procedure #3.
N-g -[Daunorubicin-3'-N-(3,3-dimethyl)butyryl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (47c)
from 47b according to general procedure #5 in 24%, mp 148-150ºC, 1H-NMR (100 MHz, CDCl3) d  (ppm) =
0.94 and 0.96 (2 s, 6H, 2 -CMe2-), 1.30 (d, 3H, 5'-Me, J = 6.5 Hz), 1.75-1.95 (3H, 2'ax-H, 2'eq-H 4'-OH), 2.00,
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2.02 and 2.04 (3 s, 9H, 3 -OAc), 2.00-2.20 (m, 3H, 8ax-H, -CMe2CH2C(O)-), 2.02, 2.03 and 2.04 (3s, 9H, 3
-OAc), 2.32 (d, 1H, 8eq-H, J = 14.8 Hz), 2.43 (s, 3H, 9-C(O)Me), 2.90 (d, 1H, 10ax-H, J = 18.8 Hz), 3.02 (dd,
1H, -CMe2CHaHbNH-, J = 14.1 Hz, J = 5.6 Hz), 3.13 (dd, 1H, -CMe2CHaHbNH-, J = 14.1 Hz, J = 3.1 Hz),
3.25 (d, 1H, 10eq-H, J = 18.8 Hz), 3.70 (s, 1H, 4'-H), 3.73 (s, 3H, C(O)OMe), 4.07 (s, 3H, 4-OMe),  4.14 (bs,
1H, 3'-H), 4.17 (d, 1H, Gluc5-H, J = 9.8 Hz), 4.22 (q, 1H, 5'-H, J = 5.6 Hz), 4.48 (s, 1H, 9-OH), 5.08 (t, 1H,
Gluc2-H, J = 8.6 Hz), 5.19 (t, 1H, Gluc4-H, J = 9.6 Hz), 5.24 (s, 1H, 7-H), 5.31 (t, 1H, Gluc3-H, J = 9.3), 5.50
(d, 1H, 1'-H, J = 3.3 Hz), 5.70 (d, 1H, Gluc1-H, J = 8.0 Hz), 5.87 (t, 1H, -CH2NH-, J = 6.6 Hz), 6.29 (d, 1H, 3'-
NH-, J = 8.2 Hz), 7.38 (d, 1H, 3-H, J = 8.5 Hz), 7.77 (t, 1H, 2-H, J = 8.1 Hz), 8.01 (d, 1H, 1-H, J = 7.6 Hz),
13.25 (s, 1H, 11-OH), 13.97 (s, 1H, 6-OH).
N- g -[Daunorubicin-3'-N-(3,3-dimethyl)butyryl] O- b -D-glucuronyl carbamate sodium salt  (DAU-GB2) from 47c
according to general procedure #6 in 82%, mp 220ºC (dec.), elem. anal.: calc. (found) for C40H47N2O19Na.6
H2O: C: 48.49 (48.03), H: 6.00 (5.74), N: 2.83 (2.92). MS (FAB+) m/z = 906 ([M+1+Na]+), 905 ([M+Na]+), 884
([M+1+H]+), 883 ([M+H]+). 1H-NMR (100 MHz, (CD3)2SO) d  (ppm) = 0.86 (s, 6H, -CMe2-), 1.13 (d, 3H, 5'-
Me, J = 6.4 Hz), 1.41 (dd, 1H, 2'eq-H, J = 12.1 Hz J = 3.6 Hz), 1.82 (td, 1H, 2'ax-H, J = 12.1 Hz J = 3.6 Hz),
1.98 (s, 2H, -C(Me)2CH2C(O)-), 2.13 (dd, 1H, 8ax-H, J = 14.3 Hz J = 5.6 Hz), 2.20 (bd, 1H, 8eq-H, J = 13.9),
2.26 (s, 3H, 9-C(O)Me), 2.87 (d, 2H, -C(Me)2CH2NH-, J = 5.8), 2.90-3.55 (m, 6H, 10eq-H 10ax-H 4'-H
Gluc2,3,4-H), 3.90-4.00 (m, 3H, 3'-H 2 -OH), 3.98 (s, 3H, 4-OMe), 4.15 (q, 1H, 5'-H, J = 6.6 Hz), 4.92 (s, 1H,
-OH), 5.02 (s, 1H, -OH), 4.97 (bs, 1H, 7-H), 5.18 (d, 1H, Gluc1-H, J = 7.9 Hz), 5.24 (bs, 1H, 1'-H), 5.46 (s, 1H,
9-OH), 7.29 (t, 1H, -CH2NH-, J = 5.9 Hz), 7.55-7.65 (m, 2H, 3-H 3'-NH-), 7.85-7.90 (m, 2H, 1-H 2-H), 13.25
(s, 1H, 11-OH), 14.00 (s, 1H, 6-OH).
Synthesis of N-g -[daunorubicin-3'-N-(4,4-dimethyl)butyryl] O-b -D-glucuronyl carbamate 
sodium salt (DAU-GB3).
4,4-Dimethyl glutaric acid mono allyl ester  (29), together with a small amount of the 2,2-dimethyl isomer 30
[15] obtained almost quantitatively from 28 according to general procedure #1. 29: 1H-NMR (100 MHz,
CDCl3) d  (ppm) = 1.23 (s, 6H, 2 -Me), 1.60-2.10 (m, 2H, -C(Me)2CH2-), 2.20-2.50 (m, 2H, -CH2CO2-), 4.57
(dt, 2H, -OCH2-, J = 5.3 Hz J = 1.2 Hz), 5.15-5.40 (m, 2H, =CH2), 5.75-6.15 (m, 1H, -CH=), 10.55 (bs, 1H,
-CO2H).
N-g -[(4,4-{And 2,2-}dimethyl)butyric acid allyl ester] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(48a {and 49a}) from 29 {and 30} according to general procedure #2 in 81% yield and 100% b -diastereo-
selectivity as a colorless oil, 48a: 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.25 (s, 3H, -CMeaMeb-), 1.29 (s,
3H, -CMeaMeb-), 2.00 (s, 9H, 3 -OAc), 2.25-2.45 (m, 2H, -C(Me)2CH2CO2-), 3.71 (s, 3H, -CO2Me), 4.14 (d,
1H, Gluc5-H, J = 9,1 Hz), 4.56 (d, 2H, -OCH2CH=, J = 5.8 Hz), 5.05-5.45 (m, 6H, =CH2 -NH- Gluc2,3,4-H),
5.65-6.10 (m, 1H, -CH=), 5.66 (d, 1H, Gluc1-H, J = 7.8 Hz).
N-g -[(4,4-{And 2,2-}dimethyl)butyric acid] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (48b {and
49b}) from 48a {and 49a} according to general procedure #3.
N- g -[Daunorubicin-3'-N-(4,4-{and 2,2-}dimethyl)butyryl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (48c {and 49c}) from 48b {and 49b} according to general procedure #5 in 58%. Both isomers
were separated and obtained in a ratio of 7.3/1. For both isomers mp 148-150ºC. 48c: 1H-NMR (400 MHz,
CDCl3) d  (ppm) = 1.24 and 1.28 (2 s, 6H, 2 -CMe2-), 1.30 (d, 3H, 5'-Me, J = 6.7 Hz), 1.75-2.20 (m, 8H, 2'ax-H
2'eq-H 4'-OH 8ax-H -CH2CH2C(O)- -CH2CH2C(O)-), 2.03 (s, 9H, 3 -OAc), 2.32 (d, 1H, 8eq-H, J = 14.8 Hz),
2.42 (s, 3H, 9-C(O)Me), 2.90 (d, 1H, 10ax-H, J = 18.8 Hz), 3.22 (d, 1H, 10eq-H, J = 18.8 Hz), 3.67 (s, 1H, 4'-H),
3.73 (s, 3H, C(O)OMe), 4.07 (s, 3H, 4-OMe), 4.14 (bs, 1H, 3'-H), 4.16 (d, 1H, Gluc5-H, J = 9.8 Hz), 4.22 (q,
1H, 5'-H, J = 6.6 Hz), 4.50 (s, 1H, 9-OH), 5.07 (t, 1H, Gluc2-H, J = 8.5 Hz), 5.19 (t, 1H, Gluc4-H, J = 9.6 Hz),
5.24 (s, 1H, 7-H), 5.30 (t, 1H, Gluc3-H, J = 9.3), 5.36 (s, 1H, -CMe2NH-), 5.49 (bs, 1H, 1'-H), 5.65 (d, 1H,
Gluc1-H, J = 7.8 Hz), 6.08 (d, 1H, 3'-NH-, J = 8.2 Hz), 7.38 (d, 1H, 3-H, J = 8.5 Hz), 7.77 (t, 1H, 2-H, J = 8.1
Hz), 8.01 (d, 1H, 1-H, J = 7.6 Hz), 13.26 (s, 1H, 11-OH), 13.97 (s, 1H, 6-OH).
49c: 1H-NMR spectrum almost similar to that of 48c except for the absence of the -CH2CH2C(O)- signal,
the presence of the signal at 3.00-3.10 (m, 2H, -CH2CH2NH-) and the -CH2NH- overlapping with other
signals.
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N-g -[daunorubicin-3'-N-(4,4-dimethyl)butyryl] O- b -D-glucuronyl carbamate sodium salt (DAU-GB3) from 48c
according to general procedure #6 in 96%, mp 200ºC (dec.), elem. anal.: calc. (found) for C40H47N2O19.6
H2O: C: 48.49 (48.22), H: 6.00 (5.65), N: 2.83 (2.88). MS (FAB+) m/z = 906 ([M+1+Na]+), 905 ([M+Na]+), 884
([M+1+H]+), 883 ([M+H]+). 1H-NMR (100 MHz, (CD3)2SO) d  (ppm) = 1.10 and 1.18 (2s, 6H, -CMe2-), 1.13
(d, 3H, 5'-Me, J = 6.4 Hz), 1.43 (bd, 1H, 2'eq-H, J = 8.4 Hz), 1.60-2.20 (m, 7H, -C(Me)2CH2CH2- 2'ax-H 8ax-H
8eq-H -CH2CH2C(O)-), 2.25 (s, 3H, 9-C(O)Me), 2.90-3.25 (m, 6H,- 10eq-H 10ax-H 4'-H Gluc2,3,4-H), 3.96 (s,
3H, 4-OMe), 4.00-4.05 (m, 2H, 3'-H Gluc5-H), 4.15 (q, 1H, 5'-H, J = 6.6 Hz),  4.91 (s, 1H, -OH), 5.00-5.05 (m,
3H, 7-H, 2 -OH), 5.03 (d, 1H, -OH, J = 5.4 Hz), 5.09 (d, 1H, Gluc1-H, J = 8.4 Hz), 5.20 (bs, 1H, 1'-H), 5.55 (s,
1H, 9-OH), 7.06 (s, 1H, -CMe2NH-), 7.61 (bs, 1H, 3-H ), 7.76 (d, 1H, 3'-NH-, J = 8.0 Hz),7.88 (bs, 2H, 1-H 2-
H), 13.18 (s, 1H, 11-OH), 13.99 (s, 1H, 6-OH).
N-g -[daunorubicin-3'-N-(2,2-dimethyl)butyryl] O- b -D-glucuronyl carbamate sodium salt (DAU-GB11) from 49c
according to general procedure #6 in 37%, mp 193ºC (dec.), elem. anal.: calc. (found) for C40H47N2O19.6
H2O: C: 48.49 (48.15), H: 6.00 (5.91), N: 2.83 (2.86). (The low yield compared to the deprotection leading to
DAU-GB3 was caused by mechanical loss during this small scale deprotection procedure). MS (FAB+)
m/z = 906 ([M+1+Na]+), 905 ([M+Na]+), 884 ([M+1+H]+), 883 ([M+H]+). 1H-NMR (100 MHz, (CD3)2SO) d
(ppm) = 1.02 and 1.06 (2s, 6H, -CMe2-), 1.13 (d, 3H, 5'-Me, J = 6.4 Hz), 1.44 (dd, 1H, 2'eq-H, J = 12.2 Hz J =
4.0 Hz), 1.50-1.70 (m, 2H, -C(Me)2CH2CH2-), 1.90 (td, 1H, 2'ax-H, J = 12.6 Hz J = 3.9 Hz), 2.11 (dd, 1H, 8ax-
H, J = 14.2 Hz J = 5.5 Hz), 2.19 (bd, 1H, 8eq-H, J = 14.0), 2.26 (s, 3H, 9-C(O)Me), 2.85-3.15 (m, 8H,
-CH2CH2NH- 10eq-H 10ax-H Gluc2,3,4-H), 3.43 (s, 1H, 4'-H), 3.98 (s, 3H, 4-OMe), 4.00-4.05 (m, 2H, 3'-H
Gluc5-H), 4.16 (q, 1H, 5'-H, J = 6.5 Hz), 4.90-5.00 (m, 3H, 7-H, 2 -OH), 5.03 (d, 1H, -OH, J = 5.4 Hz), 5.13 (d,
1H, Gluc1-H, J = 8.2 Hz), 5.24 (bs, 1H, 1'-H), 5.55 (s, 1H, 9-OH), 6.83 (d, 1H, 3'-NH-, J = 6.8 Hz), 7.13 (t, 1H,
-CH2NH-, J = 5.5 Hz), 7.64 (bs, 1H, 3-H ), 7.85-7.95 (m, 2H, 1-H 2-H), 13.27 (s, 1H, 11-OH), 14.03 (s, 1H, 6-
OH).
Attempted synthesis of N-2-[2'-(daunorubicin-3'-N-carbonyl)]biphenyl O- b -D-glucuronyl 
carbamate sodium salt (DAU-GB4).
Diphenic acid mono allyl ester (32) obtained quantitatively from 31 according to general procedure #1, 1H-
NMR (100 MHz, CDCl3) d  (ppm) = 4.42 (d, 2H, -OCH2-, J = 5.6 Hz), 4.90-5.15 (m, 2H, =CH2), 5.40-5.80 (m,
1H, -CH=), 7.00-7.55 (m, 4H, Ar3,3',4,4',5,5'-H), 7.90-8.00 (m, 2H, Ar6,6'-H), 10.83 (s, 1H, -CO2H).
N-2-[Biphenyl-2'-carboxylic acid allyl ester] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (50a) from
32 according to general procedure #2 as white needles from i-Pr2O/EtOAc, mp 63-67ºC in 89% yield and
100% b -diastereoselectivity, the 1H-NMR spectrum of 50a taken on a 400 mHz recorder in CDCl3 almost
all signals were double, indicating the existence of two rotameric forms of the compound in a ratio of
4/5. This was likely due to restricted rotation around the Ar-Ar bond. These double signals coalesce
upon heating. d  (ppm) = 1.95-2.05 (m, 9H, 3 -OAc), 3.72 and 3.73 (s, 3H, -CO2Me), 4.17 (d, 1H, Gluc5-H, J
= 9.6 Hz), 4.49 and 4.53 (2d, 2H, -OCH2CH=, J = 5.8 resp. 5.2 Hz), 5.00-5.35 (m, 5H, =CH2 Gluc2,3,4-H),
5.55-5.75 (m, 1H, -CH=), 5.73 and 5.74 (2d, 1H, Gluc1-H, J = 8.0 resp. 8.1 Hz), 6.45 and 6.51 (s, 1H, -NH-),
7.05-7.65 (m, 6H, Ar3,3',4,4',5,5'-H), 7.85-8.05 (m, 2H, Ar6,6'-H).
N-2-[Biphenyl-2'-carboxylic acid] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (50b) from 50a
according to general procedure #3 in 93%, mp 90-92ºC, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.70-2.00
(m, 9H, 3 -OAc), 3.64 and 3.67 (s, 3H, -CO2Me), 4.06 and 4.13 (2d, 1H, Gluc5-H, J = 9.0 resp. 9.2 Hz), 4.85-
5.35 (m, 3H, Gluc2,3,4-H), 5.63 and 5.66 (2d, 1H, Gluc1-H, J = 7.6 resp. 7.9 Hz), 6.62 and 6.70 (2s, 1H, -NH-
), 7.10-8.00 (m, 8H, Ar3,3',4,4',5,5',6,6'-H).
The coupling reaction of the above carboxylic acid 50b with daunorubicin using a number of different
coupling procedures all resulted in the formation of compound 52 (see scheme 3.9), This reaction is
further outlined in section 5.2, The desired product could not be obtained.
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Synthesis of N-methyl, N-2-[2'-(daunorubicin-3'-N-carbonyl)]biphenyl O- b -D-glucuronyl 
carbamate sodium salt (DAU-Me-GB4).
N-Methyl, N-2-[biphenyl-2'-carboxylic acid allyl ester] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(54a). 100 mg of 50a was dissolved in 4 mL of DMF and 57 mg (1.5 equiv.) of Ag2O and 101 m L (10 equiv.)
of MeI were added. The suspension was stirred for 4 h at ambient temperature and after that filtered and
diluted with 100 mL of EtOAc. The solution was washed 50 mL portions of aqueous 5% KHSO4 with
saturated aqueous NaHCO3 (2x) and with brine and dried over Na2SO4. The product was purified by
means of column chromatography (SiO2, Et2O/n-Hex 3/1) to obtain 42 mg (56%) of 54a as an oil (after
column chromatography, 27 mg starting material was recovered). Extremely broad signals were obtained
in the 1H-NMR spectrum [29], (100 MHz, CDCl3) d  (ppm) = 1.80-2.05 (m, 9H, 3 -OAc), 2.61 and 2.76 (2bs,
3H, -NMe-), 3.67 (bs, 3H, -CO2Me), 4.09 (bd, 1H, Gluc5-H, J = 9.5 Hz), 4.46 (bd, 2H, -OCH2CH=, J = 5.4
Hz), 4.80-5.35 (m, 5H, =CH2 Gluc2,3,4-H), 5.35-5.80 (m, 2H, Gluc1-H -CH=), 6.95-7.65 (m, 6H,
Ar3,3',4,4',5,5'-H), 7.70-8.10 (m, 2H, Ar6,6'-H).
N-Methyl, N-2-[biphenyl-2'-carboxylic acid] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (54b) from
54a according to general procedure #3.
N-methyl, N-2-[2'-(daunorubicin-3'-N-carbonyl)]biphenyl O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (54c) from 54b according to general procedure #5 in 73%, mp 150-165ºC. 1H-NMR [29] (400
MHz, CDCl3) d  (ppm) = 1.10-1.30 (m, 3H, 5'-Me), 1.55-2.35 (m, 14H, 2'ax-H 2'eq-H 4-OH 8ax-H 8eq-H 3
-OAc), 2.42 and 2.43 (2s, 3H, 9-C(O)Me), 2.99 (d, 1H, 10ax-H, J = 18.8 Hz), 3.04 and 3.35 (2s, 3H, ArNMe-),
3.23 (d, 1H, 10eq-H, J = 18.8 Hz), 3.40-4.15 (m, 4H, 4'-H Gluc5-H 5'-H -CO2Me 4-OMe), 4.59 (s, 1H, 9-OH),
5.05-5.45 (m, 6H, Gluc1,2,3,4-H 7-H 1'-H 3'-NH-), 7.05-7.70 (m, 9H, 3-H Ar3,3',4,4',5,5',6,6'-H), 7.78 (t, 1H,
2-H, J = 8.0 Hz), 8.05 (d, 1H, 1-H, J = 7.6 Hz), 13.29 and 13.30 (2s, 1H, 11-OH), 13.92, 13.95 and 13.96 (3s,
1H, 6-OH).
N-methyl, N-2-[2'-(daunorubicin-3'-N-carbonyl)]biphenyl O-b -D-glucuronyl carbamate (Dau-Me-GB4) from
54c according to general procedure #6 in 49%, mp 175-177ºC, elem. anal.: calc. (found) for C48H47N2O19.5
H2O: C: 53.93 (53.71), H: 5.37 (5.14), N: 2.62 (2.69). 1H-NMR [29] (400 MHz, (CD3)2SO) d  (ppm) = 1.10-1.20
(m, 3H, 5'-Me), 1.47-2.20 (m, 4H, 2'eq-H 2'ax-H 8ax-H 8eq-H), 2.28 (bs, 3H, -C(O)Me), 3.10-3.15 (m, 2H, 10eq-
H 10ax-H), 3.20-4.80 (m, 14H, 4'-H Gluc2,3,4,5-H 3'-H 4-OMe 5'-H 4’-OH ArNMe-), 4.90-5.30 (m, 3H, 7-H
1'-H Gluc1-H), 5.54 (s, 1H, 9-OH), 6.80-7.90 (m, 12H, 1,2,3-H 3'-NH- Ar3,3',4,4',5,5',6,6'-H) 13.20 (bs, 1H,
11-OH), 13.96 (bs, 1H, 6-OH).
Synthesis of N-2-(daunorubicin-3'-N-carbonylmethylphenyl) O-b -D-glucuronyl carbamate 
sodium salt (DAU-GB5).
Homophthalic acid w -allyl ester (34) from 33 according to general procedure #1 after crystallization from
n-Hex in 86%, mp 77-79ºC, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 4.01 (s, 1H, ArCH2-), 4.57 (d, 2H,
-OCH2-, J = 6.9 Hz), 5.05-5.40 (m, 2H, =CH2), 5.60-6.15 (m, 1H, -CH=), 7.10-7.65 (m, 3H, Ar3,4,5-H), 8.12
(d, 1H, Ar1-H, J = 8.1 Hz), 10 66 (s, 1H, -CO2H).
N-2-Phenylacetic acid allyl ester O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (55a) from 3 4
according to general procedure #2 in 86% yield and 100% b -diastereoselectivity as white needles from i-
Pr2O/EtOAc, mp 82ºC, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.98 (s, 9H, 3 -OAc), 3.51 (d, 1H, ArCHaHb-,
J = 14 Hz), 3.66 (d, 1H, ArHaHb-, J = 14 Hz), 3.67 (s, 3H, -CO2Me), 4.15 (d, 1H, Gluc5-H, J = 9.2 Hz), 4.51
(dt, 2H, -OCH2CH=, J = 1.2 Hz J = 5.7 Hz), 5.00-5.45 (m, 5H, =CH2 Gluc2,3,4-H), 5.60-6.10 (m, 1H, =CH2),
5.76 (d, 1H, Gluc1-H, J = 7.3 Hz), 7.00-7.40 (m, 3H, Ar3,4,5-H), 7.64 (d, 1H, Ar6-H, J = 7.5 Hz), 8.04 (s, 1H,
-NH-).
N-2-Phenylacetic acid O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate  ( 55c) from 55a according to
general procedure #3 in an almost quantitative yield. Compound 55c proved to be unstable and was
coupled to daunorubicin immediately.
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N-2-(Daunorubicin-3'-N-carbonylmethylphenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (55d)
from 55c according to general procedure #5 in 32%, mp 162-165ºC, 1H-NMR (100 MHz, CDCl3) d  (ppm) =
1.33 (d, 3H, 5'-Me, J = 6.5 Hz), 1.70 (m, 4H, 2'ax-H 2'eq-H 8ax-H 4'-OH), 2.05, 2.08 and 2.09 (3 s, 9H, 3 -OAc),
2.36 (d, 1H, 8eq-H, J = 14.9 Hz), 2.44 (s, 3H, 9-C(O)Me), 2.96 (d, 1H, 10ax-H, J = 18.9 Hz), 3.25 (d, 1H, 10eq-
H, J = 18.8 Hz), 3.69 (s, 1H, 4'-H), 3.73 (d, 1H, ArCHaHb-, J = 12.4 Hz), 3.74 (s, 3H, C(O)OMe), 3.77 (d, 1H,
ArHaHb-, J = 12.4 Hz),3.88 (m, 1H, 3'-H), 4.07 (s, 3H, 4-OMe), 4.11 (d, 1H, Gluc5-H, J = 9.6 Hz), 4.29 (q, 1H,
5'-H, J = 6.6 Hz), 4.55 (s, 1H, 9-OH), 5.10-5.35 (m, 5H, Gluc2,3,4-H 7-H 3'-NH-), 5.55 (d, 1H, 1'-H, J = 3.8
Hz), 5.60 (d, 1H, Gluc1-H, J = 9.7 Hz), 7.21 (s, 1H, ArNH-), 7.11 (t, 1H, Ar5-H, J = 7.5 Hz), 7.22 (t, 1H, Ar4-
H, J = 7.2 Hz) 7.38 (d, 1H, 3-H, J = 8.5 Hz), 7.78 (t, 1H, 2-H, J = 8.1 Hz), 8.04 (d, 1H, 1-H, J = 7.7 Hz), 8.16
(d, 1H, Ar3-H, J = 8.2 Hz), 8.86 (d, 1H, Ar6-H, J = 7.8 Hz), 13.29 (s, 1H, 11-OH), 13.98 (s, 1H, 6-OH).
N-2-(Daunorubicin-3'-N-carbonylmethylphenyl) O-b -D-glucuronyl carbamate sodium salt (DAU-GB5) from
55d according to general procedure #6 in 62%, mp 180ºC (dec.), elem. anal.: calc. (found) for
C42H43N2O19.6 H2O: C: 49.90 (50.34), H: 5.48 (4.88), N: 2.77 (2.82). MS (FAB+) m/z = 926 ([M+1+Na]+), 925
([M+Na]+), 904 ([M+1+H]+), 903 ([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.13 (d, 3H, 5'-Me, J
= 6.6 Hz), 1.47 (dd, 1H, 2'eq-H, J = 12.1 Hz J = 3.4 Hz), 1.82 (dt, 1H, 2'ax-H, J = 11.5 Hz J = 3.4 Hz), 2.07 (dd,
1H, 8ax-H, J = 14.1 Hz J = 6.1 Hz), 2.19 (dd, 1H, 8eq-H, J = 14.1 J = 3.1 Hz), 2.27 (s, 3H, -C(O)Me), 3.11 (d,
1H, 10eq-H, J = 18.5 Hz), 3.13 (d, 1H, 10ax-H, J = 18.5 Hz), 3.20-3.75 (m, 7H, 3',4'-H Gluc2,3,4-H ArCH2-),
3.95 (s, 3H, 4-OMe), 4.19 (q, 1H, 5'-H, J = 6.6 Hz), 4.67 (d, 1H, 4’-OH, J = 5.1 Hz), 4.75-5.35 (m, 4H, Gluc1,5-
H 7-H 1'-H), 5.53 (s, 1H, 9-OH), 5.76 (d, 1H, 3'-NH-, J = 7.9 Hz), 6.78 (t, 1H, Ar5-H, J = 7.3 Hz), 6.98 (t, 1H,
Ar4-H, J = 6.7 Hz),  7.25 (s, 1H, ArNH-), 7.30 (d, 1H, Ar3-H, J = 8.4 Hz), 7.67 (d, 1H, 3-H, J = 8.1 Hz), 7.82
(d, 1H, Ar6-H, J = 8.3 Hz), 7.94 (m, 2H, 1,2-H), 13.23 (s, 1H, 11-OH), 13.97 (s, 1H, 6-OH).
Synthesis of N-2-(daunorubicin-3'-N-carbonylbenzyl) O-b -D-glucuronyl carbamate sodium 
salt (DAU-GB8).
Homophthalic acid w -allyl- a -tert.-butyl diester (35). 538 mg of 34 (obtained as described above under DAU-
GB5) was dissolved in 25 mL of CH2Cl2 and cooled to -10ºC. Ca. 2 mL of condensed isobutene and 3
drops of concentrated H2SO4 were added to the reaction mixture which was stirred overnight in an
autoclave at room temperature. After reaction, the H2SO4 was neutralized using excess of solid NaHCO3,
the mixture was filtered and the solvent was removed by evaporation. The residue was dissolved in
n-Hex, the unreacted starting material precipitated from this solution and was removed and the hexane
was removed evaporated to furnish 478 mg, 77% of 35 (corrected for the recovered 34) as a colorless oil,
1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.46 (s, 9H, -t-Bu), 3.95 (s, 2H, ArCH2-), 4.49 (d, 2H, -OCH2-, J = 5.5
Hz), 5.00-5.30 (m, 2H, =CH2), 5.60-6.00 (m, 1H, -CH=), 7.05-7.40 (m, 3H, Ar3,4,5-H), 7.83 (dd, 1H, Ar6-H, J
= 7.2 Hz J = 2.1 Hz).
Homophthalic acid a -tert.-butyl ester (36) from 35 according to general procedure #3 in quantitative yield.
N-[Benzyl-2-carboxylic acid tert.-butyl ester] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (56b) from
36 according to general procedure #2 in 68% yield and >95% b -diastereoselectivity as white needles from
Et2O, mp 112-119ºC, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.53 (s, 9H, tert.-Bu), 1.91, 1.94 and 1.95 (3s,
9H, 3 -OAc), 3.63 (s, 3H, -CO2Me), 4.08 (d, 1H, Gluc5-H, J = 9.4 Hz), 4.45 (d, 2H, ArCH2-, J = 6.6 Hz), 4.90-
5.45 (m, 3H, Gluc2,3,4-H), 5.66 (d, 1H, Gluc1-H, J = 7.7 Hz), 6.07 (t, 1H, -NH-, J = 6.6 Hz), 7.10-7.50 (m, 3H,
Ar3,4,5-H), 7.85 (d, 1H, Ar6-H, J = 6.8 Hz).
N-[Benzyl-2-carboxylic acid] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (56c) from 56b according
to general procedure #4 in quantitative yield (according to TLC). 56c was coupled to daunorubicin
immediately to prevent deterioration.
N-2-(Daunorubicin-3'-N-carbonylbenzyl) O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (56d) from
56c according to general procedure #5 in 62% (calculated from 56b), mp 164-168, 1H-NMR (400 MHz,
CDCl3) d  (ppm) = 1.35 (d, 3H, 5'-Me, J = 6.5 Hz), 1.75-2.05 (m, 3H, 2'ax-H 2'eq-H 4-OH), 1.96, 2.01 and 2.02
(3 s, 9H, 3 -OAc), 2.14 (dd, 1H, 8ax-H, J = 14.8 Hz J = 4.0 Hz), 2.38 (d, 1H, 8eq-H, J = 14.5 Hz), 2.46 (s, 3H, 9-
C(O)Me), 2.94 (d, 1H, 10ax-H, J = 18.8 Hz), 3.25 (d, 1H, 10eq-H, J = 18.8 Hz), 3.63 (s, 3H, -CO2Me), 3.83 (s,
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1H, 4'-H), 4.07 (s, 3H, 4-OMe), 4.11 (d, 1H,Gluc5-H, J = 9.8 Hz), 4.25-4.45 (m, 4H, 5'-H ArCH2- 3'-H), 4.56
(s, 1H, 9-OH), 5.02 (t, 1H, Gluc2-H, J = 8.4 Hz), 5.16 (t, 1H, Gluc4-H, J = 9.6 Hz), 5.27 (t, 1H, Gluc3-H, J =
9.3 Hz), 5.30 (s, 1H, 7-H), 5.57 (s, 1H, 1'-H), 5.64 (d, 1H, Gluc1-H, J = 7.7 Hz), 6.40-6.45 (m, 2H, 3'-NH-
ArCH2NH-), 7.25-7.40 (m, 5H, 3-H Ar3,4,5,6-H), 7.77 (t, 1H, 2-H, J = 8.1 Hz), 8.00 (d, 1H, 1-H, J = 7.7 Hz),
13.27 (s, 1H, 11-OH), 14.00 (s, 1H, 6-OH).
N-2-(Daunorubicin-3'-N-carbonylbenzyl) O- b -D-glucuronyl carbamate sodium salt (DAU-GB8) from 56d in
77%, mp 190ºC (dec.), elem. anal.: calc. (found) for C42H43N2O19.6 H2O: C: 49.90 (50.27), H: 5.48 (4.92), N:
2.77 (2.80). MS (FAB+) m/z = 926 ([M+1+Na]+), 925 ([M+Na]+), 904 ([M+1+H]+), 903 ([M+H]+). 1H-NMR
(100 MHz, (CD3)2SO) d  (ppm) = 1.15 (d, 3H, 5'-Me, J = 6.5 Hz), 1.54 (dd, 1H, 2'eq-H, J = 12.1 Hz J = 3.9 Hz),
1.99 (dt, 1H, 2'ax-H, J = 12.9 Hz J = 3.4 Hz), 2.11 (dd, 1H, 8ax-H, J = 12.9 Hz J = 3.4 Hz), 2.22 (dd, 1H, 8eq-H,
J = 13.2 J = 2.6 Hz), 2.27 (s, 3H, -C(O)Me), 2.90-3.20 (m, 6H, 10eq-H 10ax-H 4'-H Gluc2,3,4-H), 3.61 (bs, 1H,
3'-H), 3.97 (s, 3H, 4-OMe), 4.15-4.35 (m, 4H, 5'-H Gluc5-H ArCH2-), 4.95-5.00 (m, 2H, 7-H ArCH2NH-),
5.08 (d, 1H, 4’-OH, J = 5.2 Hz), 5.13 (d, 1H, Gluc1-H, J = 8.1 Hz), 5.27 (bs, 1H, 1'-H), 5.59 (s, 1H, 9-OH),
7.20-7.40 (m, 3H, Ar3,5-H 3'-NH-), 7.55-7.65 (m, 2H, 3-H Ar4-H), 7.85-7.90 (m, 2H, 1,2-H), 7.97 (d, 1H,
Ar6-H, J = 7.8 Hz), 14.03 (s, 1H, 6-OH).
Synthesis of N-2-(daunorubicin-3'-N-carbonyl-(a -methyl)benzyl) O- b -D-glucuronyl 
carbamate sodium salt (DAU-GB9).
a -Methylhomophthalic acid w -allyl a -tert.-butyl diester (43) from 35 according to general procedure #7 in
41%, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.40-1.60 (m, 12H, -t-Bu -Me), 4.50 (dt, 2H, -OCH2-, J = 5.0 Hz
J = 1.3 Hz), 4.61 (q, 1H, ArCHMe-, J = 7.1 Hz), 4.95-5.25 (m, 2H, =CH2), 5.55-5.95 (m, 1H, -CH=), 7.10-7.50
(m, 3H, Ar3,4,5-H), 7.73 (dd, 1H, Ar6-H, J = 8.2 Hz J = 1.6 Hz).
a -Methylhomophthalic acid a -tert.-butyl ester (45) from 43 according to general procedure #3 in quantitative
yield.
N-(a -Methylbenzyl-2-carboxylic acid -tert.-butyl ester) O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(60b) from 45 according to general procedure #2 in 62% yield and 100% b -diastereoselectivity as a white
foam, mp 69-74ºC. Because the starting material 45 was used as a racemic mixture, 60b was formed as a
mixture of diastereoisomers, these could not be separated. In the 1H-NMR of this diastereoisomeric
mixture, some signals were doubled and some were broadened. 1H-NMR (100 MHz, CDCl3) d  (ppm) =
1.15-1.30 (m, 3 H. -CHMe-), 1.36 (s, 9H, t-Bu), 1.66, 1.76, 1.78 and 1.81 (s, 9H, 3 -OAc), 3.41 and 3.49 (s, 3H,
-CO2Me), 3.86 and 3.91 (d, 1H, Gluc5-H, J = 9.4 and 9.1 Hz resp.), 4.75-5.30 (m, 4H, ArCHMe- Gluc2,3,4-
H), 5.44 and 5.46 (d, 1H, Gluc1-H, J = 7.4 and 7.6 Hz resp.), 6.00 (t, 1H, -NH-, J = 8.6 Hz), 6.90-7.30 (m, 3H,
Ar3,4,5-H), 7.53 (d, 1H, Ar6-H, J = 6.4 Hz).
N-(a -Methylbenzyl-2-carboxylic acid) O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (60c) from 60b
according to general procedure #4 in quantitative yield (according to TLC). 60c was coupled to
daunorubicin immediately to prevent deterioration.
N-2-(Daunorubicin-3'-N-carbonyl-a -methylbenzyl) O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(60d) from 60c according to general procedure #5 in 86% (calculated from 60b). Because of chirality of the
spacer -C*HMe- of starting material 60d, a diastereoisomeric mixture was formed in a ratio of 1.8/1,
determined by dividing the integrals of the clear doublets of the respective 3'-NH- signals. For both
diastereoisomers, mp 165-170ºC. The isomers were separated by 3 successive runs of circular
chromatography using CH2Cl2/EtOH 40/1. Major diastereoisomer: 1H-NMR (100 MHz, CDCl3) d  (ppm)
= 1.32 (d, 3H, 5'-Me, J = 6.4 Hz), 1.46 (d, 3H, ArCHMeNH-, J = 6.9), 1.85-1.95 (m, 2H, 2'ax-H 2'eq-H), 1.90,
2.01 and 2.04 (3 s, 9H, 3 -OAc), 2.13 (dd, 1H, 8ax-H, J = 14.8 Hz J = 4.0 Hz), 2.38 (d, 1H, 8eq-H, J = 14.8 Hz),
2.44 (s, 3H, 9-C(O)Me), 2.93 (d, 1H, 10ax-H, J = 18.8 Hz), 3.24 (d, 1H, 10eq-H, J = 18.6 Hz), 3.33 (d, 1H, 4'-
OH, J = 6.0 Hz), 3.73 (s, 3H, -CO2Me), 3.92 (bd, 1H, 4'-H, J = 3.2 Hz), 4.09 (s, 3H, 4-OMe), 4.15 (d,
1H,Gluc5-H, J = 9.0 Hz), 4.27 (q, 1H, 5'-H, J = 6.6 Hz), 4.32 (bs, 1H, 3'-H), 4.57 (s, 1H, 9-OH), 5.00-5.25 (m,
4H, Gluc2,3,4-H ArCHMeNH-), 5.30 (s, 1H, 7-H), 5.54 (s, 1H, Gluc1-H, J = 7.9 Hz), 5.57 (d, 1H, 1'-H, J = 3.5
Hz), 5.91 (d, 1H, ArCHMeNH -, J = 6.7 Hz), 6.48 (d, 1H, 3'-NH-, J = 8.4 Hz), 7.20-7.40 (m, 5H, 3-H
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Ar3,4,5,6-H), 7.78 (t, 1H, 2-H, J = 8.1 Hz), 8.03 (d, 1H, 1-H, J = 7.7 Hz), 13.28 (s, 1H, 11-OH), 14.00 (s, 1H, 6-
OH).
Minor diastereoisomer: 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.37 (d, 3H, 5'-Me, J = 6.5 Hz), 1.55 (d, 3H,
ArCHMeNH-, J = 7.1), 1.80-2.00 (m, 2H, 2'ax-H 2'eq-H), 2.03, 2.04 and 2.05 (3 s, 9H, 3 -OAc), 2.15 (dd, 1H,
8ax-H, J = 15.0 Hz J = 4.3 Hz), 2.41 (d, 1H, 8eq-H, J = 14.8 Hz), 2.48 (s, 3H, 9-C(O)Me), 2.95 (d, 1H, 10ax-H, J
= 18.8 Hz), 3.25 (d, 1H, 10eq-H, J = 18.8 Hz), 3.35 (d, 1H, 4'-OH, J = 6.2 Hz), 3.66 (s, 3H, -CO2Me), 3.83 (bd,
1H, 4'-H, J = 5.1 Hz), 4.08 (s, 3H, 4-OMe), 4.09 (d, 1H,Gluc5-H, J = 9.3 Hz), 4.28 (q, 1H, 5'-H, J = 6.6 Hz),
4.33 (bs, 1H, 3'-H), 4.63 (s, 1H, 9-OH), 4.86 (k, 1H, ArCHMeNH-, J = 7.4 Hz), 5.00-5.25 (m, 4H, Gluc2,3,4-H
7-H), 5.58 (d, 1H, 1'-H, J = 3.5 Hz), 5.65 (s, 1H, Gluc1-H, J = 8.3 Hz), 6.18 (d, 1H, ArCHMeNH-, J = 8.2 Hz),
6.57 (d, 1H, 3'-NH-, J = 8.8 Hz), 7.15-7.35 (m, 5H, Ar3,4,5,6-H), 7.38 (d, 1H, 3-H, J = 8.5), 7.78 (t, 1H, 2-H, J
= 8.1 Hz), 8.03 (d, 1H, 1-H, J = 7.7 Hz), 13.29 (s, 1H, 11-OH), 14.00 (s, 1H, 6-OH).
N-2-(Daunorubicin-3'-N-carbonyl-a -methylbenzyl) O- b -D-glucuronyl carbamate sodium salt (DAU-GB9)
(mixture of both diastereoisomers) from 60d according to general procedure #6 in 95%, mp 195ºC (dec.),
elem. anal.: calc. (found) for C43H45N2O19.6 H2O: C: 50.39 (49.87), H: 5.61 (5.05), N: 2.73 (2.75). MS (FAB+)
m/z = 940 ([M+1+Na]+), 939 ([M+Na]+), 918 ([M+1+H]+), 917 ([M+H]+). 1H-NMR (100 MHz, (CD3)2SO) d
(ppm) = 1.15 and 1.18 (2d, 3H, 5'-Me, J = 6.5 and 6.4 Hz resp.), 1.29 (d, 3H, ArCHMeNH-, J = 5.7 Hz), 1.55-
1.60 (m, 1H, 2'eq-H), 1.99 (bt, 1H, 2'ax-H, J = 11.8 Hz), 2.12 (dd, 1H, 8ax-H, J = 13.7 Hz J = 5.2 Hz), 2.23 (dd,
1H, 8eq-H, J = 12.4 J = 2.8 Hz), 2.29 (s, 3H, -C(O)Me), 2.95-3.20 (m, 6H, 10eq-H 10ax-H 4'-H Gluc2,3,4-H),
3.60 and 3.67 (2bs, 1H, 3'-H), 3.98 (s, 3H, 4-OMe), 4.10-4.30 (m, 2H, 5'-H Gluc5-H), 4.64 (bs, 1H, 4’-OH),
4.85 (t, 1H, ArCHMeNH-, J = 7.5 Hz), 4.90-5.30 (m, 5H, 7-H Gluc1-H Gluc2,3,4-OH), 5.28 (bs, 1H, 1'-H),
5.58 (s, 1H, 9-OH), 7.20-7.30 (m, 2H, 3'-NH- Ar3-H), 7.39 (t, 1H, Ar5-H, J = 6.4 Hz), 7.47 (t, 1H, Ar4-H, J =
8.0 Hz), 7.62 (bs, 1H, 3-H), 7.85-7.90 (m, 2H, 1,2-H), 7.99 and 8.06 (2d, 1H, Ar6-H, J = 7.7 and 8.2 Hz resp.),
14.05 (s, 1H, 6-OH).
Attempted synthesis of N-2-(daunorubicin-3'-N-carbonyl- a ,a -dimethylbenzyl)
O- b -D-glucuronyl carbamate sodium salt (DAU-GB10)
Homophthalic acid w -allyl a -2-(trimethylsilyl)ethyl diester (37). 500 mg of 34, 0.137 mL (1.05 equiv.) of 2-
(trimethylsilyl)ethanol and a catalytic amount of DMAP were dissolved in CH2Cl2 and cooled to 0ºC. 490
mg (1.05 equiv.) of DCC were added and after 1 h, the reaction mixture was allowed to warm to ambient
temperature and stirring was continued overnight. After that, the solid material was removed by
filtration, the filtrate was diluted with ca. 100 mL of n-Hex and washed with 100 mL portions of a 5%
aqueous solution of KHSO4 (2x), saturated aqueous NaHCO3 (2x) and brine. The solution was dried over
Na2SO4 and evaporated. The crude diester was purified by column chromatography (SiO2 i-Pr2O) to
yield 679 mg, 93% of 37 as a slightly yellowish oil, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 0.01 (s, 9H,
SiMe3), 1.01 (t, 2H, -OCH2CH2Si-, J = 8.6 Hz), 3.95 (s, 1H, ArCH2-), 4.26 (t, 2H, -OCH2CH2Si-, J = 8.6 Hz),
4.48 (d, 2H, -OCH2CH=CH2, J = 5.6 Hz), 5.00-5.25 (m, 2H, =CH2), 5.60-6.00 (m, 1H, -CH=), 7.05-7.40 (m,
3H, Ar3,4,5-H), 7.91 (dd, 1H, Ar6-H, J = 7.2 Hz J = 1.8 Hz).
a ,a -Dimethylhomophthalic acid w -allyl a -2-(trimethylsilyl)ethyl) diester (38) from 37 according to general
procedure #7 in 36%, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 0.00 (s, 9H, SiMe3), 1.04 (t, 2H, -OCH2CH2Si-,
J = 8.7 Hz), 1.59 (s, 6H, -CMe2-), 4.25 (t, 2H, -OCH2CH2Si-, J = 8.7 Hz), 4.48 (dt, 2H, -OCH2CH=CH2, J = 5.0
Hz J = 1.3 Hz), 4.95-5.20 (m, 2H, =CH2), 5.60-6.00 (m, 1H, -CH=), 7.10-7.50 (m, 3H, Ar3,4,5-H), 7.81 (dd,
1H, Ar6-H, J = 7.0 Hz J = 1.3 Hz).
a ,a -Dimethylhomophthalic acid a -2-(trimethylsilyl)ethyl ester (40) from 38 according to general
procedure #3 in quantitative yield as an oil.
N-(3,3-Dimethylisoindolin-1-on) O-(methyl 2,3,4-tri-O-acetyl b -D-glucuronyl) carbamate (62) was unexpectedly
obtained in 39% from 40 as an oil following general procedure #2. The glucuronyl donor was reacted
with the in situ formed isocyanate at 95ºC, at lower temperatures no reaction took place. 62 was formed
in a 1/1 mixture of the a - and b -diastereoisomers. The absence of b -diastereoselectivity is proposed to be
due to the high reaction temperature. All double signals in the proton NMR were of a - and b -anomers.
MS (FAB+) m/z = 545 ([M+1+Na]+), 544 ([M+Na]+). 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.04 and 1.11
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(2s, 3H, ArCMeaMeb-), 1.65 and 1.70 (2s, 3H, ArCMeaMeb-), 3.62 and 3.68 (2s, 3H, -CO2Me), 4.23 (d, 0.5H,
Gluc5-H
b
, J = 9.0 Hz), 4.42 (d, 0.5H, Gluc5-H
a 
J = 10.5 Hz), 4.82 (dd, 0.5H, Gluc2-H
a
 J = 10.0 Hz J = 3.4
Hz), 4.95-5.65 (m, 3H, Gluc3,4-H 0.5Gluc2-H
b
 0.5Gluc1-H
b
), 5.93 (d, 0.5H, Gluc1-H
a
, J = 3.0 Hz), 7.30-7.70
(m, 3H, Ar3,4,5-H), 7.81 (bd, 1H, Ar6-H, J = 7.4 Hz).
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[13] Cremlyn, R.J.W. Aust. J. Chem. 1973, 26, 1591.
[14] After further reaction of 29/30 in the modified Curtius procedure the resulting mixture of 48a/49a
(scheme 3.9) was obtained in a ratio of 10/1, determined using the integrals of
AllO2CCH2CH2C(Me)2- and -NH-CH2CH2C(Me)2- from 48a and 49a, respectively.
[15] Kunz, H.; Waldmann, H. Angew. Chem. 1984, 96, 49.
[16] Kunz, H.; Unversagt, C. Angew. Chem. 1988, 100, 1763.
[17] The 2-(trimetylsilyl)ethyl ester function was developed as a protective group independently by two
researchers: a] Sieber, P. Helv. Chim. Acta 1977, 60, 2711; b] Gerlag, H. ibid 1977, 60, 3039.
[18] Ogura, H.; Kobayashi, T.; Shimizu, K.; Kwabe, K. Takeda, K. Tetrahedron Lett. 1979, 49, 4745.
[19] Diago-Meseguer, J.; Palomo-Coll, A.L.; Fernandez-Lizarbe, J.R.; Zugaza-Bilbao, A. Synthesis 1980,
547.
[20] Knorr, R.; Trzeciak, A.; Bannworth, W.; Gillessen, D. Tetrahedron Lett. 1989, 30, 1927.
[21] Castro, B.; Dormoy, J.R.; Evin, G.; Selve, C. Tetrahedron Lett. 1975, 14, 1219.
[22] Olsen, R.K. J. Org. Chem. 1970, 35, 1912.
[23] Contrarily to the infeasible deprotection of 57, it was possible to deprotect 55a to 55c because the
starting material 55a was much easier prepared than 57 and available in larger quantities. A large
scale optimized procedure was performed to deprotect 55a.
Spaced Prodrugs I Spacer Elimination by Ring-closure 67
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
[24] DAU-GB1 and -GB5 (together with DAU-GA1 (Ch. 2) and DAU-GA3 (Ch. 4) and b -D-glucuronyl
prodrugs prepared by others) were extensively characterized for use in ADEPT, see: Houba, P.H.J.;
Leenders, R.G.G.; Boven, E.; Scheeren, J.W.; Pinedo, H.M. Haisma, Biochem. Pharmacol. 1996, 52,
455. In this paper, DAU-GB5 is refered to as "GB6".
[25] pH = 6.8 was used for activation rate measurements, reflecting the tumor interstitial pH; see:
Martin, G.R.; Jain, R.K. Cancer Res. 1994, 54, 5670.
[26] Menger, F.M.; Smith, J.H. J. Am. Chem. Soc. 1969, 91, 5346.
[27] Compound 73 was prepared according to the literature procedures, see: a] Hauser, F.M.;
Ellenberger, S.R. Synthesis, 1987, 723; b] Hauser, F.M.; Rhee, R. Synthesis 1977, 245.
[28] Less than a stoichiometric amount of 9 was added because a fraction of the in situ  formed
isocyanate dimerizes. In case of 34 (scheme 3.8), 22 % of the symmetrical urea was isolated after
completion of the reaction.
[29] In the 1H-NMR spectrum of 50a almost all
signals are double, indicating the existance of
two rotameric forms of the compound caused
by restricted rotation around the Ar-Ar bond
(see experimental part of DAU-GB4). In case of
54a, additional to this restricted rotation, the
existence of two tautomers of the carbamate
also causes double signals or broadening of
signals in the 1H-NMR spectrum. This was also
observed for 54c and DAU-Me-GB4.
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4 Anthracycline-Spacer-b -D-GlucuronylCarbamates as Prodrugs [1]Spacer Expulsion by 1,6-Elimination
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
4.1 Introduction
4.1.1 General
Improvement of b -glucuronidase mediated rates of hydrolysis of prodrugs by
incorporation of a spacer moiety between daunorubicin and the b -D-glucuronyl
carbamate specifier is apparent, see chapter 3. In this respect, one of these drug-spacer-
b -D-glucuronyl carbamate prodrugs (DAU-GB8, chapter 3) was hydrolyzed up to 1000-
fold faster by b -glucuronidase compared to a non-spaced prodrug (DAU-GA1, chapter
2). Disappointingly, elimination of the spacer from the drug-spacer molecule did not
occur after the triggering step. The potential of a b -D-glucuronyl carbamate as a readily
cleavable specifier, however, is appreciated. Therefore, in the present chapter, other
self-immolating spacers in combination with a b -D-glucuronyl carbamate specifier are
investigated.
4.1.2 The 1,4- and 1,6-elimination
The 1,4- and 1,6-elimination[2]  of R-H from benzylic systems ortho or para substituted
with the strong electron-releasing amino- or hydroxy-group (2a and 2b, respectively,
scheme 4.1) has long been known and reviewed in the early nineties by Wakselman[ 3].
In order to trigger the 1,6-elimination process, the strongly electron-donating amino- or
hydroxy-group in 2a and 2b, respectively, is generated from a less electron-donating
masked amino- or hydroxy-functionality, 1a and 1b, respectively. The 1,6-elimination
reaction is a fast process and is dependent on the nature of the leaving group -R.
Literature examples of masked amine- or hydroxy-functionalities are mainly found in
protective group chemistry. These include amide-[ 4], nitro-[ 5] and azido-groups[ 6], and
ester-[ 7] and carbonate-[7] groups, respectively, which upon demasking to an amino- or
hydroxy-group trigger the 1,6-elimination process. During this elimination, the
compounds R-H and 3a  and 3b are formed, which, in aqueous media, add water
resulting in p-amino- and p-hydroxy-benzyl alcohol 4a and 4b, respectively (scheme
4.1).
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Scheme 4.1   1,4- And 1,6-elimination of hydroxy- and amino-benzyl systems.
In this regard, the use of a natural amino acid amide as a masked aminobenzyl spacer
in prodrug preparation was proposed by the group of Katzenellenbogen[ 8] (scheme
4.2). This model system 6 rapidly releases the chromophore p-nitroaniline 8 (the model
for a drug in this system) after hydrolysis by trypsin of the N a -Boc-Lys specifier group.
The half-life of decay of the intermediate 7 was estimated to be ca 1.5 min. Furthermore,
during the course the research described in this thesis, a doxorubicin-aminobenzyl
spacer-a -D-galactosyl prodrug, compound 9 chart 4.2, was reported[ 9] employing the
amino benzyl spacer. Detailed characteristics of this compound as a prodrug in ADEPT,
however, were not described probably because of a too high toxicity of the prodrug[ 10].
Additionally, collaborating  German and French  scientists  published a series of papers
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and communications on para  and
ortho -hydroxybenzyl spacer-glyco-
side anthracycline prodrugs [11].
These prodrugs are depicted in chart
4.1. Electron-withdrawing substitu-
ents on the spacer of the prodrugs in
chart 4.1 facilitate enzymatic hydro-
lysis. For unsubstituted prodrugs (X =
-H in chart 4.1), however, spacer
elimination after enzymatic hydro-
lysis of the glycosyl specifier did not
take place [11c]. This was ascribed to
the insufficient acidity of the phenolic
function of the spacer. Fast elimina-
tion of the spacer was observed for
prodrugs with a nitro group on the
spacer (X = -NO2). On account of this,
doxorubicin prodrug 10 (chart 4.2),
was selected by Bosslet and co-
workers for extensive preclinical in
vivo  studies in nude mice [12] and was
O
O
N H
H N
O
O
NH3+
H N
O
NO2
O
NH2
H N
O
NO2
trypsin
:
NH2
NO2
CO2
NH
H2O
NH2
OH
+
6
8
7
3a
4a
Scheme 4.2   Application of self-immolating
p-aminobenzyl spacer in prodrug design.
 found to possess agreeable though not ideal characteristics as a prodrug in ADEPT
(e.g. prodrug toxicity, enzyme activation rate). The enzymatic activation rate of
prodrug 10 is still not optimal even though one of the strongest electron-withdrawing
groups (the nitro group) is present on the aromatic ring of the spacer.
O
O
N H
X
glycosyl-1-O
O
O
N H
X
glycosyl-1-O
X = -H, -Cl, -NO2
glycosyl = -1-O-b -D-glucuronyl, -1-O-a -D-galactosyl
anthracycline = -3'-N-daunorubicinyl, -3'-N-doxorubicinyl
anthracycline-3'- anthracycline-3'-
Chart 4.1   p- And o-hydroxybenzyl spaced prodrugs
of anthracyclines reported in the literature [11].
 Additionally, the excretion half-life of prodrug 10 from the serum of mice is 0.4 h
precluding efficient treatment. As already stated in sections 2.2.2 and 4.1.1, a
b -D-glucuronyl carbamate group is a promising specifier because its ease of hydrolysis
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by b -glucuronidase. In this view, prodrugs of anthracyclines containing an
aminobenzyl spaced b -glycosyl carbamate specifier group and their features for use in
ADEPT and/or monotherapy[29]  were investigated.
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H O H O
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Chart 4.2   Two prodrugs reported in the literature.
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4.2 Target compounds
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Scheme 4.3   DAU-GA3 And its activation pathway to the free drug.
We focused exclusively on masked para- (and ortho) aminobenzyl systems 1a (scheme
4.1) for utilization as a self-immolating spacer to allow the use of a b -D-glucuronyl
carbamate as a masked amine. In a first study, b -D-glucuronyl carbamate based
prodrug DAU-GA3[13]  (scheme 4.3) was synthesized. Because daunorubicin is the
easiest available anthracycline, it was used for the initial prodrug preparation. Prodrug
DAU-GA3 will be activated to daunorubicin upon contact with b -glucuronidase
according to scheme 4.3. Hydrolysis of the b -D-glucuronyl specifier and loss of a
molecule of CO2 results in drug-spacer molecule 11. Compound 11 spontaneously
undergoes 1,6-elimination and concomitant loss of a second molecule of CO2 to give
daunorubicin and iminoquinone methide 3a which reacts with water to provide p-
aminobenzyl alcohol 4a. Preliminary test results[ 14] of DAU-GA3 revealed the
following: i. The half life of activation to daunorubicin by b -glucuronidase under
standard conditions (100 m M prodrug, 1 m g/mL enzyme, pH = 6.8, 37ºC) was 135 min.
ii. The IC50 value of DAU-GA3 was about 100-fold higher compared to the parent drug
and iii. DAU-GA3 was cleared from the serum of a mouse in a half life of 20 min.
Optimal prodrugs should combine fast enzymatic hydrolysis with relatively slow
clearance from the circulation (the 100-fold reduced toxicity of the prodrug was found
to be satisfactory). It was hypothesized that rates of hydrolysis for prodrug activation
and rates of clearance of the prodrug from the blood stream could be influenced by
substituents on the spacer and variation of the specifier. Accordingly, variations of
prodrug DAU-GA3 were designed (chart 4.3) possessing substituents on the spacer, or
having a different specifier group. In addition, prodrugs of doxorubicin and idarubicin
(see chart 1.3) were synthesized and evaluated. The series of target compounds thus
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derived from DAU-GA3 are collected in chart 4.3. The planned molecular variations are
summarized as follows:
1
3
4
NH
O
O
O
O
O
OR1
HO
HO
O
OH
O
O
NH
R2
O
HO
HO
R3
R4
R5
X
HO
DAU-GA3
DOX-GA3: R2 = -OH
IDA-GA3: R1 = -H
DAU-GA4: ortho analog of DAU-GA3
DAU-GA5: Y = -(CH2)5CH3
DAU-GA6: X = -2-Cl
DAU-GA7: X = -3-Cl 
DAU-GA8: X = -2-Br
DAU-GA9: X = -3-Br
DAU-GA10: X = -2-NO2
DAU-GA11: X = -3-NO2
DAU-GsA3: R5 = -CH2OH
DAU-GlA3: R3 = -H, R4 = -OH, R5 = -CH2OH
Anthracycline
Spacer
Specifier
2
Y
 R1 = -OMe, R2 = -H, R3 = -OH, R4 = -H, R5 = -CO2Na, X = -H, Y = -H
In all prodrugs,
unless indicated otherwise.
...-.. .. ..
drug
specifier spacer type
spacer number
anthracycline: DAU = daunorubicin
DOX = doxorubicin
IDA = idarubicin 
specifier: G = b -D-glucuronyl carbamate
Gs = b -D-glucosyl carbamate
Gl = b -D-galactosyl carbamate
spacer type: A =spacer expulsion by 1,4- or 1,6-elimination (Ch. 4) or  -CO2 spacer (Ch. 2) 
B = spacer expulsion by cyclization (Ch. 3)
spacer number: numbering of prodrugs of same type
(for example 
"DAU-GsA3")
nomenclature of glycosylated prodrugs:
Chart 4.3   Target compounds derived from DAU-GA3.
The specifier: b -D-glucoside and b -D-galactoside derivatives DAU-GsA3 and DAU-
GlA3, respectively, are expected to be activated by human b -glucosidase and human
b -galactosidase, respectively. These prodrugs possess a reduced polarity which might
retard rapid clearance from the blood.
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The spacer: The ortho analog of DAU-GA3, compound DAU-GA4, as well as prodrugs
DAU-GA6 - 11 containing a chlorine, bromine or nitro substituent on the aromatic ring
of the spacer will be synthesized. Apart from being electron withdrawing and,
therefore, facilitating the enzymatic hydrolysis of the b -D-glucuronyl group, chloro- and
bromo-aryl groups are known to have a high serum albumin binding potency[ 15]
which might prevent rapid prodrug excretion. Furthermore, prodrug DAU-GA5
having a lipophylic C6-tail on the benzylic carbon of the spacer was designed in order
to study excretion pharmacokinetics.
The anthracycline: Doxorubicin and idarubicin analogs DOX-GA3  and IDA-GA3,
respectively, are included in the series of targets, especially because doxorubicin is
clinically more relevant than daunorubicin.
It should be noted that DAU-GlA3 is analogous to compoud 9 (chart 4.2) except that
the anthracycline is not doxorubicin but daunorubicin and that the specifier in DAU-
G l A 3  is a b -galactosyl carbamate whereas in 9  the specifier is an a -galactosyl
carbamate. Furthermore, all compound in chart 4.1 contain a b -D-glucuronyl specifier
group but lack the connecting carbamate function between spacer and specifier which
is present in all prodrugs in chart 4.3.
4.3 Synthesis of prodrugs
4.3.1 Strategy
The designed prodrugs presented in chart 4.3 can be prepared by coupling the benzyl
alcohol group of pro-moieties 17 to the anthracycline 3'-amino group.
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H O O
N
C
O
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HO OSi O O CH3
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HO O
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coupling  to
anthracycline
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H O
X X X•
•
O
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• •
•
•
O•
•
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X
=
(chart 4.3)
Scheme 4.4   General synthetic pathways leading to pro-moiety 17.
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For the preparation of compound 17 via masked intermediates 16, in routes A and B
(scheme 4.4), introduction of a b -glycosyl carbamate group to the spacer can be
accomplished by the addition reaction of the anomerically unprotected glycosyl donor
15 to spacer isocyanate 14. As outlined in section 5.1, this isocyanate addition reaction
when performed in toluene and in the presence of triethylamine as the catalyst, leads to
a very high b -diastereoselectivity[ 16]. Depending on the availability of the starting
material for 12 and 13, the masked hydroxymethyl unit was either a protected
hydroxymethyl group an ester or a methyl group. These units can be converted into a
hydroxymethyl group by deprotection, reduction and oxidation, respectively.
Following these pathways, pro-moieties 17 can either be prepared from carboxylic acids
12, aniline-hydrochlorides 13 or isocyanates 14.
4.3.2 Synthesis of prodrugs via route A
The rearrangement of acyl azides to isocyanates can be employed in the synthesis of
prodrugs to generate isocyanates 21 from carboxylic acids 18 (scheme 4.5). Using
diphenyl phosphoryl azide 19[17] , spacer acyl azides 20 [ 18] were formed from
carboxylic acids 18. Upon heating, acyl azides 20 rearranged to isocyanates 21. After
these isocyanates had been formed, the mixture was cooled to ambient temperature and
the anomerically unprotected glycosyl donor 15 was added. Following this protocol,
b -D-glycosyl carbamates 22 were obtained in a one-pot procedure from carboxylic acids
18 in good to excellent yields and in more than 95% b -diastereoselectivity.
Attempts to remove the tert.-butyldimethylsilyl group from 22 using TBAF resulted in
multiple product formation, probably due to removal of the acetyl protection groups by
the basic TBAF. Alternatively, selective removal of the silyl protection group of
intermediates 22 using acetic acid/water/THF was successfully achieved in almost
quantitative yield. The benzyl alcohol group of 23 was coupled to daunorubicin,
doxorubicin or idarubicin making use of di-N,N'-succinimidyl carbonate (25)[ 19].
Deprotection of the carbohydrate specifier of 24 was accomplished using lithium
hydroxide in MeOH/H2O/THF at 0ºC. After neutralization of the basic solution with
ion exchange resin, the polar prodrugs were purified on a reversed phase-C18 column
and lyophilized to yield the pure prodrugs as red fluffy solids. The most troublesome
step in the preparation of prodrug DOX-GA3 was the deprotection of the glucuronyl
moiety of the protected precursor 24(DOX-GA3)[20] . A maximum yield of 37% was
obtained due to the base lability of doxorubicin, whereas for daunorubicin prodrug
DAU-GA3 deprotection was readily accomplished in 81%.
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IDA-GA3 -H -H -OAc -H -CO2Me -OH -H -CO2Na -H
DAU-GsA3 -OMe -H -OAc -H -CH2OAc -OH -H -CH2OH -H
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Scheme 4.5    Synthesis of prodrugs with unsubstituted spacer aromatic ring.
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The ortho substituted prodrug DAU-
G A 4  (chart 4.4) was synthesized
analogously to DAU-GA3 (scheme
4.5) starting from the silyl-protected o-
hydroxymethyl benzoic acid 27 (chart
4.4).
DAU-GA5 was synthesized according
to scheme 4.5, with Y = -n-hexyl . The
starting material 18  (Y = -n-hexyl),
was obtained by following scheme
4.6. The secondary benzyl alcohol
group of pro-moiety 24 was coupled
to daunorubicin using the more
reactive N-succinimidyl chloro-
formate [21] (26, scheme 4.5).
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Chart 4.4   Ortho analog of DAU-GA3.
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 in scheme 4.5)
*
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*
*
Scheme 4.6   Preparation of 18.
4.3.3 Preparation of prodrugs containing electron-withdrawing substituents on the 
spacer.
Pro-moieties for prodrugs DAU-GA6 - -GA11 containing an additional chlorine,
bromine or nitro group on the spacer were synthesized according to scheme 4.7.
Depending on the availability of the starting material, the pro-moieties were prepared
either from substituted anilines 31 [ 22], toluic isocyanates 32 or terephthalic acid
derivatives 36. The spacer-2-chloro and spacer-2-bromo substituted pro-moieties for
prodrugs DAU-GA6 and DAU-GA8, respectively, were prepared in moderate yield
starting from 4-methyl-2-chloroaniline-HCl and 4-methyl-2-bromoaniline-HCl (31, X =
-2-Cl and -2-Br, respectively) using diphosgene (41)[ 23] to make the respective
isocyanates 32. After the addition of glucuronyl donor 42 to isocyanates 32, the 4-Me
group b -D-glucuronyl carbamates 33 was brominated. The crude bromides 34 were
hydrolyzed using silver nitrate in acetone/water yielding pro-moieties 35 (X = -2-Cl)
and 35 (X = -2-Br) in 50 - 80% yield.
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Scheme 4.7   Synthesis of substituted prodrugs [13].
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The pro-moieties for prodrugs DAU-GA7, -GA10 and -GA11 were analogously
synthesized starting from the respective commercially available isocyanates 32 (X = -3-
Cl, -2-NO2 and -3-NO2, respectively). As 3-bromo-4-methyl isocyanate 32 (X = -3-Br)
was not commercially available, the corresponding pro-moiety 35 (X = -3-Br) was
synthesized from bromoterephthalic acid (36, X = -Br) by esterification of one carboxylic
acid group and selective crystallization of the C(4) allyl ester bromo terephthalic acid
derivative 37 (X = -3-Br). Isocyanate 38 (X = -3-Br) was generated from carboxylic acid
37 (X = -3-Br) employing the Curtius rearrangement. This isocyanate was further
reacted with anomerically unprotected glucuronate 42 to give 39 (X = -3-Br). Removal
of the allyl protection group and reduction of the resulting carboxylic acid to a benzyl
alcohol group using BH3-THF[ 24] resulted in pro-moiety 35 (X = -3-Br) in excellent
yield.
The thus obtained six pro-moieties 35 were coupled to daunorubicin using di-N,N'-
succinimidyl carbonate (25)[19] to give protected prodrugs 40.
The procedure to hydrolyze the three acetyl groups and the methyl ester of the
glucuronyl fragment of the protected prodrugs, proved to be the most troublesome
step. Deprotection of the prodrug precursors 40 having the electronegative substituent
on the 2-position of the aromatic ring led to extensive decomposition products. In case
of both DAU-GA6 and -GA8 (X = -2-Cl and -2-Br, respectively), about 35% yield was
attained.
O
O
N H
N H
OMeO
44
daunorubicin-3'-
O
AcO
AcO
AcO MeO2C
O
O
N H
N H
OO
daunorubicin-3'-
O
(Ac,H)O
(Ac,H)O
(Ac,H)O
(Me,Li)O2C
O
O
N H
N H
OO
daunorubicin-3'-
40
X X X
O
O
N H
NH2
daunorubicin-3'-
X
:
CO2
NH2
daunorubicin-3'-
NH
X
NH2
X
HO
CO2
45
H2O
LiOH
MeOH/H2O/THF
+
+
O
(Ac,H)O
(Ac,H)O(Ac,H)O
(Me,Li)O2C
OH
O
O
N H
N H
OH O
daunorubicin-3'-
X
-OMe
-O H
43
MeOH
HO-
Scheme 4.8   Decomposition pathways during deprotection of protected prodrugs 40.
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Deprotection of 40 (X = -2-NO2) did not led to the desired prodrug DAU-GA10, but in
nearly quantitative yield methyl carbamate 43 (X = -2-NO2, scheme 4.8) was formed.
Deprotection of the prodrug precursors 40 having the electronegative substituent on the
3-position of the aromatic ring was accomplished in satisfactory yields in case of DAU-
GA7 (67%) and DAU-GA9 (50%). DAU-GA11, however, could not be obtained pure.
Deprotection of 40 (X = -3-NO2) led to extensive decomposition and multiple side-
product formation and only a small amount of impure DAU-GA11 was obtained.
The problematic base mediated demasking of the protected prodrugs 40 is very likely
due to hydrolysis of the spacer carbamate group leading to product 44 (scheme 4.8)
which further decomposes to daunorubicin. In the case of 40 (X = -2-NO2) formation of
methyl carbamate 43 (scheme 4.8) was observed.
To be able to prepare a prodrug containing a 2-nitro group on the spacer, it was
anticipated to methylate the spacer nitrogen atom in order to prevent hydrolysis of the
b -glucuronyl carbamate during base mediated deprotection of the prodrug as depicted
in scheme 4.8. In this respect, when N -(2-nitro-4-methylphenyl) O- b -D-glucuronyl
carbamate 33 b  (X = -2-NO2, scheme 4.9) was treated with silver oxide and methyl
iodide in DMF[ 25], the nitrogen atom was methylated and yielded the N-methyl
derivative 47 b . Along with the N-methylated b -product, the N-methylated a -product
47 a  was formed (reaction at 20ºC, ratio of 47a / b  = 1/3, at 0ºC no a -product was
formed). This anomerization can be envisioned when methyl carbamate 46  and
glucuronate 42 are formed in the reaction medium leading to both the a - and the
b -anomer after recurring addition reaction[26] .
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Scheme 4.9   N-Methylation of b -D-glucuronyl carbamate 33 (X = -2-NO2).
Following scheme 4.7, starting from 47 b -instead of 33, the spacer-N-Me analog of
prodrug DAU-GA11 could not be obtained. Bromination at the 4-Me group of 47 b  and
subsequent hydrolysis of the resulting bromide using silver oxide, led to multiple
product formation. The corresponding N-Me hydroxymethyl derivative 35 (X = -2-NO2)
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was obtained in only minor amounts and attempts to couple this compound to
daunorubicin were not undertaken.
4.4 Evaluation of all synthesized prodrugs for application in 
ADEPT
4.4.1 Cytotoxicities
The in vitro cytotoxicities of all prodrugs prepared in section 4.3 were determined on
OVCAR-3 cells and compared to IC50 values of the respective parent drugs (table 4.1).
In these in vitro experiments, all prodrugs displayed an antiproliferative effect that was
at least 10-fold lower than their respective parent drug. In addition, in in vivo
experiments, maximum tolerated doses (MTD) of daunorubicin prodrug DAU-GA3
and doxorubicin prodrug DOX-GA3 in nude mice bearing OVCAR-3 implants were 30
to 50 times higher (table 4.1) than the MTD of daunorubicin and doxorubicin,
respectively. These findings indicate that these prodrugs possess a strongly decreased
cytotoxicity in comparison to the parent drugs and are much better tolerated by a test
animal, which is an essential feature for a prodrug. The large difference in the
antiproliferative effects of prodrugs in in vitro and in vivo experiments can presumably
be attributed to the rapid clearance from the circulation in the in vivo experiments. In in
vitro experiments, b -glucuronidase liberated by defective cells activated the prodrug to
some extent so that the free drug was generated, higher toxicities therefore were found.
Compound IC50 (m M)# Activation
t1/2(min)
MTD ¶
(mg/kg)
DAU-GA3 10 135 * 250
DOX-GA3 10 170 * 500
IDA-GA3 1 120 * n.d.
DAU-GsA3 1.5 300 ‡ n.d.
DAU-GlA3 2.5 400 ‡ n.d.
DAU-GA4 11 125 * n.d.
DAU-GA5 n.d. 950 * n.d.
DAU-GA6 n.d. 150 * n.d.
DAU-GA7 8.5 90 * n.d.
DAU-GA8 n.d. 150 * n.d.
DAU-GA9 n.d. 170 * n.d.
DAU-GA11 n.d. 75 *,† n.d.
daunorubicin 0.1 - 10
doxorubicin 0.05 - 8
idarubicin 0.01 -
 n.d.: not determined.
# Inhibition concentration on OVCAR-3 cells.
* 100 m M Prodrug, 0.03 U/mL human b -glucuronidase, pH = 6.8, 37ºC.
‡ 100 m M Prodrug, 0.3 U/mL b -galactosidase [28], pH = 6.8, 37ºC.
† Hydrolysis to drug-spacer molecule, no conversion to daunorubicin.
¶ Maximal tolerated dose in nude mice.
Table 4.1   Cytotoxicities, enzymatic activation rates and MTD of prodrugs.
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In in vivo experiments, less premature prodrug activation will occur because
b -glucuronidase levels in blood are very low[ 27] due to the excretion of the highly polar
b -glucuronidase enzyme.
4.4.2 Pharmacokinetics
Disappointingly, the cellular accumulation and clearance from the circulation of nude
mice of the glucosyl and galactosyl based prodrugs DAU-GsA3 and DAU-GlA3, and of
the more lipophylic prodrug DAU-GA5, was similar to these characteristics of DAU-
G A 3 . Contrastingly, their water solubility compared with DAU-GA3 was
unfavourable. The in vitro serum protein binding of the halogen containing prodrugs
DAU-GA6 - -GA9  was found to be higher than that of DAU-GA3. In contrast,
elimination of these prodrugs from the blood stream of mice was comparable to that of
DAU-GA3. The serum protein binding haloarylated drug derivatives described in the
literature [15], possess a relatively small molecular mass (M = –  250 g/mol). The
halogenated prodrugs DAU-GA6 - -GA9 have a molecular mass of approximately 1000
g/mol. Probably the serum binding capacity of the halogenated prodrugs is too small
to retain the prodrug in the bloodstream.
4.4.3 Enzymatic prodrug activation rates
For determination of the enzymatic activation rates, the prodrugs were incubated with
the matching enzyme[28] . Incubation of DAU-GA3 with human b -glucuronidase
results in complete activation of the prodrug and on HPLC, no intermediate drug-
spacer molecule was detected [14]. All prodrugs in the present chapter were
quantitatively activated to the parent drug except the spacer-3-nitro substituted
prodrug DAU-GA11. When the b -glucuronidase mediated activation of DAU-GA11
was examined on HPLC the prodrug disappeared with a half-live of 75 min. Instead of
daunorubicin, however, a peak of an unknown compound was detected which was
assumed to be the drug-spacer molecule. Probably, electron density in the spacer
aromatic ring is too strongly diminished by the presence of the nitro group for the 1,6-
elimination process to take place.
Prodrugs of daunorubicin, doxorubicin and idarubicin containing the para or ortho
glucuronyl carbamate pro-moiety were activated by b -glucuronidase at approximately
the same rate. Half-lives between 2 and 3 hours were recorded (table 4.1). The glucosyl
and galactosyl based prodrugs, however, were activated at a two-fold reduced rate
compared with the glucuronyl based prodrugs. From the derivatives having an
electron-withdrawing group on the spacer, only DAU-GA7 displayed an accelerated
activation rate as can be deduced from table 4.1.
4.4.4 Conclusions
As can be concluded from the data presented in the preceeding sections, the
b -glucuronyl-based prodrugs of daunorubicin and doxorubicin, DAU-GA3 and DOX-
GA3, respectively, are acceptable prodrugs in selective chemotherapy (ADEPT). In
monotherapy experiments (in which the mAb-enzyme conjugate is not given prior to
prodrug administration) favorable selective toxicities of these prodrugs for target tissue
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were observed, caused by endogenous b -glucuronidase liberated from necrotic tumor
areas[29] . For more detailed studies using these prodrugs in both ADEPT and
monotherapy experiments, see chapter 6. IDA-GA3 was only studied in preliminary
experiments.
Until now, structural variation of the spacer moiety of the prodrugs did not
significantly improve prodrug characteristics, such as the rate of enzymatic hydrolysis
and retention in the circulation of the prodrug.
4.5 Experimental Part
4.5.1 Biological evaluation
Cytotoxicities
The cytotoxicities of daunorubicin, doxorubicin, idarubicin and of all ten prodrugs on
OVCAR-3 cells were determined by measuring cell growth with a protein dye stain[ 30].
Cells were harvested with 0.25% trypsin and 0.2% EDTA in PBS to obtain a single cell
suspension and seeded in 96-wells tissue culture plates (2 x 106 cells/mL 10 m L/well, 3
wells per concentration). Drug or prodrug was added (10 m L/well) at different
concentrations with a range of 3 or more logs. After incubation for 24 h, 200 m L of
culture medium (supplemented DMEM) was added and the cells were grown for
another 72 h. Cells were fixed with 25% trichloroacetic acid for 1 h at 4ºC and washed
with water. After staining the cells with 0.4% sulforhodamine B in 1% (v/v) acetic acid
for 15 min at room temperature, they were washed with 1% acetic acid and air-dried.
The bound dye was solubilized with 10 mM unbuffered Tris and the absorbance was
read at 492 nm. The absorbance was linear with cell concentrations from 1,000 to
200,000 cells/well. Separate wells were fixed 24 h after seeding to substract background
staining. The anti-proliferative effects were determined and expressed as IC50 values
which are the (pro)drug concentrations that gave 50% growth inhibition when
compared to control cell growth.
Maximal tolerated dose (MTD)
The MTD (expressed in mg prodrug/kg mouse) of DAU-GA3 and DOX-GA3 was
determined by intravenously injecting 1000, 500 or 250 mg/kg of prodrug in 3 groups
of nude mice for each drug. The weight loss of the mice was followed in time. In was
concluded that the MTD was given to the group of mice which received the highest
dose of prodrug while showing not more than 5% weight loss.
Enzymatic prodrug activation rates
The enzymatic activation rates of the b -D-glucuronyl containing prodrugs were
determined by incubation of 100 m M of prodrug in 0.1% BSA/PBS at pH = 6.8 with 0.03
U/mL human b -glucuronidase at 37ºC. The b -D-glucose and b -D-galactose based
prodrugs were incubated with 0.3 U/mL bovine liver b -galactosidase[28] in 0.1%
BSA/PBS at pH = 6.8 and 37ºC. Samples were prepared and analyzed on reversed
phase SiO2-C18 HPLC as described by us[14].
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Pharmacokinetics
Protein binding properties of the halogenated prodrugs 25 (X = -Cl, -Br) were
determined by the use of a Dianorm dialysis apparatus (Diachema, Zürich, Switzer-
land). Two 500 m L chambers were separated by a 5000 Da cut-off dialysis membrane.
One chamber was filled with prodrug or drug diluted in 4% human serum albumin
(HSA) in PBS at pH = 7.4. The second chamber was filled with PBS. After closing the
chambers, the respective samples were incubated for 4 h at 37ºC under rotation.
Samples from both chambers were diluted 20 times in 7.5% MeCN in PBS, the pH was
adjusted to 3.5 with 1 M H3PO4. The fluorescence of the samples was recorded and
compared to fluorescence properties of standard solutions of each (pro)drug in the
same diluent (0.01 to 10 m M).
Circulation half-live were determined in BALB/c mice. 10 mg/kg of prodrug in 0.9%
aqueous NaCl were intravenously injected into the animals. Over a period of 24 h,
serial blood samples were collected from the eye plexus with the use of heparinized
glass capillaries. Samples were centrifuged at 16,000 g for 4 min to prepare plasma. The
samples were prepared and analyzed on reversed phase SiO2-C18 HPLC as
described[14] .
4.5.2 Chemistry
General
Daunorubicin-, doxorubicin- and idarubicin hydrochlorides were a generous gift of
Pharmachemie BV (Haarlem, The Netherlands). Chromatotron model 7924-T Harrison
Research (Palo Alto, California, USA) equipped with plates (thickness 2 mm, diameter
8.5 cm) made from Merck silicagel 60 PF254 which contains gypsum (art. 7749) was used
when circular chromatography is indicated. When cation exchange material was
indicated, amberlite resin IR-120 (Na) BDH (Poole, Dorset, England) was converted to
the H+-form using 1 N HCl prior to use. Reversed phase chromatography was
performed with a liquid chromatography pump LC-410 (Kontron) using a pre-packed
column (24 cm, diameter 11 mm) containing octadecylsilane (40-63 m m) Merck
(Darmstadt, Germany). Prior to use the RP-C1 8  column was equilibrated with
demineralized water. 1H-NMR spectra at 400 MHz were obtained on a Bruker AM-400
spectrometer and 100 MHz spectra on a Bruker AM100 spectrometer. Chemical shifts
are expressed in ppm downfield from internal standard Me4Si. All solvents except
MeCN and i-Pr2O were dried before use: Et3N, CCl4, CH2Cl2 and PhMe were dried by
distillation over CaH2, pyridine by distillation over CaCl2 and THF by distillation over
LiAlH4 or sodium. i-Pr2NEt was dried over KOH pellets. In all cases demineralized
H2O was used. Allyl alcohol was dried by distillation over Mg/I2.
General procedure #1: Modified Curtius reaction for conversion of carboxylic acids 18 (scheme
4.5) and 37 (scheme 4.7) to b -D-glycosyl carbamates.
500 mg of a carboxylic acid 18 or 37 was stirred overnight with 1.1 equiv. of (PhO)2P(O)N3 and 1.1 equiv.
of Et3N in 15 mL of dry PhMe under an argon atmosphere at room temperature. The reaction mixture
was subsequently heated for 2 h until gas evolution was observed, occurring between 65-100ºC
depending on the actual substrate. The reaction mixture was allowed to cool to ambient temperature and
0.5-0.75 equivalents [31] of the anomerically unprotected glycosyl donor 15 (scheme 4.4) or 42 (scheme
4.6) was added. The reaction mixture was stirred until 15 or 42 had almost disappeared on TLC (SiO2,
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Et2O) and worked-up in the following fashion: The reaction mixture was diluted with 100 mL of Et2O
and successively washed with 200 mL portions of aqueous 0.5 N KHSO4, with saturated aqueous
NaHCO3 (3x) and with brine. The organic layer was dried over Na2SO4 and evaporated. The residual
material was purified by column chromatography (SiO2, Et2O/n-Hex 4/1) to yield 1-O-b -D-glycosyl
carbamates 2 2  (scheme 4.5) or 3 9  (scheme 4.7) in good to excellent yield and 95-100 %
b -diastereoselectivity.
General procedure #2: Removal of tert.-butyldimethylsilyl group from b -D-glycosyl 
carbamates 22 (scheme 4.5).
1.00 g of 22 was stirred in 100 mL of THF/H2O/AcOH 1/1/1. The course of the deprotection reaction
was followed on TLC (SiO2, Et2O). After ca. 3 h, the reaction mixture was diluted with 200 mL of H2O
and the THF was removed by evaporation. The aqueous layer was washed 5 times with 100 mL portions
of CH2Cl2, the organic extracts were combined and washed successively with aqueous saturated
NaHCO3 until gas evolution ceased, and with brine. The organic layer was dried over Na2SO4 and
evaporated. The resulting foam was sonicated in i-Pr2O and collected by filtration. Traces of t-
BuMe2SiOH were removed under reduced pressure to give 23 in almost quantitative yield.
General procedure #3: Coupling of pro-moieties 23 (scheme 4.5) and 35 (scheme 4.7) to 
anthracyclines.
100 mg of 23 or 35 was stirred with (1.1 equiv.) of di-N-N'-succinimidyl carbonate (25) and 2.5 equiv. of i-
Pr2NEt in 10 mL of CH2Cl2. Alternatively, 23 (Y = -(CH2)5CH3) was coupled using 2.0 equiv. of N-
succinimidyl chloroformate 26 and 3.0 equiv. of pyridine. After no starting material was detected on TLC
(SiO2, Et2O) a solution of 1.1 equiv. of the anthracycline DAU-, DOX- or IDA-HCl and 2.5 equiv. of i-
Pr2NEt in 10 mL of DMF were added. The course of the reaction was monitored by TLC (SiO2,
CH2Cl2/EtOH 10/1). After all of the active ester starting material had disappeared, the reaction mixture
was diluted with 200 mL of CH2Cl2 and washed successively with 100 mL portions of aqueous 0.5 N
KHSO4 (3x), with H2O, with aqueous saturated NaHCO3 (2x), H2O (2x), and with brine. The organic layer
was dried over Na2SO4 and evaporated. The resulting red residue was purified by  circular
chromatography using a chromatotron supplied with a 2 mm thick silica plate and mixtures of
CH2Cl2/EtOH 10/1 (first run) and 30/1 (successive runs) until the protected prodrug 24 (scheme 4.5) or
40 (scheme 4.7) was a single spot on TLC (SiO2, CH2Cl2/EtOH 20/1). After evaporation of the eluent, the
resulting red product was sonicated in i-Pr2O and collected by filtration to yield 24 or 40 as a red powder
in low to good yield, depending on the starting material.
General procedure #4: Deprotection of the b -D-glycosyl specifier in the protected prodrugs 24 
(scheme 4.5) and 40 (scheme 4.7).
To the protected prodrug 24 (scheme 4.5) or 40 (scheme 4.7) was added 6 equiv. of a 0.10 N LiOH
solution in MeOH/H2O/THF 2.5/1/0.5. The resulting deep blue solution was stirred at 0ºC under an
argon atmosphere and progress of the deprotection reaction was continuously monitored by reversed
phase TLC (SiO2-C18, MeCN/H2O 1/1). After 15-90 min of deprotection, the reaction mixture was diluted
to ca. twice the volume with H2O, 25 vol% of THF was added and the mixture was neutralized by adding
ca. 2 g of amberlite cation exchange material (H+ form) per 100 mg of 24 or 40. The amberlite material was
removed by filtration and in case of a b -glucuronyl prodrug, ca. 10 equiv. of NaHCO3 was added to
convert the glucuronyl carboxylic acid group to the sodium salt. The MeOH and THF suspended in the
water layer were removed by evaporation and the red aqueous product solution was transferred to a
reversed phase column packed with RP-C18 material. To remove the excess of NaCO3, the column was
eluted with ca. 300 mL of H2O. The column was washed with MeCN/H2O 1/4 to elute the product and
the MeCN was removed by evaporation. When the prodrug was not a single spot on TLC, the aqueous
solution was transferred to the reversed phase column and purified again by eluting a MeCN/H2O
mixture in a ratio of 1/4 to 1/10. The MeCN was removed by evaporation and freeze drying of the
aqueous product fraction afforded prodrugs DAU-, DOX- or IDA-GA3, DAU-GsA3 or DAU-GlA3 or
DAU-GA4 to -GA9 or a small amount of impure DAU-GA11 as red fluffy solids.
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General procedure #5: a -Bromination of 33 (scheme 4.7).
300 mg of 33 was dissolved in 10 mL of CCl4 and 1.1 equiv. of NBS and a catalytic amount of AIBN were
added. The solution was irradiated for 1 h using a 250 W lamp. the temperature was allowed to raise to
reflux. After cooling, the reaction mixture was filtered evaporated and dried under reduced pressure (0.1
mm Hg) to give the crude 34. This was used in the next step without further purification.
General procedure #6: Hydrolysis of benzylic bromides 34 (scheme 4.7).
The crude 34 was dissolved in 10 mL of acetone and 10 mL (3 equiv.) of an aqueous 0.2 N AgNO3
solution were added. Conversion of 34 to 35 was monitored on TLC (SiO2, Et2O), additional AgNO3 was
added when progress of the hydrolysis stopped. This procedure was repeated until no further reaction
took place. The mixture was filtered and evaporated. The resulting oil was redissolved in CH2Cl2 and
washed with saturated aqueous NaHCO3 (2x), with brine and dried over Na2SO4 and the CH2Cl2 was
evaporated to give the crude 35. This was used without further purification.
Synthesis of N-[4-(daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -D-glucuronyl carbamate 
sodium salt (DAU-GA3).
N-[4-(tert.-Butyldimethylsilyloxymethyl)phenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(22(GA3))  [20] from 18 (Y = -H) [32] according to general procedure #1 as white needles from i-Pr2O/n-
Hex mp 128ºC in 95% yield and in 100% b -diastereoselectivity, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 0.00
(s, 6H, -SiMe2-), 0.84 (s, 9H, -SiCMe3), 1.95 (s, 9H, 3 -OAc), 3.64 (s, 3H, -CO2Me), 4.12 (d, 1H, Gluc5-H, J =
9.3 Hz), 4.54 (s, 2H, ArCH2- ), 5.10-5.20 (m, 3H, Gluc2,3,4-H), 5.68 (d, 1H, Gluc1-H, J = 7.9 Hz), 6.63 (s, 1H,
ArNH-), 7.15-7.30 (m, 4H, Ar2,3,5,6-H).
N-[4-(Hydroxymethyl)phenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate ( 23(GA3)) from 22(GA3)
according to general procedure #2 as a white powder, mp 173ºC in 92%. 1H-NMR (100 MHz, CDCl3) d
(ppm) = 1.96 (s, 9H, 3 -OAc), 3.64 (s, 3H, -CO2Me), 4.13 (d, 1H, Gluc5-H, J = 9.3 Hz), 4.61 (s, 2H, ArCH2-),
5.00-5.35 (m, 3H, Gluc2,3,4-H), 5.71 (d, 1H, Gluc1-H, J = 7.5 Hz), 6.92 (s, 1H, ArNH-), 7.20-7.30 (m, 4H,
Ar2,3,5,6H).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(24(DAU-GA3)) from 23(GA3) according to general procedure #3 in 84%, mp 163-164ºC. 1H-NMR (400 MHz,
CDCl3) d  (ppm) = 1.28 (d, 3H, 5'-Me, J = 6.6 Hz), 1.78 (dt, 1H, 2'ax-H, J = 12.9 Hz J = 3.8 Hz), 1.87 (dd, 1H,
2'eq-H, J = 13.3 Hz J = 5.8 Hz), 2.05 (s, 9H, 3 -OAc), 2.09 (dd, 1H, 8ax-H, J = 15,2 Hz J = 3.7 Hz), 2.30 (d, 1H,
8eq-H, J = 14.9 Hz), 2.41 (s, 3H, 9-C(O)Me), 2.88 (d, 1H, 10ax-H, J = 18.8 Hz), 3.20 (d, 1H, 10eq-H, J = 18.8
Hz), 3.67 (s, 1H, 4'-H), 3.72 (s, 3H, -CO2Me), 3.88 (m, 1H, 3'-H), 4.05 (s, 3H, 4-OMe), 4.22 (d, 1H, Gluc5-H, J
= 9.8 Hz), 4.15-4.25 (m, 1H, 5'-H), 4.48 (s, 1H, 9-OH), 4.89 (d, 1H, ArCHaHb-, J = 12.2 Hz), 4.95 (d, 1H,
ArCHaHb-, J = 12.2 Hz), 5.15-5.30 (m, 4H, Gluc2,4-H 7-H 3'-NH-), 5.38 (t, 1H, Gluc3-H, J = 9.3 Hz), 5.47 (d,
1H, 1'-H, J = 3.1 Hz), 5.77 (d, 1H, Gluc1-H, J = 8.0 Hz), 7.16 (s, 1H, ArNH-), 7.18 (d, 2H, Ar3,5-H, J = 8.0
Hz), 7.24 (d, 2H, Ar2,6-H, J = 8.0 Hz) 7.37 (d, 1H, 3-H, J = 8.4 Hz), 7.76 (t, 1H, 2-H, J = 8.0 Hz), 8.00 (d, 1H,
1-H, J = 7.7 Hz), 13.22 (s, 1H, 11-OH), 13.94 (s, 1H, 6-OH).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -D-glucuronyl carbamate sodium salt (DAU-GA3) from
24(DAU-GA3) according to general procedure #4 in 81%, mp 175ºC (dec.). Anal.: calc. (found) for
C42H43N2O20Na.4 H2O: C: 50.91 (50.73), H: 4.19 (4.96), N: 2.83 (2.94). MS (FAB+) m/z = 942 ([M+1+Na]+),
941 ([M+Na]+), 920 ([M+1+H]+), 919 ([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.11 (d, 3H, 5'-
Me, J = 6.6 Hz), 1.47 (dd, 1H, 2'eq-H, J = 12.1 Hz J = 3.4 Hz), 1.82 (dt, 1H, 2'ax-H, J = 11.5 Hz J = 3.4 Hz),
2.07 (dd, 1H, 8ax-H, J = 14.1 Hz J = 6.1 Hz), 2.19 (dd, 1H, 8eq-H, J = 14.1 J = 3.1 Hz), 2.27 (s, 3H, -C(O)Me),
3.11 (d, 1H, 10eq-H, J = 18.5 Hz), 3.13 (d, 1H, 10ax-H, J = 18.5 Hz), 3.20-3.65 (m, 4H, 4'-H Gluc2,3,4-H), 3.71
(m, 1H, 3'-H), 3.95 (s, 3H, 4-OMe), 4.16 (q, 1H, 5'-H, J = 6.6 Hz), 4.70 (d, 1H, 4’-OH, J = 5.1 Hz), 4.75-5.35
(m, 4H, Gluc5-H Gluc2,3,4-OH), 4.84 (d, 1H, ArCHaHb-, J = 12.8 Hz), 4.88 (d, 1H, ArCHaHb-, J = 12.8 Hz),
4.90 (t, 1H, 7-H, J = 5.1 Hz), 5.20 (d, 1H, 1'-H, J = 3.0 Hz), 5.28 (d, 1H, Gluc1-H, J = 8.2 Hz), 5.52 (s, 1H, 9-
OH), 6.84 (d, 1H, 3'-NH-, J = 8.0 Hz), 7.23 (d, 2H, Ar3,5-H, J = 8.4 Hz), 7.43 (d, 2H, Ar2,6-H, J = 8.4 Hz),
7.60 (dd, 1H, 3-H, J = 6.8 Hz J = 3.0 Hz), 7.80-7.90 (m, 2H, 1,2-H), 9.90 (s, 1H, ArNH-) 13.25 (s, 1H, 11-OH),
13.99 (s, 1H, 6-OH).
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Synthesis of N-[4-(doxorubicin-N-carbonyl-oxymethyl)phenyl] O-b -D-glucuronyl carbamate 
sodium salt (DOX-GA3).
N-[4-(Doxorubicin-N-carbonyl-oxymethyl)phenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(24(DOX-GA3)) from 23(GA3) according to general procedure #3 in 69%, mp 165-167ºC. 1H-NMR (400 MHz,
CDCl3) d  (ppm) = 1.28 (d, 3H, 5'-Me, J = 6.5 Hz), 1.75-1.90 (m, 3H, 2'eq-H 2'ax-H 4'-OH), 2.05 (s, 9H, 3
-OAc), 2.14 (dd, 1H, 8ax-H, J = 14.7 Hz J = 3.9 Hz), 2.32 (d, 1H, 8eq-H, J = 14.7 Hz), 2.97 (d, 1H, 10ax-H, J =
18.9 Hz), 3.06 (s, 1H, 14-OH), 3.24 (d, 1H, 10eq-H, J = 18.9 Hz), 3.66 (m, 1H, 4'-H), 3.72 (s, 3H, -CO2Me),
3.86 (m, 1H, 3'-H), 4.06 (s, 3H, 4-OMe), 4.13 (q, 1H, 5'-H, J = 6.5 Hz), 4.22 (d, 1H, Gluc5-H, J = 9.7 Hz), 4.55
(s, 1H, 9-OH), 4.75 (s, 2H, 9-C(O)CH2-), 4.93 (d, 1H, ArCHaHb-, J = 12.4 Hz), 4.96 (d, 1H, ArCHaHb-, J =
12.4 Hz), 5.15-5.30 (m, 4H, 7-H 3'-NH- Gluc2,4-H), 5.36 (t, 1H, Gluc3-H, J = 9.3 Hz), 5.48 (d, 1H, 1'-H, J =
3.0 Hz), 5.77 (d, 1H, Gluc1-H, J = 8.0 Hz), 7.20 (d, 2H, Ar3,5-H, J = 7.0 Hz), 7.20-7.35 (m, 3H, Ar2,6-H
ArNH-), 7.38 (d, 1H, 3-H, J = 8.5 Hz), 7.78 (t, 1H, 2-H, J = 8.0 Hz), 8.01 (d, 1H, 1-H, J = 7.8 Hz), 13.19 (s, 1H,
11-OH), 13.93 (s, 1H, 6-OH).
N-[4-(Doxorubicin-N-carbonyl-oxymethyl)phenyl] O-b -D-glucuronyl carbamate sodium salt (DOX-GA3) from
24(DOX-GA3) according to general procedure #4 in 37%, mp 191ºC (dec.). Anal.: calc. (found) for
C42H43N2O21Na.4 H2O: C: 50.10 (50.31), H: 5.11 (4.81), N: 2.78 (3.00). MS (FAB+) m/z = 958 ([M+1+Na]+),
957 ([M+Na]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.12 (d, 3H, 5'-Me, J = 6.3 Hz), 1.47 (d, 1H, 2'eq-
H, J = 12.3 Hz), 1.83 (dt, 1H, 2'ax-H, J = 12.9 Hz J = 3.5 Hz), 2.12 (dd, 1H, 8ax-H, J = 14.2 Hz J = 5.6 Hz), 2.20
(d, 1H, 8eq-H, J = 11.9 Hz), 2.95 (d, 1H, 10eq-H, J = 18.8 Hz), 3.01 (d, 1H, 10ax-H, J = 18.8 Hz), 3.05-3.60 (m,
4H, 4'-H Gluc2,3,4-H), 3.71 (m, 1H, 3'-H), 3.99 (s, 3H, 4-OMe), 4.15 (q, 1H, 5'-H, J = 6.3 Hz), 4.57 (s, 2H, 9-
C(O)CH2-), 4.62-4.71 (m, 1H, Gluc5-H), 4.68 (d, 1H, 4’-OH, J = 4.9 Hz), 4.80-5.30 (m, 4H, 14-OH Gluc2,3,4-
OH), 4.88 (s, 2H, ArCH2-), 4.94 (t, 1H, 7-H, J = 4.2 Hz), 5.21 (d, 1H, 1'-H, J = 2.7 Hz), 5.33 (d, 1H, Gluc1-H, J
= 8.0 Hz), 5.46 (s, 1H, 9-OH), 6.83 (d, 1H, 3'-NH-, J = 8.0 Hz), 7.24 (d, 2H, Ar3,5-H, J = 8.1 Hz), 7.43 (d, 2H,
Ar2,6-H, J = 8.1 Hz), 7.65 (t, 1H, 3-H, J = 4.8 Hz), 7.85-7.95 (m, 2H, 1,2-H), 9.91 (s, 1H, ArNH-) 13.28 (s, 1H,
11-OH), 14.03 (s, 1H, 6-OH).
Synthesis of N-[4-(idarubicin-N-carbonyl-oxymethyl)phenyl] O-b -D-glucuronyl carbamate 
sodium salt (IDA-GA3).
N-[4-(Idarubicin-N-carbonyl-oxymethyl)phenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (24(IDA-
GA3)) from 23(GA3) according to general procedure #3 in 81%, mp 156-157 ºC. 1H-NMR (400 MHz, CDCl3)
d  (ppm) = 1.29 (d, 3H, 5'-Me, J = 6.6 Hz), 1.64 (s, 1H, 4'-OH), 1.80 (dt, 1H, 2'ax-H, J = 13.1 Hz J = 3.9 Hz),
1.92 (dd, 1H, 2'eq-H, J = 13.4 Hz J = 5.0 Hz), 2.04 (s, 9H, -OAc), 2.06 (dd, 1H, 8ax-H, J = 15,2 Hz J = 3.8 Hz),
2.33 (d, 1H, 8eq-H, J = 14.9 Hz), 2.42 (s, 3H, 9-C(O)Me), 2.97 (d, 1H, 10ax-H, J = 18.8 Hz), 3.26 (d, 1H, 10eq-
H, J = 18.8 Hz), 3.68 (d, 1H, 4'-H, J = 6.3 Hz), 3.72 (s, 3H, -C(O)OMe), 3.91 (m, 1H, 3'-H), 4.22 (d, 1H,
Gluc5-H, J = 9.6 Hz), 4.20-4.30 (m, 1H, 5'-H), 4.47 (s, 1H, 9-OH), 4.95 (s, 2H, ArCH2-), 5.15-5.30 (m, 4H, 7-H
3'-NH- Gluc2,4-H), 5.36 (t, 1H, Gluc3-H, J = 9.3 Hz), 5.47 (d, 1H, 1'-H, J = 3.1 Hz), 5.77 (d, 1H, Gluc1-H, J =
8.0 Hz), 7.12 (s, 1H, ArNH-), 7.21 (d, 2H, Ar3,5-H, J = 7.8 Hz), 7.27 (d, 2H, Ar4,6-H, J = 7.8 Hz), 7.80-7.85
(m, 2H, 2,3-H), 8.30-8.35 (m, 2H, 1,4-H), 13.30 (s, 1 H, 11-OH), 13.56 (s, 1 H, 6-OH).
N-[4-(Idarubicin-N-carbonyl-oxymethyl)phenyl] O- b -D-glucuronyl carbamate sodium salt (IDA-GA3) from
24(IDA-GA3) according to general procedure #4 in 79%, mp 187ºC (dec.). Anal.: calc. (found) for
C41H41N2O19Na.3 H2O: C: 52.23 (52.48), H: 5.02 (4.87), N: 2.97 (2.84). MS (FAB+) m/z = 912 ([M+1+Na]+),
911 ([M+Na]+), 890 ([M+1+H]+), 889 ([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.12 (d, 3H, 5'-
Me, J = 6.3 Hz), 1.48 (d, 1H, 2'eq-H, J = 12.6 Hz), 1.84 (dt, 1H, 2'ax-H, J = 12.6 Hz J = 3.4 Hz), 2.12 (dd, 1H,
8ax-H, J = 14.3 Hz J = 5.7 Hz), 2.22 (d, 1H, 8eq-H, J = 14.3), 2.27 (s, 3H, 9-C(O)Me), 2.96 (d, 1H, 10eq-H, J =
18.4 Hz), 3.03 (d, 1H, 10ax-H, J = 18.4 Hz), 3.20-3.65 (m, 4H, 4'-H Gluc2,3,4-H), 3.73 (m, 1H, 3'-H), 4.18 (q,
1H, 5'-H, J = 6.3 Hz), 4.71 (d, 1H, 4’-OH, J = 5.5 Hz), 4.75-4. 85 (m, 1H, Gluc5-H), 4.87 (s, 2H, ArCH2-), 4.95
(t, 1H, 7-H, J = 4.6 Hz), 5.22 (d, 1H, 1'-H, J = 2.6 Hz), 5.15-5.35 (m, 3H, Gluc2,3,4-OH), 5.35 (d, 1H, Gluc1-
H, J = 8.1 Hz), 5.58 (s, 1H, 9-OH), 6.85 (d, 1H, 3'-NH-, J = 7.9 Hz), 7.24 (d, 2H, Ar3,5-H, J = 8.2 Hz), 7.43 (d,
2H, Ar2,6-H, J = 8.2 Hz), 7.95-8.05 (m, 2H, 2,3-H), 8.25- 8.35 (m, 2H, 1,4-H), 9.94 (s, 1H, ArNH-) 13.35 (s,
1H, 11-OH), 13.54 (s, 1H, 6-OH).
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Synthesis of N-[4-(daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -D-glucosyl carbamate 
(DAU-GsA3).
N-[4-(tert.-Butyldimethylsilyloxymethyl)phenyl] O- b -(2,3,4,6-tetra-O-acetyl D-glucosyl) carbamate (22(GsA3))
from 18 (Y = -H) [32] according to general procedure #1 as white needles from i-Pr2O/n-Hex mp 99-100ºC
in 77% yield and in 100% b -diastereoselectivity. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 0.00 (s, 6H, -SiMe2-
), 0.84 (s, 9H, -SiCMe3), 1.95 (s, 3H, -OAc), 1.96 (s, 3H, -OAc), 1.97 (s, 3H, -OAc), 2.00 (s, 3H, -OAc), 3.70-
3.85 (m, 1H, Gluc5-H), 4.00 (dd, 1 H, Gluc6-HaHb-, J = 12.6 Hz, J = 2.1), 4.24 (dd, 1H, Gluc6-HaHb-, J = 12.6
Hz J = 4.3 Hz), 4.60 (s, 2H, ArCH2-), 5.00-5.30 (m, 3H, Gluc2,3,4-H), 5.67 (d, 1 H, Gluc1-H, J = 7.8 Hz), 6.85
(s, 1 H, ArNH-), 7.17 (d, 2H, Ar3,5-H, J = 9.1 Hz), 7.28 (d, 2H, Ar2,6-H, J = 9.1 Hz).
N-[4-(Hydroxymethyl)phenyl] O- b -(2,3,4,6-tetra-O-acetyl D-glucosyl) carbamate (23(GsA3)) from 22(GsA3)
according to general procedure #2 in 68% as an oil, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.91, 1.92, 1.94
and 1.96 (4s, 12H, 4 -OAc), 3.70-3.85 (m, 1H, Gluc5-H), 3.98 (dd, 1H, Gluc6-HaHb-, J = 12.4 Hz, J = 2.0),
4.22 (dd, 1H, Gluc6-HaHb-, J = 12.4 Hz J = 4.3 Hz), 4.54 (s, 2H, ArCH2-), 4.90-5.20 (m, 3H, Gluc2,3,4-H),
5.62 (d, 1H, Gluc1-H, J = 7.8 Hz), 6.93 (s, 1H, ArNH-), 7.15-7.25 (m, 4H, Ar2,3,5,6-H).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O-b -( 2,3,4,6-tetra-O-acetyl D-glucosyl) carbamate (24(DAU-
GsA3)) from 23(GsA3) according to general procedure #3 in 58%, mp 145-148ºC. 1H-NMR (400 MHz,
CDCl3) d  (ppm) = 1.29 (d, 3H, 5'-Me, J = 6.5 Hz), 1.70-1.95 (m, 3H, 2'eq-H 2'ax-H 4'-OH), 2.02, 2.04, 2.06 and
2.07 (4s, 12H, 4 -OAc), 2.11 (dd, 1H, 8ax-H, J = 14.8 Hz J = 3.9 Hz), 2.31 (d, 1H, 8eq-H, J = 14.8 Hz), 2.41 (s,
3H, 9-C(O)Me), 2.91 (d, 1H, 10ax-H, J = 18.7 Hz), 3.22 (d, 1H, 10eq-H, J = 18.7 Hz), 3.65 (m, 1H, 4'-H), 3.85-
3.95 (m, 2H, 3'-H Gluc5-H), 4.07 (s, 3H, 4-OMe), 4.12 (d, 1H, Gluc6-HaHb-, J = 11.7 Hz), 4.21 (q, 1H, 5'-H, J
= 6.5 Hz), 4.31 (dd, 1H, Gluc6-HaHb-, J = 11.7 Hz J = 4.6 Hz), 4.48 (s, 1H, 9-OH), 4.92 (d, 1H, ArCHaHb-, J =
12.2 Hz), 4.97 (d, 1H, ArCHaHb-, J = 12.2 Hz), 5.10-5.35 (m, 5H, 7-H 3'-NH- Gluc2,3,4-H), 5.48 (d, 1H, 1'-H,
J = 3.3 Hz), 5.75 (d, 1H, Gluc1-H, J = 8.1 Hz), 7.10 (s, 1H, ArNH-), 7.22 (d, 2H, Ar3,5-H, J = 7.9 Hz), 7.31 (d,
2H, Ar2,6-H, J = 7.9 Hz), 7.38 (d, 1H, 3-H, J = 8.6 Hz), 7.78 (t, 1H, 2-H, J = 8.0 Hz), 8.02 (d, 1H, 1-H, J = 7.5
Hz), 13.26 (s, 1H, 11-OH), 13.96 (s, 1H, 6-OH).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -D-glucosyl carbamate (DAU-GsA3) from 24(DAU-
GsA3) according to general procedure #4 in 79%, mp 182-184ºC. Anal.: calc. (found) for C42H46N2O19.2.5
H2O: C: 54.37 (54.45), H: 5.54 (5.24), N: 3.02 (2.88). MS (FAB+) m/z = 906 ([M+1+Na]+), 905 ([M+Na]+). 1H-
NMR (400 MHz, (CD3)2SO) d  (ppm) = -0.06 (s, 4H, Gluc2,3,4,6-OH), 1.13 (d, 3H, 5'-Me, J = 6.5 Hz), 1.47 (d,
1H, 2'eq-H, J = 12.8 Hz), 1.83 (dt, 1H, 2'ax-H, J = 12.8 Hz J = 3.5 Hz), 2.08 (dd, 1H, 8ax-H, J = 14.4 Hz J = 5.4
Hz), 2.20 (d, 1H, 8eq-H, J = 14.4 Hz), 2.27 (s, 3H, 9-C(O)Me),2.93 (s, 2H, Gluc6-H2), 3.00-3.80 (m, 10H, 10eq-
H 10ax-H 3',4'-H 9,4’-OH Gluc2,3,4,5-H), 3.97 (s, 3H, 4-OMe), 4.17 (q, 1H, 5'-H, J = 6.5 Hz), 4.87 (s, 2H,
ArCH2-), 4.92 (t, 1H, 7-H, J = 4.4 Hz), 5.21 (d, 1H, 1'-H, J = 2.6 Hz), 5.35 (d, 1H, Gluc1-H, J = 8.2 Hz), 6.83
(d, 1H, 3'-NH-, J = 8.0 Hz), 7.24 (d, 2H, Ar3,5-H, J = 8.3 Hz), 7.42 (d, 2H, Ar2,6-H, J = 8.3 Hz), 7.62 (dd, 1H,
3-H, J = 6.2 Hz J = 3.5 Hz), 7.85-7.90 (m, 2H, 1,2-H), 9.88 (s, 1H, ArNH-) 13.26 (s, 1H, 11-OH), 14.00 (s, 1H,
6-OH).
Synthesis of N-[4-(daunorubicin-N-carbonyl-oxymethyl)phenyl] O-b -D-galactosyl carbamate 
(DAU-GlA3).
N-[4-(tert.-Butyldimethylsilyloxymethyl)phenyl] O-b -(2,3,4,6-tetra-O-acetyl D-galactosyl) carbamate (22(GlA3))
from 18 (Y = -H) [32] according to general procedure #1 as a white foam mp 69-71ºC in 57% yield and in
100% b -diastereoselectivity, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 0.00 (s, 6H, -SiMe2-), 0.84 (s, 9H,
-SiCMe3), 1.91 (s, 3H, -OAc), 1.96 (s, 3H, -OAc), 2.04 (s, 3H, -OAc), 2.08 (s, 3H, -OAc), 3.90-4.15 (m, 3H,
Gal5,6-H2), 4.61 (s, 2H, ArCH2-), 5.03 (dd, 1H, Gal3-H, J = 3.2 Hz, J = 10.3 Hz), 5.25 (d, 1H. Gal2-H, J = 8.0
Hz), 5.36 (d, 1H, Gal4-H, J = 3.2 Hz), 5.66 (d, 1H, Gal1-H, J = 8.0 Hz), 6.93 (s, 1H, ArNH-).7.17 (d, 2H,
Ar3,5-H, J = 8.8 Hz), 7.30 (d, 2H, Ar2,6-H, J = 8.8 Hz).
N-[4-(Hydroxymethyl)phenyl] O-b -(2,3,4,6-tetra-O-acetyl D-galactosyl) carbamate (23(GlA3)) from 22(GlA3)
according to general procedure #2 in 100% as an oil. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.92, 1.95, 1.99
and 2.04 (4s, 12H, 4 -OAc), 3.90-4.20 (m, 3H, Gal5,6-H), 4.55 (s, 2H, ArCH2-), 5.05 (dd, 1H, Gal3-H, J = 10.1
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Hz, J = 3.3 Hz), 5.27 (t, 1 H. Gal2-H, J = 7.9 Hz), 5.37 (d, 1H, Gal4-H, J = 2.9 Hz), 5.64 (d, 1H, Gal1-H, J =
7.8 Hz), 7.20 (d, 2H, Ar3,5-H, J = 10.1 Hz), 7.30 (d, 2H, Ar2,6-H, J = 10.1 Hz), 7.65 (s, 1H, ArNH-).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -(2,3,4,6-tetra-O-acetyl D-galactosyl) carbamate (24(DAU-
GlA3)) from 23(GlA3) according to general procedure #3 in 45%, mp 170-173ºC. 1H-NMR (400 MHz,
CDCl3) d (ppm) = 1.29 (d, 3H, 5'-Me, J = 6.5 Hz), 1.77 (s, 1H, 4'-OH), 1.78 (dt, 1H, 2'ax-H, J = 13.1 Hz J = 4.0
Hz), 1.88 (dd, 1H, 2'eq-H, J = 13.2 Hz J = 5.0 Hz), 2.00, 2.03, 2.05 and 2.17 (4s, 12H, 4 -OAc), 2.11 (dd, 1H,
8ax-H, J = 14.8 Hz J = 4.0 Hz), 2.31 (d, 1H, 8eq-H, J = 14.9 Hz), 2.42 (s, 3H, 9-C(O)Me), 2.91 (d, 1H, 10ax-H, J
= 18.8 Hz), 3.22 (d, 1H, 10eq-H, J = 18.8 Hz), 3.67 (d, 1H, 4'-H, J = 5.9 Hz), 3.91 (bs, 1H, 3'-H), 4.07 (s, 3H, 4-
OMe), 4.05-4.25 (m, 4H, 5'-H Gal5,6-H2), 4.49 (s, 1H, 9-OH), 4.92 (d, 1H, ArCHaHb-, J = 12.3 Hz), 4.98 (d,
1H, ArCHaHb-, J = 12.3 Hz), 5.12 (dd, 1H, Gal3-H, J = 10.4 Hz J = 3.1 Hz), 5.19 (d, 1H, 3'-NH-, J = 8.3 Hz),
5.25 (s, 1H, 7-H), 5.35 (t, 1H, Gal2-H, J = 9.4 Hz), 5.44 (d, 1H, Gal4-H, J = 3.1 Hz), 5.49 (d, 1H, 1'-H, J = 3.4
Hz), 5.71 (d, 1H, Gal1-H, J = 8.3 Hz), 7.14 (s, 1H, ArNH-), 7.22 (d, 2H, Ar3,5-H, J = 7.9 Hz), 7.31 (d, 2H,
Ar2,6-H, J = 7.9 Hz), 7.38 (d, 1H, 3-H, J = 8.5 Hz), 7.78 (t, 1H, 2-H, J = 8.1 Hz), 8.02 (d, 1H, 1-H, J = 7.7 Hz),
13.25 (s, 1H, 11-OH), 13.96 (s, 1H, 6-OH).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O-b -D-galactosyl carbamate (DAU-GlA3) from 24(DAU-
GlA3) according to general procedure #4 in 77%, mp 206-210ºC. Anal.: calc. (found) for C42H46N2O19.2
H2O: C: 54.90 (54.90), H: 5.48 (5.44), N: 3.05 (3.10). MS (FAB+) m/z = 906 ([M+1+Na]+), 905 ([M+Na]+). 1H-
NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.11 (d, 3H, 5'-Me, J = 6.4 Hz), 1.46 (dd, 1H, 2'eq-H, J = 12.8 Hz J =
3.8 Hz), 1.82 (dt, 1H, 2'ax-H, J = 12.8 Hz J = 3.5 Hz), 2.08 (dd, 1H, 8ax-H, J = 14.1 Hz J = 5.7 Hz), 2.19 (d, 1H,
8eq-H, J = 14.7 Hz), 2.25 (s, 3H, 9-C(O)Me), 2.93 (t, 2H, Gal6-H2, J = 19.8 Hz), 3.30-3.75 (m, 9H, 10eq-H 10ax-
H 3',4'-H 4’-OH Gal2,3,4,5-H), 3.97 (s, 3H, 4-OMe), 4.16 (q, 1H, 5'-H, J = 6.6 Hz), 4.50 (d, 1H, -OH, J = 3.9
Hz), 4.63 (d, 1H, -OH, J = 5.0 Hz), 5.68 (d, 1H, -OH, J = 5.5 Hz), 4.86 (s, 2H, ArCH2-), 4.92 (t, 1H, 7-H, J =
4.3 Hz), 5.04 (d, 1H, -OH, J = 4.6 Hz), 5.20 (d, 1H, 1'-H, J = 2.6 Hz), 5.30 (d, 1H, Gal1-H, J = 8.0 Hz), 5.51 (s,
1H, 9-OH), 6.82 (d, 1H, 3'-NH-, J = 8.0 Hz), 7.23 (d, 2H, Ar3,5-H, J = 8.4 Hz), 7.421 (d, 2H, Ar2,6-H, J = 8.3
Hz), 7.62 (t, 1H, 3-H, J = 7.6 Hz), 7.85-7.90 (m, 2H, 1,2-H), 9.83 (s, 1H, ArNH-) 13.24 (s, 1H, 11-OH), 14.00
(s, 1H, 6-OH).
Synthesis of N-[2-(daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -D-glucuronyl carbamate 
sodium salt (DAU-GA4).
N-[2-(tert.-Butyldimethylsilyloxymethyl)phenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(22(GA4)) from 27 (chart 4.4) according to general procedure #1 as a white foam mp 92-94ºC in 69% yield
and in 100% b -diastereoselectivity, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 0.00 (s, 3H, SiMeaMeb-), 0.05 (s,
3H, SiMeaMeb-), 0.83 (s, 9H, SiCMe3), 1.96 (s, 9H, 3 -OAc), 3.66 (s, 3H, -CO2Me), 4.16 (d, 1H, Gluc5-H, J =
9.4 Hz), 4.60 (d, 1H, ArCHaHb-, J  = 18.1 Hz), 4.72 (d, 1H, ArCHaHb-, J = 18.1 Hz), 5.00-5.35 (m, 3H,
Gluc2,3,4-H), 5.76 (d, 1H, Gluc1-H, J = 7.8 Hz), 6.90-7.35 (m, 3H, Ar3,4,5-H), 7.90 (d, 1H, Ar6-H, J = 8.0
Hz), 8.61 (s, 1H, ArNH-).
N-[2-(Hydroxymethyl)phenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate ( 23(GA4)) from 22(GA4)
according to general procedure #2 in 68% as a white amorphous powder, mp 132ºC. 1H-NMR (100 MHz,
CDCl3) d  (ppm) = 1.96 (s, 9H, 3 -OAc), 3.64 (s, 3H, -CO2Me), 4.11 (d, 1H, Gluc5-H, J = 9.4 Hz), 4.59 (s, 2H,
ArCH2-) , 5.10-5.20 (m, 3H, Gluc2,3,4-H), 5.74 (d, 1H, Gluc1-H, J = 7.5 Hz), 6.95-7.30 (m, 3H, Ar3,4,5-H),
7.70 (d, 1H, Ar6-H, J = 7.7 Hz), 8.15 (s, 1H, ArNH-).
N-[2-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(24(DAU-GA4)) from 23(GA4) according to general procedure #3 in 62%, mp 151-153ºC. 1H-NMR (400 MHz,
CDCl3) d  (ppm) = 1.30 (d, 3H, 5'-Me, J = 6.5 Hz), 1.80-1.85 (m, 3H, 2'eq-H 2'ax-H 4'-OH) 2.00, 2.04 and 2.05
(3s, 9H, 3 -OAc), 2.16 (dd, 1H, 8ax-H, J = 14,8 Hz J = 4.1 Hz), 2.33 (d, 1H, 8eq-H, J = 15.2 Hz), 2.43 (s, 3H, 9-
C(O)Me), 2.95 (d, 1H, 10ax-H, J = 18.9 Hz), 3.23 (d, 1H, 10eq-H, J = 18.9 Hz), 3.67 (d, 1H, 4'-H, J = 6.7 Hz),
3.72 (s, 3H, -CO2Me), 3.90 (m, 1H, 5'-H), 4.07 (s, 3H, 4-OMe), 4.20-4.25 (m, 2H, 3'-H Gluc5-H), 4.46 (s, 1H,
9-OH), 4.96 (d, 1H, ArCHaHb-, J = 12.6 Hz), 5.07 (d, 1H, ArCHaHb-, J = 12.6 Hz), 5.16 (t, 1H, Gluc2-H, J =
8.0 Hz), 5.25-5.35 (m, 4H, 7-H 3'-NH- Gluc3,4-H), 5.50 (m, 1H, 1'-H), 5.80 (d, 1H, Gluc1-H, J = 7.5), 7.08 (t,
1H, Ar4-H, J = 7.4 Hz), 7.26 (d, 1H, Ar3-H, J = 8.8 Hz), 7.32 (t, 1H, Ar5-H, J = 7.7 Hz), 7.39 (d, 1H, 3-H, J =
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8.5 Hz), 7.78 (t, 1H, 2-H, J = 8.1 Hz), 7.84 (m, 1H, Ar6-H), 8.03 (d, 1H, 1-H, J = 7.7 Hz), 8.20 (s, 1H, ArNH-),
13.28 (s, 1H, 11-OH), 13.97 (s, 1H, 6-OH).
N-[2-(Daunorubicin-N-carbonyl-oxymethyl)phenyl] O- b -D-glucuronyl carbamate sodium salt (DAU-GA4) from
24(DAU-GA4) according to general procedure #4 in 69%, mp 171ºC (dec.). Anal.: calc. (found) for
C42H43N2O20Na.3.5 H2O: C: 51.38 (51.36), H: 5.13 (4.86), N: 2.85 (2.69). MS (FAB+) m/z = 942 ([M+1+Na]+),
941 ([M+Na]+), 920 ([M+1+H]+), 919 ([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.12 (d, 3H, 5'-
Me, J = 6.4 Hz), 1.46 (dd, 1H, 2'eq-H, J = 12.6 Hz), 1.85 (dt, 1H, 2'ax-H, J = 12.6 Hz J = 3.5 Hz), 2.11 (dd, 1H,
8ax-H, J = 14.4 Hz J = 5.8 Hz), 2.20 (d, 1H, 8eq-H, J = 14.4 Hz), 2.26 (s, 3H, 9-C(O)Me), 2.93 (d, 1H, 10eq-H, J
= 18.2 Hz), 2.99 (d, 1H, 10ax-H, J = 18.2 Hz), 3.15-3.65 (m, 4H, 4'-H Gluc2,3,4-H), 3.72 (m, 1H, 3'-H), 3.99 (s,
3H, 4-OMe), 4.17 (q, 1H, 5'-H, J = 6.4 Hz), 4.70-4.90 (m, 2H, 4’-OH, Gluc5-H), 4.94 (t, 1H, 7-H, J = 4.4 Hz),
4.98 (s, 2H, ArCH2-), 5.20-5.25 (m, 2H, 2 Gluc-OH), 5.22 (d, 1H, 1'-H, J = 3.1 Hz), 5.32 (d, 1H, Gluc-OH, J =
5.5 Hz), 5.34 (d, 1H, Gluc1-H, J = 8.0 Hz), 5.55 (s, 1H, 9-OH), 7.03 (d, 1H, 3'-NH-, J = 8.0 Hz), 7.15 (t, 1H,
Ar4-H, J = 7.3), 7.27 (t, 1H, Ar5-H, J = 7.7), 7.33 (d, 1H, Ar3-H, J = 7.6 Hz), 7.40 (d, 1H, Ar6-H, J = 7.8 Hz),
7.66 (dd, 1H, 3-H, J = 5.9 Hz J = 3.9 Hz), 7.90-7.95 (m, 2H, 1,2-H), 9.25 (s, 1H, ArNH-) 13.29 (s, 1H, 11-OH),
14.04 (s, 1H, 6-OH).
Synthesis of N-[4-(daunorubicin-N-carbonyl-1-oxyheptyl)phenyl] O-b -D-glucuronyl carbamate
sodium salt (DAU-GA5).
4-(1-Hydroxyheptyl) bromobenzene (29, scheme 4.6). 0.78 g (0.9 equiv.) of Mg turnings, a crystal of I2 and 30
mL of THF were brought into a 3-necked flask connected with a dropping funnel and a reflux condenser
under an argon atmosphere. Approximately one third of 6.26 g (= 1 equiv.) of n-hexyl bromide in 10 mL
of THF was added to the reaction vessel with the aid of a dropping funnel. The Grignard reagent was
agitated and the rest of the n-hexyl bromide solution was added. When the magnesium had almost
disappeared, the reaction mixture was cooled to -10ºC and 7.0 g (1.0 equiv.) of 4-bromobenzaldehyde 28
in 10 mL of THF were added slowly. Stirring was continued for 10 min at -10ºC and the reaction mixture
was quenched on 20 g of ice containing 10 mL of 15% H2SO4 and the reaction mixture was extracted with
350 mL portions of Et2O. The organic layer was washed with brine and dried over Na2SO4. Purification
by column chromatography (SiO2, n-Hex) yielded 2.9 g, 34%, of 22 as a colorless oil. 1H-NMR (100 MHz,
CDCl3) d  (ppm) = 0.86 (t, 3H, Alk7-H, J = 5.6 Hz), 1.10-1.70 (m, 10H, Alk2,3,4,5,6-H), 2.35 (bs, 1H, OH),
4.58 (t, 1H, Alk1-H, J = 6.3 Hz), 7.17 (d, 2H, Ar3,5-H, J = 8.3 Hz), 7.45 (d, 2H, Ar2,6-H, J = 8.3 Hz).
4-(1-tert.-Butyldimethylsilyloxyheptyl) bromobenzene (30). 655 mg of 29, 247 mg (1.5 equiv.) of imidazole,
1.46 g (4.0 equiv.) of TBDMS-Cl and a catalytic amount of DMAP were dissolved in 20 mL of CH2Cl2 and
stirred for 3 days under an argon atmosphere. After that, the reaction mixture was diluted with 200 mL
of Et2O, washed with 100 mL portions of aqueous 0.5 N NaHSO4, aqueous saturated NaHCO3 and brine.
The organic layer was dried over NaSO4 and evaporated. The product was purified by means of column
chromatography (SiO2, n-Hex) to give 602 mg of 30, 65%, as a colorless oil. 1H-NMR (100 MHz, CDCl3) d
(ppm) = -0.14 (s, 3H, SiMeaMeb), 0.02 (s, 3H, SiMeaMeb), 0.67 (s, 9H, Si-tBu), 0.70-1.75 (m, 13H,
Alk2,3,4,5,6,7-H), 4.58 (t, 1H, Alk1-H, J = 5.8 Hz), 7.15 (d, 2H, Ar3,5-H, J = 8.5 Hz), 7.42 (d, 2H, Ar2,6-H, J
= 8.4 Hz).
4-(1-tert.-Butyldimethylsilyloxyheptyl) benzoic acid (18, Y = -(CH2)5CH3). To 1.1 mL (1.6 equiv.) of a 1.6 N n-
BuLi solution and 1 mL of THF in a 3-necked flask connected with a dropping funnel under an argon
atmosphere, 437 mg (= 1.0 equiv.) of 30 dissolved in 10 mL of THF were added slowly at -78ºC. The
reaction mixture was stirred at -50ºC for 15 min and carefully added to a few grams of solid CO2 in 10 mL
of THF under an argon atmosphere. The reaction mixture was quenched with ice and 20 mL of aqueous
0.5 N KHSO4 were added. The product was extracted with 100 mL portions of Et2O (3x) and the
combined organic extracts were washed with brine and dried over Na2SO4. The product was purified by
means of column chromatography (SiO2, CH2Cl2/EtOH 10/1) to yield 179 mg, 45%, of 18  (Y =
-(CH2)5CH3 as a colorless oil. 1H-NMR (100 MHz, CDCl3) d  (ppm) = -0.14 (s, 3H, SiMeaMeb), 0.03 (s, 3H,
SiMeaMeb), 0.88 (s, 9H, Si-t-Bu), 0.70-1.70 (m, 13H, Alk2,3,4,5,6,7-H), 4.69 (t, 1H, Alk1-H, J = 5.5 Hz), 7.37
(d, 2H, Ar3,5-H, J = 8.1 Hz), 8.04 (d, 2H, Ar2,6-H, J = 8.1 Hz).
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N-[4-(1-tert.-Butyldimethylsilyloxyheptyl)phenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(22(GA5)) from 18 (Y = -(CH2)5CH3) according to general procedure #1 as a colorless oil in 73%. Due to the
racemic starting material, a diastereomeric mixture of 23(GA5) must have been formed, conversely, this
was not observed in the proton NMR spectrum. 1H-NMR (100 MHz, CDCl3) d  (ppm) = -0.23 (s, 3H,
SiMeaMeb), 0.07 (s, 3H, SiMeaMeb), 0.59 (s, 9H, Si-t-Bu), 0.50-1.65 (m, 13H, Alk2,3,4,5,6,7-H), 1.98 (bs, 9H, 3
-OAc), 3.66 (s, 3H, -CO2Me), 4.15 (d, 1H, Gluc5-H, J = 9.4 Hz), 4.51 (t, 1H, Alk1-H, J = 6.3 Hz), 5.10-5.45
(m, 3H, Gluc2,3,4-H), 5.73 (d, 1H, Gluc1-H, J = 7.6 Hz), 6.95 (bs, 1H, ArNH-), 7.13 (d, 2H, Ar3,5-H, J = 8.7
Hz), 7.03 (d, 2H, Ar2,6-H, J = 8.7).
N-[4-(1-Hydroxyheptyl)phenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (23(GA5)) from 22(GA5)
according to general procedure #2 in 92%, as a colorless oil. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 0.80-
1.90 (m, 13H, Alk2,3,4,5,6,7-H), 2.05 (s, 9H, 3 -OAc), 3.73 (s, 3H, -CO2Me), 4.19 (d, 1H, Gluc5-H, J = 8.9
Hz), 4.63 (t, 1H, Alk1-H, J = 6.8 Hz), 5.15-5.30 (m, 3H, Gluc2,3,4-H), 5.76 (d, 1H, Gluc1-H, J = 7.4 Hz), 7.12
(bs, 1H, ArNH-), 7.22 (bs, 4H, Ar2,3,5,6-H).
N-[4-(Daunorubicin-N-carbonyl-(1-oxyheptyl))phenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(24(DAU-GA5)) from 23(GA5) according to general procedure #3 in 36%, mp 71ºC. Because of chirality of
the spacer -ArC*H(alkyl)(O)-, a diastereomeric mixture was formed in a ratio of approximately 1/1,
determined by dividing the integrals of the clear singlets of the respective ArNH- signals. 1H-NMR (400
MHz, CDCl3) d  (ppm) = 0.80-1.90 (m, 18H, Alk2,3,4,5,6,7-H 5'-Me 2'ax-H 2'eq-H), 2.00-2.05 (m, 9H, 3 -OAc),
2.09 (dd, 1H, 8ax-H, J = 15,2 Hz J = 3.7 Hz), 2.30 (d, 1H, 8eq-H, J = 14.9 Hz), 2.40 (bs, 3H, 9-C(O)Me), 2.88
(d, 1H, 10ax-H, J = 18.8 Hz), 3.20 (d, 1H, 10eq-H, J = 18.8 Hz), 3.65-3.90 (m, 5H, 3'-H 4'-H -CO2Me), 4.06 and
4.09 (s, 3H, 4-OMe), 4.22 (bd, 1H,Gluc5-H, J = 9.8 Hz), 4.15-4.25 (m, 1H, 5'-H), 4.48 (s, 1H, 9-OH), 4.90-5.55
(m, 7H, ArCHalkyl- Gluc2,3,4-H 7-H 3'-NH- 1'-H), 5.79 (bd, 1H, Gluc1-H, J = 8.0 Hz), 6.77 and 6.86 (s, 1H,
ArNH-), 7.15-7.25 (m, 4H, Ar2,3,5,6-H), 7.38 (bd, 1H, 3-H, J = 9.4 Hz), 7.77 (bt, 1H, 2-H, J = 9.0 Hz), 8.02
(bd, 1H, 1-H, J = 7.5 Hz), 13.26 and 13.28 (s, 1H, 11-OH), 13.95 and 13.98 (s, 1H, 6-OH).
N-[4-(Daunorubicin-N-carbonyl-(1-oxyheptyl))phenyl] O- b -D-glucuronyl carbamate sodium salt (DAU-GA5)
from 24(DAU-GA5) according to general procedure #4 in 39%, mp = 193ºC (dec.). Anal.: calc. (found) for
C48H55N2O20Na.5 H2O: C: 52.75 (52.73), H: 5.99 (5.69), N: 2.56 (2.70). MS (FAB+) m/z = 1026 ([M+1+Na]+),
1025 ([M+Na]+), 1004 ([M+1+H]+), 1003 ([M+H]+). Because of chirality of the spacer -ArC*H(alkyl)(O)-, a
diastereomeric mixture was formed in a ratio of approximately 1/0.2, determined by dividing the
integrals of the clear singlets of the respective ArNH- signals in the proton-NMR spectrum. 1H-NMR (400
MHz, (CD3)2SO) d  (ppm) = 0.76 and 0.81 (t, 3 H Alk7-H, J = 6.8 Hz resp. 6.7 Hz), 1.05-1.25 (m, 16H, 5'-Me
Alk2,3,4,5,6,7-H), 1.39 and 1.46 (dd, 1H, 2'eq-H, J = 12.3 Hz J = 4.1 Hz resp. 12.3 and 4.0 Hz), 1.79 (dt, 1H,
2'ax-H, J = 12.9 Hz J = 3.9 Hz), 2.08 (m, 1H, 8ax-H), 2.15 (d, 1H, 8eq-H, J = 13.4 Hz), 2.23 (s, 3H, 9-C(O)Me),
2.90 (d, 1H, 10eq-H, J = 18.4 Hz), 2.97 (d, 1H, 10ax-H, J = 18.4 Hz), 3.00-3.45 (m, 4H, 4'-H Gluc2,3,4-H), 3.65
(m, 1H, 3'-H), 3.97 and 3.98 (s, 4-OMe), 4.12 (q, 1H, 5'-H, J = 6.2 Hz), 4.66 and 4.68 (d, 1H, 4'-OH, J = 5.4
Hz resp. J = 5.5 Hz), 4.91 (t, 1H, 7-H, J = 4.3 Hz), 5.00 (t, 1H, Alk1-H, J = 4.7 Hz), 5.18 and 4.21 (d, 1H, 1'-H,
J = 1.6 Hz resp J = 2.4 Hz), 5.10-5.15 (m, 1H, Gluc5-H), 5.25 (d, 1H, Gluc1-H, J = 8.0 Hz), 5.50 (s, 1H, 9-
OH), 6.72 (d, 1H, 3'-NH-, J = 7.8 Hz), 7.16 and 7.20 (d, 2H, Ar3,5-H, J = 8.5 Hz resp. J = 8.5 Hz), 7.37 and
7.41 (d, 2H, J = 8.2 Hz resp. J = 8.3 Hz), 7.63 (m, 1H, 3-H), 7.85-7.95 (m, 2H, 1,2-H), 9.78 and 9.84 (s, 1H,
ArNH-), 13.19 (s, 1H, 11-OH), 14.01 (s, 1H, 6-OH).
Synthesis of N-methyl-[4-(daunorubicin-N-carbonyl-oxymethyl) 2-chlorophenyl]
O- b -D-glucuronyl carbamate sodium salt (DAU-GA6).
N-(4-Methyl 2-chlorophenyl) O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (33 , X = -2-Cl). Since
4-methyl-2-chlorophenyl isocyanate (32, X = -2-Cl, scheme 4.7) was not commercially available, it was
prepared from 500 mg of 4-methyl-2-chloroaniline-HCl (31, X = -2-Cl) by refluxing the latter compound
for 2 h with 339 m L (1.0 equiv.) of diphosgene 41 in 20 mL of PhMe under an argon atmosphere. The
reaction mixture was allowed to cool to ambient temperature and 1.5 mL (ca. 4 equiv.) of Et3N were
added to combine with the liberated HCl. 469 mg (0.5 equiv.) of 42 were added. After 0.5 h, 42 had
disappeared and the reaction mixture was worked up according to general procedure #1, the product
fraction was crystallized from i-Pr2O to give 645 mg, 92%, of 33 (X = -2-Cl) as white crystals, mp 142-
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143ºC. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 2.05 (s, 9H, 3 -OAc), 2.29 (s, 3H, ArMe), 3.74 (s, 3H,
-CO2Me), 4.26 (d, 1H, Gluc5-H, J = 9.5 Hz), 5.10-5.55 (m, 3H, Gluc2,3,4-H), 5.86 (d, 1H, Gluc1-H, J = 7.4
Hz), 7.07 (d, 1H, Ar4-H, J = 8.3 Hz), 7.10-7.30 (m, 2H, Ar3-H, ArNH-), 7.92 (d, 1H, Ar6-H, J = 8.3 Hz).
N-[4-(Bromomethyl)-2-chlorophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (34, X = -2-Cl)
from 33 (X = -2-Cl) according to general procedure #5. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 2.05 (s, 9H,
3 -OAc), 3.75 (s, 3H, -CO2Me), 4.25 (d, 1H, Gluc5-H, J = 9.2 Hz), 4.42 (s, 2H, ArCH2-), 5.10-5.45 (m, 3H,
Gluc2,3,4-H), 5.85 (d, 1H, Gluc1-H, J = 7.6 Hz), 7.10-7.50 (m, 3H, Ar3,5-H ArNH-), 8.09 (d, 1H, Ar6-H, J =
8.4 Hz).
N-[4-(Hydroxymethyl)-2-chlorophenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (35, X = -2-Cl)
from 34 (X = -2-Cl) according to general procedure #6 in 52%, from 33 (X = -2-Cl), 1H-NMR (100 MHz,
CDCl3) d  (ppm) = 1.98 (s, 9H, 3 -OAc), 3.67 (s, 3H, -CO2Me), 4.16 (d, 1H, Gluc5-H, J = 9.3 Hz), 4.56 (s, 2H,
ArCH2-), 5.00-5.40 (m, 3H, Gluc2,3,4-H), 5.75 (d, 1H, Gluc1-H, J = 7.5 Hz), 7.17 (d, 1H, Ar5-H, J = 8.4 Hz),
7.31 (bs, 2H, Ar3-H ArNH-), 7.37 (d, 1H, Ar6-H, J = 8.4 Hz).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-2-chlorophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (40, X = -2-Cl) from 35 (X = -2-Cl) according to general procedure #3 in 28%, mp 150-155ºC. 1H-
NMR (400 MHz, CDCl3) d  (ppm) = 1.29 (d, 3H, 5'-Me, J = 6.6 Hz), 1.74 (dt, 1H, 2'ax-H, J = 13.1 Hz J = 4.1
Hz), 1.90 (dd, 1H, 2'eq-H, J = 13.1 Hz J = 4.8 Hz), 2.05 (s, 9H, 3 -OAc), 2.12 (dd, 1H, 8ax-H, J = 14,9 Hz J =
4.1 Hz), 2.32 (d, 1H, 8eq-H, J = 14.8 Hz), 2.41 (s, 3H, 9-C(O)Me), 2.95 (d, 1H, 10ax-H, J = 18.8 Hz), 3.25 (d,
1H, 10eq-H, J = 18.8 Hz), 3.65 (s, 1H, 4'-H), 3.73 (s, 3H, -CO2Me), 3.87 (m, 1H, 3'-H), 4.08 (s, 3H, 4-OMe),
4.21 (d, 1H, Gluc5-H, J = 9.5 Hz), 4.20-4.25 (m, 1H, 5'-H), 4.44 (s, 1H, 9-OH), 4.95 (d, 1H, ArCH2-), 5.10-5.30
(m, 4H, Gluc2,4-H 7-H 3'-NH-), 5.35 (t, 1H, Gluc3-H J = 8.9 Hz), 5.49 (d, 1H, 1'-H, J = 3.7 Hz), 5.81 (d, 1H,
Gluc1-H, J = 7.9 Hz), 7.21 (d, 1H, Ar5-H, J = 8.3 Hz), 7.26 and 7.34 (2s, 2H, Ar3-H ArNH-), 7.40 (d, 1H, 3-
H, J = 8.4 Hz), 7.79 (t, 1H, 2-H, J = 8.1 Hz), 8.00-8.10 (m, 2H, 1-H Ar6-H), 13.29 (s, 1H, 11-OH), 13.99 (s, 1H,
6-OH).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-2-chlorophenyl] O- b -D-glucuronyl carbamate sodium salt ( DAU-
GA6) from 40 (X = -2-Cl) according to general procedure #4 in 37%, mp 175-179ºC. Anal.: calc. (found) for
C42H42N2O20ClNa.5 H2O: C: 48.38 (48.22), H: 5.02 (4.70), N: 2.69 (3.08). MS (FAB+) m/z = 975 ([M+Na]+),
955 ([M+2+H]+), 954 ([M+1+H]+), 953 ([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) = 1.12 (d, 3H, 5'-
Me, J = 6.4 Hz), 1.48 (d, 1H, 2'eq-H, J = 12.6), 1.85 (t, 1H, 2'ax-H, J = 13.4 Hz), 2.05 (m, 2H, 8ax-H 8eq-H), 2.25
(s, 3H, 9-C(O)Me), 2.90 (m, 6H, 10eq-H 10ax-H 4'-H Gluc2,3,4-H), 3.73 (m, 1H, 3'-H), 3.98 (s, 3H, 4-OMe),
4.16 (m, 1H, 5'-H), 4.73 (d, 1H, 4'-OH, J = 5.1 Hz), 4.85 (m, 2H, ArCH2-), 5.00 (d, 1H, 7-H, J = 5.2 Hz), 5.23
(bs, 1H, 1'-H), 5.27 (d, 1H, Gluc1-H, J = 7.9 Hz), 5.53 (s, 1H, 9-OH), 7.27 (d, 1H, Ar5-H, J = 7.3 Hz), 7.44 (s,
1H, Ar3-H), 7.57 (d, 1H, Ar6-H, J = 8.12 Hz), 7.64 (m, 1H, 3-H), 7.85-8.00 (m, 2H, 1,2-H), 9.22 (s, 1H,
ArNH-).
Synthesis of N-methyl-[4-(daunorubicin-N-carbonyl-oxymethyl) 3-chlorophenyl] 
O- b -D-glucuronyl carbamate sodium salt (DAU-GA7).
N-(4-Methyl-3-chlorophenyl) O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (33, X = -3-Cl). 200 mg
(1.19 mmol) of commercially available 4-methyl-3-chlorophenyl isocyanate 32 (X = -3-Cl) was dissolved
in 10 mL of PhMe under an argon atmosphere. 199 mg (0.5 equiv.) of 42 and one drop of Et3N was added.
The course of the reaction was followed by means of TLC (SiO2, Et2O). After 42 had disappeared, the
reaction mixture was taken to dryness ( a / b  = 1/10 by 1H-NMR) and sonicated in Et2O. The solid material
was removed and the solution was concentrated and refrigerated overnight. 434 mg, 81%, of 33 (X = -3-
Cl) was obtained as white crystals, mp 155ºC. The a -isomer stayed in solution. 1H-NMR (100 MHz,
CDCl3) d  (ppm) = 1.99 (s, 9H, 3 -OAc), 2.24 (s, 3H, ArMe), 3.66 (s, 3H, -CO2Me), 4.16 (d, 1H, Gluc5-H, J =
9.4 Hz), 5.00-5.45 (m, 3H, Gluc2,3,4-H), 5.71 (d, 1H, Gluc1-H, J = 7.6 Hz), 6.90-7.15 (m, 3H, Ar2,5,6-H), 7.39
(s, 1H, ArNH-).
N-[4-(Bromomethyl)-3-chlorophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (34, X = -3-Cl)
from 33 (X = -3-Cl) according to general procedure #5. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.99 (s, 9H,
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3 -OAc), 3.66 (s, 3H, -CO2Me), 4.20 (d, 1H, Gluc5-H, J = 8.9 Hz), 4.47 (s, 2H, ArCH2-), 5.05-5.45 (m, 3H,
Gluc2,3,4-H), 5.71 (d, 1H, Gluc1-H, J = 7.5 Hz), 6.90-7.50 (m, 3H, Ar2,5,6-H), 7.63 (s, 1H, ArNH-).
N-[4-(Hydroxymethyl)-3-chlorophenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (35, X = -3-Cl)
from 34 (X = -3-Cl) according to general procedure #6 in 76% from 33 (X = -3-Cl), as a yellowish powder.
1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.99 (s, 9H, 3 -OAc), 3.66 (s, 3H, -CO2Me), 4.16 (d, 1H, Gluc5-H, J =
9.3 Hz), 4.63 (s, 2H, ArCH2-), 5.00-5.45 (m, 3H, Gluc2,3,4-H), 5.69 (d, 1H, Gluc1-H, J = 7.5 Hz), 7.10-745 (m,
3H, Ar2,4,5-H), 7.55 (s, 1H, ArNH-).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-3-chlorophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (40, X = -3-Cl) from 35 (X = -3-Cl) according to general procedure #3 in 76%, mp 154-158ºC. 1H-
NMR (400 MHz, CDCl3) d  (ppm) = 1.29 (d, 3H, 5'-Me, J = 6.5 Hz), 1.78 (dt, 1H, 2'ax-H, J = 13.0 Hz J = 3.9
Hz), 1.85-1.90 (m, 2H, 2'eq-H 4'-OH), 2.05 (s, 9H, 3 -OAc), 2.05-2.15 (m, 1H, 8ax-H), 2.28 (d, 1H, 8eq-H, J =
14.9 Hz), 2.42 (s, 3H, 9-C(O)Me), 2.87 (d, 1H, 10ax-H, J = 19.0 Hz), 3.19 (d, 1H, 10eq-H, J = 18.8 Hz), 3.68 (bs,
1H, 4'-H), 3.74 (s, 3H, -CO2Me), 3.87 (bs, 1H, 3'-H), 4.05 (s, 3H, 4-OMe), 4.15-4.20 (m, 1H, 5'-H), 4.24 (d,
1H,Gluc5-H, J = 9.8 Hz), 4.46 (s, 1H, 9-OH), 4.97 (d, 1H, ArCHaHb-, J = 12.7 Hz), 5.01 (d, 1H, ArCHaHb-, J
= 12.7 Hz), 5.12-5.40 (m, 4H, Gluc3,4-H 7-H 3'-NH-), 5.48 (d, 1H, 1'-H, J = 2.4 Hz), 5.73 (d, 1H, Gluc1-H, J
= 8.0 Hz), 7.00-7.50 (m, 5H, 3-H Ar2,5,6-H ArNH-), 7.76 (t, 1H, 2-H, J = 8.1 Hz), 8.00 (d, 1H, 1-H, J = 8.2
Hz), 13.24 (s, 1H, 11-OH), 13.95 (s, 1H, 6-OH).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-3-chlorophenyl] O- b -D-glucuronyl carbamate sodium salt ( DAU-
GA7) from 40 (X = -3-Cl) according to general procedure #4 in 67%, mp 205ºC (dec.). Anal.: calc. (found)
for C42H42N2O20ClNa.6 H2O: C: 47.53 (47.25), H : 5.13 (4.75), N: 2.64 (2.64). MS (FAB+ ) m/z = 977
([M+2+Na]+), 976 ([M+1+Na]+), 975 ([M+Na]+), 955 ([M+2+H]+), 954 ([M+1+H]+), 953 ([M+H]+). 1H-NMR
(400 MHz, (CD3)2SO) d  (ppm) = 1.11 (d, 3H, 5'-Me, J = 6.4 Hz), 1.46 (dd, 1H, 2'eq-H, J = 12.0 Hz J = 3.6 Hz),
1.81 (dd, 1H, 2'ax-H, J = 12.7 Hz J = 3.2 Hz), 2.08 (dd, 1H, 8ax-H, J = 13.9 Hz J = 5.2 Hz), 2.17 (d, 1H, 8eq-H, J
= 13.6 Hz), 2.24 (s, 3H, 9-C(O)Me), 3.00 (m, 6H, 10eq-H 10ax-H 4'-H Gluc2,3,4-H), 3.70 (m, 1H, 3'-H), 3.96
(s, 3H, 4-OMe), 4.13 (q, 1H, 5'-H, J = 6.5 Hz), 4.69 (d, 1H, 4’-OH, J = 3.9 Hz), 4.94 (s, 2H, ArCH2-), 5.07 (bs,
1H, 7-H), 5.21 (s, 1H, 1'-H), 5.28 (d, 1H, Gluc1-H, J = 8.1 Hz), 5.51 (s, 1H, 9-OH), 6.95 (d, 1H, 3'-NH-, J = 7.9
Hz), 7.23 (d, 1H, Ar5-H, J = 8.4 Hz), 7.35-7.40 (m, 2H, Ar2,6-H), 7.55-7.60 (m, 2H, 3-H Ar2-H), 7.80-7.95
(m, 2H, 1,2-H), 10.14 (s, 1H, ArNH-).
Synthesis of N-methyl-[4-(daunorubicin-N-carbonyl-oxymethyl)-2-bromophenyl] 
O- b -D-glucuronyl carbamate sodium salt (DAU-GA8).
N-[4-(Methyl)-2-bromophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (33, X = -2-Br). 263 mg
(1.20 mmol) of 31 (X = -2-Br) and 145 m L (1.0 equiv.) of diphosgene 41 were dissolved in 10 mL of PhMe
and the reaction mixture was refluxed for 2 h under an argon atmosphere. When HCl evolution ceased,
the mixture was cooled to 0ºC and 834 m L (5.0 equiv.) of Et3N and 200 mg (0.5 equiv.) of 42 were added.
The reaction mixture was stirred for 1 h at 0ºC and processed according to general procedure #1. The
crude product was purified by means of column chromatography (SiO2, Et2O/n-Hex 1/1) to give 310 mg
(95% from 42) of 33 (X = -2-Br), mp 139ºC. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 2.05 (s, 9H, 3 -OAc), 2.30
(s, 3H, ArMe), 3.75 (s, 3H, -CO2Me), 4.22 (d, 1H, Gluc5-H, J = 9.1 Hz), 5.10-5.45 (m, 3H, Gluc2,3,4-H), 5.83
(d, 1H, Gluc1-H, J = 7.8 Hz), 7.15-7.45 (m, 2H, Ar5-H ArNH-), 7.35 (d, 1H, Ar3-H, J = 2.0 Hz) 7.93 (d, Ar6-
H, J = 8.3 Hz).
N-[4-(Bromomethyl)-2-bromophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate ( 34, X = -2-Br)
from 33 (X = -2-Br) according to general procedure #5, 1H-NMR (100 MHz, CDCl3) d  (ppm) = 2.05 (s, 9H,
3 -OAc), 3.75 (s, 3H, -CO2Me), 4.23 (d, 1H, Gluc5-H, J = 9.1 Hz), 4.42 (s, 3H, ArCH2-), 5.10-5.45 (m, 3H,
Gluc2,3,4-H), 5.83 (d, 1H, Gluc1-H, J = 7.8 Hz), 7.35 (dd, 1H, Ar5-H, J = 8.4 Hz J = 2.0 Hz), 7.40 (s, 1H,
ArNH-), 7.59 (d, 1H, Ar3-H, J = 2.0 Hz), 8.09 (d, Ar6-H, J = 8.4 Hz).
N-[4-(Hydroxymethyl)-2-bromophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (35, X = -2-Br)
from 34 (X = -2-Br) according to general procedure #6 in 80% from 33 (X = -2-Br), as an oil, 1H-NMR (100
MHz, CDCl3) d  (ppm) = 2.04 (s, 9H, 3 -OAc), 3.75 (s, 3H, -CO2Me), 4.22 (d, 1H, Gluc5-H, J = 9.2 Hz), 4.65
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(s, 3H, ArCH2-), 5.20-5.40 (m, 3H, Gluc2,3,4-H), 5.83 (d, 1H, Gluc1-H, J = 7.5 Hz), 7.20-7.40 (m, 2H, Ar5-H
ArNH-), 7.57 (d, 1H, Ar3-H, J = 1.8 Hz), 8.07 (d, Ar6-H, J = 8.1 Hz).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-2-bromophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (40, X = -2-Br) from 35 (X = -2-Br) according to general procedure #3 in 14%, mp 149ºC. 1H-
NMR (400 MHz, CDCl3) d  (ppm) = 1.22 (d, 3H, 5'-Me, J = 6.4 Hz), 1.58 (s, 1H, 4'-OH), 1.70 (dt, 1H, 2'eq-H, J
= 13.2 Hz J = 4.2 Hz), 1.82 (dd, 2'ax, 1H, J = 13.3 Hz J = 5.1 Hz), 1.95 (s, 9H, 3 -OAc), 2.04 (dd, 1H, 8ax-H, J =
14.9 Hz J = 4.1 Hz), 2.24 (d, 1H, 8eq-H, J = 14.4 Hz), 2.34 (s, 3H, 9-C(O)Me), 2.83 (d, 1H, 10ax-H, J = 18.8
Hz), 3.16 (d, 1H, 10eq-H, J = 18.8 Hz), 3.59 (m, 1H, 4'-H), 3.68 (s, 3H, -CO2Me), 3.81 (m, 1H, 3'-H), 4.01 (s,
3H, 4-OMe), 4.15 (d, 1H, Gluc5-H, J = 9.6 Hz), 4.10-4.20 (m, 1H, 5'-H), 4.38 (s, 1H, 9-OH), 4.86 (d, 1H,
ArCHaHb-, J = 12.5 Hz), 4.89 (d, 1H, ArCHaHb-, J = 12.5 Hz), 5.05-5.25 (m, 4H, Gluc2,4-H 7-H 3'-NH-), 5.28
(t, 1H, Gluc3-H, J = 9.3 Hz), 5.42 (d, 1H, 1'-H, J = 3.7 Hz), 5.74 (d, 1H, Gluc1-H, J = 8.0 Hz), 7.15-7.25 (m,
2H, Ar5,6-H), 7.32 (d, 1H, 3-H, J = 8.6 Hz), 7.41 (s, 1H, Ar3-H), 7.71 (t, 1H, 2-H, J = 8.0 Hz), 7.96 (d, 1H, 1-
H, J = 7.6 Hz), 7.90-8.00 (m, 1H, ArNH-), 13.19 (s, 1H, 11-OH), 13.90 (s, 1H, 6-OH).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-2-bromophenyl] O-b -D-glucuronyl carbamate sodium salt  (DAU-
GA8) from 40 (X = -2-Br) according to general procedure #4 in 34%, mp 213ºC (dec.). Anal.: calc. (found)
for C42H42N2O20BrNa.3 H2O: C: 47.96 (47.75), H: 4.60 (4.59), N: 2.66 (3.08). MS (FAB+) m/z = 1021
([M+2+Na]+), 1019 ([M+Na]+), 999 ([M+2+H]+), 997 ([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) =
1.13 (d, 3H, 5'-Me, J = 6.5 Hz), 1.48 (dd, 1H, 2'eq-H, J = 12.4 Hz J = 5.3 Hz), 1.83 (dt, 1H, 2'ax-H, J = 13.3 Hz J
= 3.5 Hz), 2.10-2.20 (m, 2H, 8ax-H 8eq-H), 2.26 (s, 3H, 9-C(O)Me), 2.94 (d, 1H, 10ax-H, J = 18.5 Hz), 3.10-3.65
(m, 5H, 10eq-H 4'-H Gluc2,3,4-H), 3.73 (m, 1H, 3'-H), 3.99 (s, 3H, 4-OMe), 4.18 (q, 1H, 5'-H, J = 6.3 Hz), 4.72
(d, 1H, 4'-OH, J = 5.6 Hz), 4.75-5.20 (m, 2H, 7-H Gluc5-H), 4.93 (s, 2H, ArCH2-), 5.22 (d, 1H, 1'-H, J = 3.5
Hz), 5.27 (d, 1H, Gluc1-H, J = 8.1 Hz), 5.55 (s, 1H, 9-OH), 6.98 (d, 1H, 3'-NH-, J = 8.0 Hz), 7.31 and 7.52
(2d, 2H, Ar5-H or Ar6-H, J = 8.4 resp. 8.2 Hz), 7.61 (s, 1H, Ar3-H), 7.67 (t, 1H, 3-H, J = 7.8 Hz), 7.90-8.00
(m, 2H, 1,2-H). 8.31 (s, 1H, ArNH-).
Synthesis of N-methyl-[4-(daunorubicin-N-carbonyl-oxymethyl)-3-bromophenyl] 
O- b `D-glucuronyl carbamate sodium salt (DAU-GA9).
3-Bromoterephthalic acid allyl ester (37, X = -3-Br). 3.0 g (12 mmol) of bromo terephthalic acid (36, X = -Br)
were dissolved in 150 mL of THF under an argon atmosphere and 1.25 mL (1.5 equiv.) of AllOH and a
catalytic amount of DMAP was added. After cooling the mixture to 0ºC, 2.2 g (1.0 equiv.) of DCC were
added and the reaction mixture was stirred at 0ºC for 2 h and overnight at room temperature. The
reaction mixture was filtrated and evaporated, the product was purified by means of column
chromatography (SiO2, CH2Cl2/EtOH 10/1) and crystallized from n-Hex to yield 893 mg, 26%, of 37 (X =
-3-Br) as white needles, mp 117ºC. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 4.88 (d, 2H, All1-H, J = 5.6 Hz),
5.30-5.55 (m, 2H, 2 All3-H), 5.90-6.25 (m, 1H, All2-H), 7.79 (d, 1H, Ar5-H, J = 8.0 Hz), 8.10 (dd, 1H, Ar6-H,
J = 8.0 Hz J = 1.5 Hz), 8.40 (d, 1H, Ar2-H, J = 1.5 Hz).
N-[4-(Carboxylic acid allyl ester)-3-bromophenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (39 (X
= -3-Br) from 37 (X = -3-Br) according to general procedure #1 in 80% as a white powder, mp 61ºC. 1H-
NMR (100 MHz, CDCl3) d  (ppm) = 2.05 (s, 9H, 3 -OAc), 3.72 (s, 3H, -CO2Me), 4.24 (d, 1H, Gluc5-H, J = 9.5
Hz), 4.79 (d, 2H, 2 All1-H, J = 5.6 Hz), 5.10-5.50 (m, 5H, Gluc2,3,4-H All3-H), 5.77 (d, 1H, Gluc1-H, J = 7.6
Hz), 5.70-6.25 (m, 1H, All2-H), 7.34 (dd, 1H, Ar6-H, J = 8.6 Hz J = 2.2 Hz), 7.58 (s, 1H, ArNH-), 7.74 (d, 1H,
Ar2-H, J = 2.2 Hz), 7.83 (d, Ar5-H, J = 8.6 Hz).
N-[4-(Hydroxymethyl)-3-bromophenyl] O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl) carbamate (35, X = -3-Br).
263 mg (0.427 mmol) of 39 (X = -3-Br), 186 m L (5 equiv.) of morpholine in 20 mL of THF were stirred for 2
h at room temperature while bubbling argon through the solution. After that, a catalytic amount of
Pd(PPh3)4 was added. After 15 min 39 (X = -3-Br) had disappeared on TLC (SiO2, Et2O) and the reaction
mixture was diluted with 100 mL of Et2O and washed with 100 mL portions of aqueous 0.5 N KHSO4 (3x)
and with brine. The organic layer was dried over Na2SO4 and evaporated to obtain 246 mg of the
carboxylic acid in a quantitative yield, mp 110ºC. This was used without further purification in the next
reduction reaction. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 2.04 (s, 9H, 3 -OAc), 3.73 (s, 3H, -CO2Me), 4.23
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(d, 1H, Gluc5-H, J = 9.5 Hz), 5.10-5.40 (m, 3H, Gluc2,3,4-H), 5.77 (d, 1H, Gluc1-H, J = 7.6 Hz), 7.36 (dd,
1H, Ar6-H, J = 8.6 Hz J = 2.2 Hz), 7.56 (s, 1H, ArNH-), 7.79 (d, 1H, Ar2-H, J = 2.2 Hz) 7.96 (d, Ar5-H, J =
8.6 Hz).
153 mg (0.265 mmol) of the latter carboxylic acid were stirred in 15 mL of THF at room temperature
under an argon atmosphere. 1.33 mL (5.0 equiv.) of a 1 M BH3-THF solution were added slowly over a
period of 20 min. The reaction mixture was stirred overnight at room temperature. When the acid had
almost disappeared on TLC (SiO2, Et2O), the reaction mixture was quenched with 15 mL of H2O. When
gas evolution ceased, the reaction mixture was diluted with 200 mL of EtOAc and washed with 100 mL
portions of saturated aqueous NaHCO3 (3x) and with brine. The organic layer was dried over Na2SO4
and evaporated to yield 140 mg, 94%, of the pure 35 (X = -3-Br) as an oil, 1H-NMR (100 MHz, CDCl3) d
(ppm) = 2.00 (s, 9H, 3 -OAc), 3.67 (s, 3H, -CO2Me), 4.14 (d, 1H, Gluc5-H, J = 9.6 Hz), 4.63 (s, 2H, ArCH2-),
5.00-5.30 (m, 3H, Gluc2,3,4-H), 5.69 (d, 1H, Gluc1-H, J = 7.6 Hz), 7.15-7.40 (m, 3H, Ar5,6-H ArNH-), 7.63
(d, 1H, Ar2-H, J = 2.2 Hz).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-3-bromophenyl] O- b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (40, X = -3-Br) from 35 (X = -3-Br) according to general procedure #3 in 56%, mp 147ºC. 1H-
NMR (400 MHz, CDCl3) d  (ppm) = 1.13 (d, 3H, 5'-Me, J = 6.5 Hz), 1.62 (s, 1H, 4'-OH), 1.81 (dt, 1H, 2'eq-H, J
= 13.2 Hz J = 3.3 Hz), 1.89 (dd, 1H, 2'ax-H, J = 13.2 Hz J = 5.0 Hz), 2.06 (s, 9H, 3 -OAc), 2.09 (dd, 1H, 8ax-H,
J = 14.7 Hz J = 3.8 Hz), 2.30 (d, 1H, 8eq-H, J = 14.7 Hz), 2.42 (s, 3H, C(O)Me), 2.88 (d, 1H, 10ax-H, J = 18.8
Hz), 3.20 (d, 1H, 10eq-H, J = 18.7 Hz), 3.69 (m, 1H, 4'-H), 3.72 (s, 3H, -CO2Me), 3.90 (m, 1H, 3'-H), 4.04 (s,
3H, 4-OMe), 4.20-4.25 (m, 2H, 5'-H Gluc5-H), 4.50 (s, 1H, 9-OH), 4.95 (d, 1H, ArCHaHb-, J = 12.8 Hz), 5.00
(d, 1H, ArCHaHb-, J = 12.8 Hz), 5.15-5.30 (m, 4H, Gluc2,4-H 7-H 3'-NH-), 5.40 (t, 1H, Gluc3-H, J = 9.4 Hz),
5.47 (d, 1H, 1'-H, J = 2.7 Hz), 5.75 (d, 1H, Gluc1-H, J = 8.0 Hz), 7.08 and 7.16 (2d, 2H, Ar5-H or Ar6-H, J =
8.2 Hz), 7.36 (d, 1H, 3-H, J = 8.5 Hz), 7.54 or 7.60 (2s, 2H, ArNH- Ar2-H), 7.76 (t, 1H, 2-H, J = 8.0 Hz), 7.99
(d, 1H, 1-H, J = 7.8 Hz), 13.22 (s, 1H, 11-OH), 13.94 (s, 1H, 6-OH).
N-[4-(Daunorubicin-N-carbonyl-oxymethyl)-3-bromophenyl] O- b -D-glucuronyl carbamate sodium salt  (DAU-
GA9) from 40 (X = -3-Br) according to general procedure #4 in 50%, mp 181ºC. Anal.: calc. (found) for
C42H42N2O20BrNa.5 H2O: C : 46.38 (46.37), H : 4.82 (4.49), N : 2.58 (2.68). MS (FAB+ ) m/z  = 1021
([M+2+Na]+), 1019 ([M+Na]+), 999 ([M+2+H]+), 997 ([M+H]+). 1H-NMR (400 MHz, (CD3)2SO) d  (ppm) =
1.11 (d, 3H, 5'-Me, J = 6.4 Hz), 1.47 (dd, 1H, 2'eq-H, J = 11.6 Hz J = 3.1 Hz), 1.82 (dt, 1H, 2'ax-H, J = 12.4 Hz J
= 3.3 Hz), 2.08 (dd, 1H, 8ax-H, J = 13.4 Hz J = 5.0 Hz), 2.19 (dd, 1H, 8eq-H, J = 13.4 Hz J = 2.5 Hz), 2.25 (s,
3H, 9-C(O)Me), 3.05-3.65 (m, 7H, 10ax-H 10eq-H 3',4'-H Gluc2,3,4-H), 3.97 (s, 3H, 4-OMe), 4.16 (q, 1H, 5'-H,
J = 6.6 Hz), 4.70 (d, 1H, 4'-OH, J = 5.5 Hz), 4.85 -4.95 (m, 1H, Gluc5-H), 4.90 (d, 1H, ArCHaHb-, J = 13.5
Hz), 4.93 (d, 1H, ArCHaHb-, J = 13.5 Hz), 5.20-5.25 (m, 2H, 1'-H 7-H), 5.28 (d, 1H, Gluc1-H, J = 8.0 Hz),
5.54 (s, 1H, 9-OH), 6.96 (d, 1H, 3'-NH-, J = 7.9 Hz), 7.36 and 7.44 (2d, 2H, Ar5-H or Ar6-H, J = 8.4 Hz), 7.63
(t, 1H, 3-H, J = 4.5 Hz), 7.77 (s, 1H, Ar2-H), 7.85 -7.90 (m, 2H, 1,2-H), 10.15 (s, 1H, ArNH-), 13.23 (s, 1H, 11-
OH), 14.01 (s, 1H, 6-OH).
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5 Diastereoselective Synthesis ofAnomeric b -D-Glycosyl Carbamates [1]
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
In the preceding chapters all synthesized prodrugs possess a b -D-glycosyl carbamate
specifier, with the exception of the phosphate- and sulfate-based prodrugs. In the multi-
step syntheses of these prodrugs, the glycosyl carbamate moiety is introduced in a very
high to nearly 100% b -diastereoselective manner by addition reaction of an
anomerically unprotected glycosyl donor to an isocyanate. More detailed mechanistic
and synthetic aspects of this reaction will be presented in section 5.1 of this chapter. In
section 5.2 a novel b -D-glucuronyl carbamate forming reaction is described.
5.1 Addition of 1-OH of glycosyl donors to isocyanates
5.1.1 Introduction
b -Glucuronyl carbamates of type 1 and 2 (chart 5.1) are well known metabolites of
drugs containing a primary [2] or a secondary[ 3] amino group, respectively. Reports on
synthetic methods to prepare these b -D-glucuronyl carbamates, or in a more general
sense b -D-glycosyl carbamates of general structure 3, are very scarce [4].
OH O
H O
HO2C
H O
O
H N
O
DRUG
O
H N
O
R
SUGAR-1
OH O
H O HO2C
H O
O
N
O
DRUG
1 32
Chart 5.1   Glycosyl carbamates.
Despite the extensive literature on the addition reaction of alcohols to isocyanates
leading to carbamates[5] , only a few examples concerning the addition reaction of the
anomeric hydroxyl group of glycosides to isocyanates are described (scheme 5.1). In
this context, 2,3,6-tri-O-methyl D-glucose 4 and phenyl isocyanate were allowed to react
under a variety of conditions resulting in a - and b -dicarbamates 5 and 6, respectively,
with b -diastereoselectivities ranging from 30% to 80% [6]. Unprotected lactose 7 reacted
regioselectively with C11 - C18 alkyl isocyanates to afford 1-O- b -lactosyl carbamates 8 in
yields between 24% and 41%[ 7]. Finally, allyl isocyanate was reacted with a variety of
carbohydrates, for example with 2,3,4,6-tetra-O-acetyl D-galactose 9 , to give the
corresponding N-allyl 1-O-a - and - b -D-galactosyl carbamates 10 and 11 in 84% yield
and 80% b -diastereoselectivity [8].
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Scheme 5.1   Literature examples of the addition reaction
of the anomeric hydroxyl-group of glycosides to isocyanates.
5.1.2 Model studies
In order to establish optimal conditions leading to high b -diastereoselectivities (>>
80%), the addition reaction of methyl 2,3,4-tri-O-acetyl D-glucuronate 12 and phenyl-
benzyl- and ethyl isocyanate (table 5.1, R = -Ph, -Bn and -Et ,respectively) was
investigated using different tertiary amines as the catalyst as well as different solvents.
NH
OO
OAcOAcO
MeO2C
AcO
OAcOAcO
MeO2C
AcO OH
R
C
O
N
R
+
solvent
catalyst
12 13 14
a: R = -Ph
b: R = -Bn
c: R = -Et
isocyanate PhMe
-
PhMe
Pyr.
PhMe
i-Pr2NEt
PhMe
Et3N
CH2Cl2
Et3N
THF
Et3N
13a 95 95 >98 100 95 88
13b 88 95 90 >98 88 90
13c † no reaction - * >98
Addition of 12 (20 mg/mL) to 2.0 equiv. of 13 at 20 ºC and 0.3 equiv. of amine.
For reactions in MePh/Et3N c.y. >90%, determined by NMR.† Addition of 12 to the 13c at 60ºC.
* Low yield, extensive formation of side products.
Table 5.1   % b -Diastereoselectivity during formation of 14.
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The anomeric composition of the products 14 was determined by integration of the
clear doublets of H-1( a ) and H-1(b ) which were obtained on a 100 MHz FT-NMR from
the crude reaction mixture. For details concerning the determination of the anomeric
composition, see section 5.1.5. The data in table 5.1 reveal that the addition reaction of
12 to isocyanates 13 in toluene and triethylamine as the catalyst proceeds with optimal
b -diastereoselectivity. These optimal conditions were employed for the synthesis of the
b -D-glucuronyl carbamate pro-moieties from glucuronyl donor 12 and a variety of
isocyanates. The results are collected in table 5.2. In an analogous manner, using these
reaction conditions, 2,3,4,6-tetra-O-acetyl D-glucose 18 and 2,3,4,6-tetra-O-acetyl D-
galactose 19 (chart 5.2) were added to phenyl isocyanate in 100% b -diastereoselectivity.
Benzyl 2,3,4-tri-O-benzyl D-glucuronate 17 reacted with phenylisocyanate in 95%
b -diastereoselectivity. Reactions of 18 and 19 with other isocyanates resulted in
similarly high b -diastereoselectivities as obtained for 12.
OAcOAcO
MeO2C
AcO O H12
OBnOBnO
BnO2C
BnO O H
OAcOAcO
AcO O H
AcO
O
AcO
AcO
AcO O H
AcO
17 18 19
Chart 5.2   Glycosyl donors.
5.1.3 Isocyanates from amines and diphosgene
Isocyanates that were not commercially available, were prepared in situ from the
corresponding amine hydrochlorides 15 and diphosgene (16) (scheme 5.2). The liquid
diphosgene is a saver alternative for phosgene and is handled more easily than
phosgene. After the isocyanate was formed, excess of triethylamine was added to
scavenge the liberated HCl and the glucuronyl donor 12 was added to the reaction
mixture to furnish b -D-glucuronyl carbamates 14. In a classical fashion, isocyanates can
be prepared from amine hydrochlorides using phosgene. The isocyanate is then
obtained by distillation of the reaction mixture. When this procedure was followed for
the preparation of 2-bromo-4-methylphenyl isocyanate (entry #3 in table 5.2), the
isocyanate decomposed during distillation. Decomposition of the isocyanate was
circumvented by using the isocyanate without purification.
C
O
N
R
13
R
NH2-HCl
O
R
HN
O
Cl
OCCl3Cl
O
Cl Cl
2 HCl15 + HCl
16 PhMe, D NH
OO
OAcOAcO
MeO2C
AcO
R
14
12
Et3N
Scheme 5.2   Preparation of isocyanates from amines-HCl using diphosgene.
5.1.4 Isocyanates via the modified Curtius rearrangement
Since a multitude of carboxylic acids are commercially available, the preparation of an
isocyanate from a carboxylic acid via the Curtius rearrangement gives access to a large
number of target compounds.
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The rearrangement of acyl azides to isocyanates and molecular nitrogen was discovered
more than a century ago by the German scientist Curtius [9]. This ancient reaction can
be employed in the synthesis of prodrugs to generate isocyanates 13 from carboxylic
acids 20 (scheme 5.3). Using diphenyl phosphoryl azide (21) [10], acyl azides 23[11] were
formed from carboxylic acids 20 via mixed phosphorus anhydrides 22[12] . On heating,
acyl azides 23 rearrange to isocyanates 13 according to the mechanism depicted in 24.
Diphenyl phosphoryl azide 21 appeared to be an invaluable reagent for a convenient
one-pot preparation of acyl azides directly from carboxylic acids. After isocyanates had
been formed, the mixture was cooled to ambient temperature (for aromatic and
benzylic isocyanates, for aliphatic isocyanates to 50 - 60ºC) and anomerically unprotec-
ted glucuronate 12 was added to the reaction mixture. Following this protocol, b -D-
glucuronyl carbamates 14 were obtained in a one-pot procedure from acids 20 in good
to excellent yields in more than 95% b -diastereoselectivity.
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N H
H O O
N
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OAcOAcO
MeO2C
AcO OH
13
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14
N3P
OPh
OPh
O
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65 - 100ºC
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PhMe,Et3N
R
R R
O O
R
P
OPhO
PhO
N3 O
R
+
N O
R
NN
+
N2
N3-
O-P
OPh
OPh
O22 23
-
24
Scheme 5.3   Modified Curtius rearrangement and further reaction to 14.
Table 5.2 summarizes the results obtained for the modified Curtius reactions carried
out in connection with the synthesis of b -D-glucuronyl carbamate containing prodrugs.
It was demonstrated by several experiments that reactions of glucosyl donor 18 and
galactosyl donor 19 with isocyanates result in similar b -diastereoselectivities as
obtained for the corresponding b -D-glucuronyl carbamates. These results were not
included in table 5.2.
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entry isocyanate 13 general
procedure †
rx conditions
equiv. Et3N, T
% b -diastereo-
selectivity
%
yield
mp of 14
(crystallized from)
#1 N C O
Cl
2 >1, 20ºC 100 92 142 - 143
(i-Pr2O)
#2 N C O
Cl
1 0.1, 20ºC 91 95 155
(Et2O)
#3 N C O
Br
2 >1, 0ºC 100 95 139
(i-Pr2O)
#4 N C OAllO2C
Br
3 0.1, 20ºC >95 80 61 (foam)
#5 N C OBr 1
1.0, 0ºC
1.5, 0ºC
2.0, 0ºC
86
93
100 94
120 - 123
(i-Pr2O/EtOAc)
#6 N C O
NO2
1
0, 0ºC
0.3, 0ºC
1.0, 0ºC
56
62
100 100
169
(i-Pr2O/EtOAc)
#7 N C O
O2N
1 1.0 - 3.0, 0ºC 80 100
153 - 156
(i-Pr2O/EtOAc)
#8 N C O
OSi
3 0.1, 0ºC 100 80
128
(i-Pr2O/n-Hex)
#9
N C O
O
O 3 0.1, 0ºC 100 86 82
(i-Pr2O/EtOAc)
#10
N C O
O
O 3 0.1, 0ºC 100 89 63 - 67
(i-Pr2O/EtOAc)
#11
N C O
O
O
3 0.1, 0ºC >95 68 112 - 119
(Et2O)
#12 N C O
O
O 3 0.1, 0ºC 100 62 69 - 74
(Et2O)
#13 N C OO
O
2 0.1, 50ºC 95 74 oil
#14
N C OO
O 3 0.1, 60ºC 95 80
30 - 33
foam
#15 N C OO
O
3 0.1, 60ºC 100 81 oil
† For the reaction procedure, see the corresponding general procedure # in the experimental section.
1: Commercially available isocyanate; 2: Isocyanate from amine-HCl and diphosgene;
3: Isocyanate from carboxylic acid following the modified Curtius procedure.
Table 5.2 b -Diastereoselectivity and yield of addition reaction of methyl 2,3,4-tri-O-acetyl
D-glucuronate 12 and isocyanates 13 to b -D-glucuronyl carbamates 14.
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5.1.5 Determination of the anomeric composition by 1H-NMR
In general, the stereochemical identity of glucuronides at C(1) can easily be deduced
from their proton NMR spectra[13] . Both the chemical shift and the coupling constant
of the glucuronide H-1 differ for a -D-glucuronides and b -D-glucuronides. In an
a -D-glucuronide, typically, d  (1-H
a
) = 5.2 - 5.5 ppm and the 1-H - 2-H coupling constant
(equatorial-axial interaction) is small, J = 2.2 - 2.7 Hz. In a b -D-glucuronide, d  (1-H
b
) =
4.6 - 4.9 ppm and the diaxial coupling constant between 1-H and 2-H is larger, J = 7.3 to
7.9 Hz. For an a -D-glucuronyl carbamate, typically, d  (1-H
a
) = 6.1 - 6.4 ppm and J1-2 =
2.5 - 2.7 Hz, whereas for a b -D-glucuronyl carbamate d  (1-H
b
) = 5.4 - 5.9 ppm and J1-2 =
7.4 - 8.1 Hz.
Using these characteristics the anomeric composition of the b -D-glucuronyl carbamate
products 14 was determined by integration of the clear doublets of H-1(a ) and H-1(b )
which were obtained from the crude reaction product using a 100 MHz FT-NMR.
In addition, the optical rotation in CHCl3 of a number of representative b -D-glucuronyl
carbamate products 14 was determined, see table 5.3.
NH
OOO
AcO
AcO
MeO2C
AcO
NH
OOO
AcO
AcO
MeO2C
AcO
O
O
NH
OO
OAcOAcO
MeO2C
AcO
Cl
[a ] D
22  = -12.6º [ a ] D
22  = +5.4º [ a ] D
22  = -14.8º *
NH
OO
OAcOAcO
MeO2C
AcO
OSi
NH
OO
OAcOAcO
AcO
OSi
AcO NH
OOO
AcO
AcO
AcO
OSi
AcO
[a ] D
22  = -10.0º [ a ] D
22  = -16.3º [ a ] D
22  = +1.7º
in all cases c = 1.0 in CHCl3 except:  
*c = 0.5 in CHCl3
Table 5.3   Some representative optical rotation values.
5.1.6 High b -diastereoselectivities
The extremely high b -diastereoselectivities encountered in all addition reactions of the
glucuronide-, glucoside- and galactoside anomeric hydroxyl group to isocyanates is
clearly no reflection of the anomeric compositions of the respective glycopyranoside
hemi acetals in solution. In a number of different organic solvents, the glucuronide
hemi acetal 12 appeared[ 14] to be predominantly in its a -configuration (table 5.4).
When triethylamine was added to solutions of 12, the anomeric composition was even
more in favour of the a -isomer as was demonstrated by NMR.
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solvent a / b   of 12 in solution
CDCl3  * 4.9/1 (lit.: 100/0  [15], 4/1 [16])
CD3OD 4/1
MePh-D8 5/1
THF-D8 5.1/1
* for 12 and 1 equiv. of Et3N in CDCl3,
only the a -anomer was detected
Table 5.4   Anomeric composition of 12 in different solvents.
Despite only approximately one-sixth of the anomeric hydroxyl groups of 12 in toluene
are in the b -position (table 5.4), the addition reaction of 12 to isocyanates in the absence
a catalyst (table 5.1) results in a high b -diastereoselectivity. The Curtin-Hammett
principle, stating that the position of the equilibrium between both anomers 25 and 27
(scheme 5.4) is irrelevant for the product ratio of 26 and 28, applies to this reaction.
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Scheme 5.4   Curtin-Hammett principle in the b -diastereoselective addition reaction.
When triethylamine is added to the reaction mixture the b -diastereoselectivity is even
more pronounced, implying that the amine catalyzes the formation of the b -product
more efficiently than that of the a -product.
The high selectivity probably originates from the 1,3-diaxial steric hindrance in the
a -transition state, obstructing the tertiary amine to properly catalyze the addition
reaction. Moreover, the 1-OH group is known to be more nucleophilic in the b - than in
the a -configuration [17]. Additional evidence supporting the assumption that the
b -product formation is more efficiently catalyzed is obtained using very reactive
isocyanates. When 12 reacted with 4-methyl-2-nitrophenyl isocyanate (table 5.2) in
toluene at 0ºC in the absence of a catalyst  a mixture of the a - and b -products in a ratio
of 1/1 was formed. When the reaction was caried out in the presence of 0.3 equiv. of
triethylamine an a / b  ratio of 1/2 was obtained. When a stoichiometric amount of
triethylamine was used in this reaction, only the b -product was formed (table 5.2). Also
in agreement with this supposition is the observation that the use of a sterically
hindered amine (diisopropyl ethyl amine, table 5.1) catalyzes the addition reaction less
efficiently[5] resulting in lower b -diastereoselectivities.
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5.1.7 High a -diastereoselectivities
Alternatively, to prepare a -glucuronyl carbamates, when glucuronyl donor 12 was
reacted with N-succinimidyl chloroformate (29) followed by a reaction of the resulting
active carbonate 30 with an amine R1R2NH, the a -anomer 31 a  was almost exclusively
obtained (% of a -anomer > 98, scheme 5.5). Thus, the use of chloroformate 29 [ 18]
provides a synthetic route to a -D-glycosyl carbamates[ 19].
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Scheme 5.5   Preparation of a -D-glucuronyl carbamates using a chloroformate.
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5.2 A novel b -D-glycosyl carbamate forming reaction
5.2.1 Introduction
In an attempt to couple the carboxylic acid group of 35a to the amino group of
daunorubicin (DAU) using the BOP coupling reagent 36, carbamate 37a was obtained
in 89 % together with 6(5H)-phenanthridinone (38) (scheme 5.6) instead of the expected
amide product. This coupling reaction was carried out in an attempt to synthesize
DAU-GB4 (see section 3.3.3 and scheme 3.9). Variation of the peptide coupling reagent,
solvent and base did not lead to the desired product; in all cases b -D-glucuronyl
carbamate 37a was isolated. This compound was previously prepared in a more
complicated manner during the synthesis of DAU-GA1 (see section 2.5.2 and scheme
2.11). In the literature, a comparable example of such an intramolecular elimination
reaction leading to phenanthridinone 38 has not been reported.
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a: R1 = -OAc, R2 = -H, R3 = -CO2Me (glucuronyl)
b: R1 = -H, R2 = -OAc, R3 = -CH2OAc (galactosyl)
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Scheme 5.6   Transfer of b -D-glucuronyl carbonyl fragment.
As was mentioned in section 2.5.3, the synthesis of DAU-GlA1 was accomplished using
the galactosyl analog of the reaction in scheme 5.6. In this fashion, compound 37b was
prepared from 35b in 70% yield. This proved that the novel reaction also worked for the
galactosyl analog. Deprotection of 37b resulted in prodrug DAU-GlA1.
The unexpected sequence depicted in scheme 5.6 can be rationalized as follows (see
scheme 5.7). The coupling reagent (i.e. BOP) activates the carboxylic acid in the normal
manner. Then an intramolecular reaction with the carbamate nitrogen takes place to
give the N-phenanthridinone O-b -D-glucuronyl carbamate 39. The phenanthridinone
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moiety serves as a leaving group in the subsequent reaction with daunorubicin to give
product 37a and phenanthridinone 38.
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2Cl2
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R = 3'-N-daunorubicinyl
DAU-
HClH
N O
38
+
Scheme 5.7   Cyclization of 32a and further reaction with amines to form 46.
Unequivocal evidence for this mechanism was obtained by a reaction of 35a with
coupling reagent BOP (36) in the absence of a nucleophilic amine. This reaction led to
the high yield formation of compound 39 (90%). An independent reaction of compound
39 with daunorubicin resulted in carbamate 37a and phenanthridinone 38.
It should be noted that the amino group of daunorubicin cannot be converted into an
isocyanate group in order to react with a glycosyl donor, because of the presence of the
four hydroxyl groups present elsewhere in the molecule which would react with the
isocyanate function. Also secondary amines are of interest as a substrate for this novel
glycosyl carbamate forming reaction as they principally cannot be transferred into
isocyanates.
5.2.2 Application of the novel transfer reaction
Application of the reaction to the synthesis of b -D-glucuronyl carbamates of secondary
amines was first tested in a model system (scheme 5.8). When 1,2,3,4-tetrahydro-
isoquinoline 40 was reacted with N-2-biphenyl-2'-carboxylic acid O-(methyl 2,3,4-tri-O-
acetyl b -D-glucuronyl) carbamate (35a, scheme 5.6), the b -D-glucuronyl carbamate 41
was obtained in 70% yield. This proved that the reaction also worked for a secondary
amine.
As already mentioned in section 5.1.1, b -D-glucuronyl carbamates are well known
metabolites of drugs containing a primary [2] or a secondary [3] amino group. In this
respect, in rats the b -D-glucuronyl carbamate 44 (scheme 5.7) was found to be a
metabolite of the anti-hypertensive drug carvedilol 42 [20]. The metabolite had been
prepared for use as a reference compound in vitro using dog and rat liver microsomes
[21]. Using the novel b -D-glucuronyl carbonyl transfer reaction compound 43 could be
prepared in 92% yield from ( – )-carvedilol 42. This is the protected precursor of
metabolite 44 . The preparation of N -daunorubicinyl- and N-carvediloyl O-
b -D-glucuronyl carbamates 37a and 43, respectively, exemplifies the value of the
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reaction in the preparation b -D-glucuronyl carbamates of relatively complicated
primary and secondary amines.
36, i-Pr2NEt, CH2Cl2, 70%
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Scheme 5.8   b -Glucuronyl carbamates of secondary amines.
5.3 Experimental part
General
Daunorubicin hydrochloride was a generous gift of PharmaChemie BV (Haarlem, The
Netherlands), ( – )-carvedilol was a gift of Boehringer Mannheim GmbH (Mannheim,
Germany). 1H-NMR spectra at 100 MHz were obtained on a Bruker AM-100
spectrometer, spectra at 400 MHz on a Bruker AM-400 spectrometer. Chemical shifts
are expressed in ppm downfield from internal standard Me4Si. In all cases, CH2Cl2,
Et3N and PhMe were dried by distillation over CaH2 and i-Pr2NEt was dried over KOH
pellets.
General procedure #1: Reaction of glucuronyl donor 12 with commercially available 
isocyanates 13 to obtain b -D-glucuronyl carbamates 14 (scheme 5.2).
To a solution of 200 mg of isocyanate 13 and 0.1 to 2.0 equiv. (see table 5.2) of Et3N in 20 mL of dry PhMe,
0.5 equiv. of glycosyl donor 12 was added. After 2 h, the reaction mixture was concentrated to dryness
and subjected to flash column chromatography (SiO2, Et2O/n-Hex) to yield 1-O-b -(methyl 2,3,4-tri-O-
acetyl)-D-glucuronyl carbamates 14 in good to excellent yield and in 95-100% b -diastereoselectivity. In
most cases the pure b -isomer was crystallized (see table 5.2).
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General procedure #2: Reaction of glucuronyl donor 12 with isocyanates in situ prepared from
an amine-HCl 15 and diphosgene 16 to obtain b -D-glucuronyl carbamates 14 (scheme 5.2).
200 mg of amine-HCl 15 and 1.0 equiv. of diphosgene (16) were dissolved in 10 mL of PhMe and the
reaction mixture was refluxed for 2 h under an argon atmosphere. When the HCl evolution had ceased,
the mixture was cooled to 0ºC and 5.0 equiv. of Et3N were added. After that, 0.5 equiv. of 12 was added.
The reaction mixture was stirred for 1 h at 0ºC and processed according to general procedure #3. The
crude product was purified by column chromatography (SiO2, Et2O/n-Hex 1/1) to give 1-O-b -(methyl
2,3,4-tri-O-acetyl)-D-glucuronyl carbamates 14 in good to excellent yield and in 95-100% b -diastereo-
selectivity. In most cases the pure b -isomer was crystallized (see table 5.2).
General procedure #3: Modified Curtius reaction for conversion of carboxylic acids 20 to b -D-
glucuronyl carbamates 14 (scheme 5.3).
500 mg of a carboxylic acid 20 was stirred overnight with 1.1 equiv. of (PhO)2P(O)N3 (21) and 1.1 equiv.
of Et3N in 15 mL of PhMe under an argon atmosphere at room temperature. The reaction mixture was
subsequently heated until gas evolution was observed, occurring between 65-100ºC depending on the
actual substrate. Heating was continued for 2 h. After that, for aromatic and benzylic isocyanates the
reaction mixture was allowed to cool to ambient temperature. Aliphatic isocyanates were allowed to cool
down to 50-60ºC. 0.5-0.75 equiv. [22] of the glucuronate 12 was added. The reaction mixture was stirred
until 12 had almost disappeared on TLC (SiO2, Et2O) and worked-up in the following fashion: The
reaction mixture was diluted with 100 mL of Et2O and successively washed with 200 mL portions of
aqueous 0.5 N KHSO4, with saturated aqueous NaHCO3 (3x) and with brine. The organic layer was dried
over Na2SO4 and evaporated. The residual material was purified by column chromatography (SiO2,
Et2O/n-Hex) to yield the 1-O-b -(methyl 2,3,4-tri-O-acetyl)-D-glucuronyl carbamates 14 in good to
excellent yield and in 95-100% b -diastereoselectivity. In most cases the pure b -isomer was crystallized
(see table 5.2).
General procedure #4: Preparation of b -D-glucuronyl carbamates of amines using the novel 
b -glycosyl carbamate forming reaction.
100 mg of 35a [23], 1.1 equiv. of BOP (36), 3 equiv. of i-Pr2NEt and 1 - 2 equiv. of the amine-substrate were
dissolved in 20 mL of CH2Cl2 and stirred overnight under an argon atmosphere at ambient temperature.
The course of the coupling reaction was monitored on TLC (SiO2, Et2O). After that, the reaction mixture
was diluted with 150 mL of CH2Cl2 and successively washed with 200 mL portions of aqueous 0.5 N
KHSO4 (3x), saturated aqueous NaHCO3 and brine. The organic layer was dried over Na2SO4 and
evaporated. The residual material was purified by column chromatography (SiO2 Et2O/n-Hex or
CH2Cl2/EtOH) to yield the respective 1-O-b -(methyl 2,3,4-tri-O-acetyl)-D-glucuronyl carbamates in good
to excellent yield and in 100% b -diastereoselectivity (the starting material 35a was 100% b -anomer, see
entry #10 in table 5.2. No anomerization was detected after completion of the reaction).
–––––––––––––
Synthesis of N-3'-daunorubicinyl O- b -(2,3,4-tri-O-acetyl D-glucuronyl) carbamate
(37a scheme 5.6).
According to general procedure #4 in 89%. For the physical data of 37a, see the experimental part of
chapter 2 where this compound is prepared differently [compound 38 b  under "synthesis of N-3'-
daunorubicinyl O- b -D-glucuronyl carbamate (DAU-GA1)"]. For this alternative synthesis, see section
2.5.2 and scheme 2.11.
Synthesis of N-3'-daunorubicinyl O- b -(2,3,4,6-tetra-O-acetyl D-galactosyl)
carbamate (37b scheme 5.6).
N-2-[Biphenyl-2'-carboxylic acid allyl ester] O- b -(2,3,4,6-tetra-O-acetyl D-galactosyl) carbamate (34b) from 33b
and 32 (scheme 5.6) according to general procedure #3 in 65% yield and 100% b -diastereoselectivity as an
oil. In the 1H-NMR spectrum of 34b taken on a 100 MHz recorder in CDCl3, two ArNH- signals were
present (in a ratio close to 1/1) and almost all other signals were broadened. This was also seen in the
NMR spectrum of the b -D-glucuronyl analog 34a and indicated the existence of two rotameric forms of
the compound. This is likely due to restricted rotation around the Ar-Ar bond. 1H-NMR (100 MHz,
Diastereoselective Synthesis of b -Glycosyl Carbamates 111
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CDCl3) d  (ppm) = 1.91, 1.96, 1.98 and 2.10 (4s, 12H, 4 -OAc), 3.95-4.15 (m, 3H, Gal5,6-H2), 4.44 (bd, 2H,
-OCH2CH=, J = 5.6 Hz), 4.90-5.25 (m, 4H, =CH2 Gal2,3-H), 5.34 (d, 1H, Gal4-H, J = 3.0 Hz), 5.50-5.85 (m,
1H, -CH=), 5.62 (d, 1H, Gal1-H, J = 7.7 Hz), 6.45 and 6.49 (2s, 1H, ArNH-), 7.00-7.65 (m, 6H,
Ar3,3',4,4',5,5'-H), 7.70-8.00 (m, 2H, Ar6,6'-H).
N-2-[Biphenyl-2'-carboxylic acid] O-b -(2,3,4,6-tetra-O-acetyl D-galactosyl) carbamate (35b) from 34b according
to general procedure #3 of chapter 3 in 93% as an oil.
N-3'-Daunorubicinyl O- b -(2,3,4,6-tetra-O-acetyl D-galactosyl) carbamate (37b) from 35b analogously to
general procedure #4 (35b is used instead of 35a) in 70%, mp 160-162ºC, 1H-NMR (400 MHz, CDCl3) d
(ppm) = 1.30 (d, 3H, 5'-Me, J = 6.4 Hz), 1.79 (dt, 1H, 2'ax-H, J = 13.0 Hz J = 4.2 Hz), 1.90 (dd, 1H, 2'eq-H, J =
13.0 Hz J = 5.0 Hz), 1.98 (s, 6H, 2 -OAc), 2.04, and 2.14 (2s, 6H, 2 -OAc), 2.11 (dd, 1H, 8ax-H, J = 14.8 Hz J =
4.0 Hz), 2.31 (d, 1H, 8eq-H, J = 14.8 Hz), 2.42 (s, 3H, 9-C(O)Me), 2.48 (s, 1H, 4'-OH), 2.90 (d, 1H, 10ax-H, J =
18.8 Hz), 3.22 (d, 1H, 10eq-H, J = 18.8 Hz), 3.65 (d, 1H, 4'-H, J = 7.0 Hz), 3.88 (bs, 1H, 3'-H), 4.07 (s, 3H, 4-
OMe), 3.95-4.15 (m, 3H, Gal5,6-H2) 4.22 (q, 1H, 5'-H, J = 4.22 Hz), 4.45 (s, 1H, 9-OH), 5.05 (dd, 1H, Gal3-H,
J = 10.4 Hz J = 3.3 Hz), 5.20-5.35 (m, 3H, 3'-NH- 7-H Gal2-H), 5.39 (d, 1H, Gal4-H, J = 3.7 Hz), 5.50 (d, 1H,
1'-H, J = 3.5 Hz), 5.58 (d, 1H, Gal1-H, J = 8.3 Hz), 7.38 (d, 1H, 3-H, J = 8.4 Hz), 7.77 (t, 1H, 2-H, J = 8.4 Hz),
8.02 (d, 1H, 1-H, J = 7.7 Hz), 13.24 (s, 1H, 11-OH), 13.97 (s, 1H, 6-OH).
Synthesis of N-2-(1,2,3,4-tetrahydroisoquinolinyl) O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (41 scheme 5.8).
According to general procedure #4 in 70% (calculated from 35a) from 35a and 1,2,3,4-tetrahydro-
isoquinoline (40) (2.0 equiv.) as an oil. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.90-2.10 (m, 2H, 4-H2), 2.04
(s, 9H, 3 -OAc). 2.65-3.00 (m, 2H, 3-H2), 3.72 (s, 3H, -CO2Me), 4.22 (d, 1H, Gluc5-H, J = 9.3 Hz), 4.51 (d,
1H, 1-HaHb, J = 12.1 Hz), 4.68 (d, 1H, 1-HaHb, J = 12.1 Hz), 5.15-5.50 (m, 3H, Gluc2,3,4-H), 5.76 (d, 1H,
Gluc1-H, J = 7.0 Hz), 7.05-7.30 (m, 4H, 4Ar-H).
Synthesis of N-4'-carvediloyl O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (43 scheme 5.8).
According to general procedure #4 in 92% (calculated from 42) from 35a and ( – )-carvedilol (42) (0.9
equiv.), mp 58ºC, MS (FAB+) m/z = 789 ([M+Na]+), 766 ([M]+), 317 ([C13H17O9]+). Because a racemic
mixture of carvedilol was used, two diastereomeric carbamoyl glucuronides were obtained. This resulted
in overlapping and broadening of signals in the proton NMR. 1H-NMR (100 MHz, CDCl3) d  (ppm) = 1.90,
1.93, 1.95, 1.97 and 2.03 (5s, 9H, 3 -OAc), 3.40-5.20 (m, 9H, aliphatic carvedilol), 3.73 (s, 6H, -OMe
-CO2Me), 4.25 (bd, 1H, Gluc5-H, J = 9.2 Hz), 5.10-5.50 (m, 3H, Gluc2,3,4-H), 5.79 (bd, 1H, Gluc1-H, J = 7.1
Hz), 6.60-7.60 (m, 10H, 10 Ar-H), 8.09 and 8.12 (2s, 1H, ArN-H), 8.20-8.40 (m, 1H, Ar5-H).
N-6-Phenanthridinone-5-yl O-b -(methyl 2,3,4-tri-O-acetyl D-glucuronyl)
carbamate (39 scheme 5.7).
According to general procedure #4 (no amine was added) in 90% yield from 35a as an oil, 1H-NMR (100
MHz, CDCl3) d  (ppm) = 2.04, 2.07 and 2.20 (3s, 9H, 3 -OAc), 3.80 (s, 3H, -CO2Me), 4.35 (d, 1H, Gluc5-H, J
= 9.3 Hz), 5.15-5.55 (m, 3H, Gluc2,3,4-H), 6.08 (d, 1H, Gluc1-H, J = 7.6 Hz), 7.10-8.35 (m, 7H,
Ar3,3',4,4',5,5',6'-H), 8.39 (dd, 1H, Ar6-H, J = 7.8 Hz J = 1.5 Hz). MS (FAB+) m/z = 578([M+Na]+), 317
([C13H17O9]+).
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6.1 Introduction
The practical application of ADEPT in patients suffering from a malignant disease
requires multidisciplinary research. In this perspective a collaboration was set-up
between the synthesis group of the University of Nijmegen and the Department of
Medical Oncology, Vrije Universiteit Hospital of Amsterdam (Dr. H.J. Haisma, Dr. E.
Boven). Within the framework of the PhD research of Ir. P.H.J. Houba, this group
investigated the preparation of a suitable mAb- b -glucuronidase conjugate and the bio-
logical and biochemical aspects of the ADEPT concept.
In our approach toward the development of an
effective anti-cancer drug treatment according to the
ADEPT concept, a number of stages can be discerned.
an enzyme in combination with a prodrug prototype
was selected that met specific requirements (see
section 1.4). The selection of a suitable ADEPT system
was outlined in chapter 2. This resulted in the choice
of human b -glucuronidase as the enzyme in
combination with a b -D-glucuronide containing
prodrug. In stage two (chapters 3 and 4) prodrugs
were synthesized which were screened initially with
respect to the rate of activation to the parent drug by
human b -glucuronidase and with respect to the
prodrug cytotoxicity. In subsequent research the
pharmacokinetics (e.g. plasma clearance half-life) of a
number of selected prodrugs were studied and
derivatives of these prodrugs were synthesized in
order to optimize these pharmacokinetics. As a result
of these investigations one daunorubicin and one
doxorubicin   prodrug,    DAU-GA3   and  DOX-GA3
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(chart 6.1) respectively, were selected as the most promising prodrugs in ADEPT. The
synthesis, activation rates and toxicities of these prodrugs were reported in chapter 4.
During the development of a suitable prodrug for ADEPT described in this thesis,
research focusing on the preparation of a mAb-enzyme conjugate was undertaken at
the department of Medical Oncology, Vrije Universiteit Hospital of Amsterdam.
Subsequent investigations in this group were devoted to the development of ADEPT in
vitro (stage 2) and in vivo (stage 3). These investigations will be presented in the thesis of
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Ir P.H.J Houba [1] and have been partly published already [3, 4]. A brief summary of this
work is given in the subsequent sections.
6.2 The mAb-enzyme conjugate
6.2.1 Monoclonal antibody
For the preparation of mAb-enzyme conjugates mAb 323/A3 was used. This mAb is
reactive with antigens highly expressed on the surface of most carcinomas including
breast, ovary, lung and colon tumors. Breast cancer and ovarian cancer are considered
to be sensitive to anthracyclines.
6.2.2 Enzyme
Human b -glucuronidase (GUS) was chosen for use in ADEPT for the following reasons.
First, GUS is localized intracellularly in microsomes and lysosomes. Enzyme activity is
not detectable in human blood and premature activation of a b -D-glucuronide
containing prodrug is minimized because the hydrophilic prodrugs do not enter cells.
Second, b -D-glucuronide containing prodrugs could be prepared which met some
essential primary requirements for prodrugs in ADEPT, viz. i. stability under
physiological conditions, ii. reduced toxicity compared with the parent drug and iii.
rate of activation to the parent drug. Third, GUS was chosen because it is of human
origin and therefore, it is expected to be less immunogenic than enzymes derived from
other species than man [2].
GUS was produced by a mouse cell line (L-MPR cells) transfected with the human
b -glucuronidase gene and secreted in the culture medium from which it was isolated by
ion exchange chromatography.
A disadvantage of the use of GUS in ADEPT is the low pH-optimum of 4.2. The
enzyme has an approximately 10-fold lower rate of hydrolysis at pH = 6.8 found in the
interstitium of tumor tissue. Another disadvantage is that GUS has a rapid glycan-
specific hepatic clearance from the blood and is accumulated in the liver; hepatic
receptors recognize specific sugar moieties on the enzyme surface. GUS was cleared
from the circulation of mice after intravenous administration with a half-life of 30 min.
The mAb 323/A3-GUS conjugate showed a half-life even faster than that of native GUS,
possibly making it ineffective for use in ADEPT. To decrease the clearance rate of the
enzyme, the carbohydrate groups of GUS were modified by subsequent treatment of
GUS with NaIO4 and with NaBH4. The enzyme activity of the resulting modified GUS
was not decreased by these chemical reactions.
6.2.3 mAb-enzyme conjugate
Modified GUS (mGUS) was coupled to mAb 323/A3 and the clearance rate of this
conjugate in mice was greatly improved to a half-life of 8.6 h. The conjugate retained
>95% of the GUS activity and also >95%  of the immunoreactivity. A radioactive [125I]-
323/A3-mGUS conjugate was prepared to study the localization of the conjugate in
tumor and other tissue. After coupling the conjugate was purified using a size
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exclusion column which separates molecules with different molecular weight. The
preparation of these conjugates was published [3] in 1996.
6.3 In vitro experiments
6.3.1 Characterization of prodrugs
The GUS mediated activation was determined for all anthracycline prodrugs which
were synthesized and described in chapters 2, 3 and 4. In this context, Km and Vmax
values were calculated and the half-life of the reaction was determined. In this thesis,
the prodrug activation rates were given at the end of each respective chapter and were
expressed as half-lives (t1/2) determined under standard conditions (100 m M Prodrug in
0.1% BSA/PBS, 0.03 U/mL GUS, pH = 6.8, 37ºC). Cytotoxicities of prodrugs which
were activated to their parent drug at an agreeable rate were determined. In most cases
where a prodrug could not be enzymatically activated to the parent drug, determina-
tion of the cytotoxicity was omitted. A comprehensive overview of enzymatic prodrug
activation characteristics and cytotoxicities will be described in the thesis of Ir Houba
[1]. An evaluation of four prodrugs for use in ADEPT described in this thesis [DAU-
GA1  (Ch. 2), DAU-GB1 and DAU-GB5 (Ch. 3), DAU-GA3 (Ch. 4)] and of two
prodrugs prepared by others has been published [4]. In addition to the prodrug
activation rate and cytotoxicity, the hydrophilicity, protein binding and cellular uptake
of the prodrugs were determined. Based on these results prodrugs DAU-GA3 and
DOX-GA3 (chart 6.1) were chosen as most promising to be used in ADEPT.
6.3.2 In vitro efficacy of ADEPT
Pretreatment of OVCAR-3 cells with the mAb 323/A3-mGUS conjugate and removal of
the non-bound conjugate followed by the addition of prodrug DAU-GA3 to the cells,
resulted in a cytotoxicity reaching the same value as that for treatment of daunorubicin
alone. When OVCAR-3 cells were preincubated with excess of mAb followed by
exposure to the mAb-enzyme conjugate, prodrug DAU-GA3 was not activated to
daunorubicin. These results indicate the specificity of the conjugate. When prodrug was
added 24 h after treatment of the OVCAR-3 cells with mAb 323/A3-mGUS, no
reduction in cytotoxicity was found. This indicates that the enzyme activity of the
bound conjugate is retained, that the conjugate is not internalized by the cells and that
shedding of the antigen did not take place (shedding is release of antigen from the cell).
6.4 In vivo experiments; animal models
6.4.1 In vivo characterization of prodrug and mAb-enzyme conjugate
The elimination of DAU-GA3  from the circulation of BALB/c mice was determined at
a dose of 10 and 100 mg/kg. In both cases an elimination half-life time of 20 min was
found. Daunorubicin was eliminated from the circulation with a half-life of 720 min.
These results are comparable to those of DOX-GA3 and doxorubicin. The maximum
tolerated dose (MTD) in mice of DAU-GA3 and DOX-GA3 was found to be 2x 250 and
2x 500 mg/kg, respectively, (7 days between first and second dose). Compared to
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daunorubicin (MTD = 2x 10 mg/kg) and doxorubicin (MTD = 2x 8 mg/kg) these
prodrugs were much less toxic.
The pharmacokinetics in BALB/c mice of 323/A3-mGUS and [125I]-323/A3-mGUS
conjugates were found to be identical. Blood t1/2 = 8.6 h were found for both
conjugates. The distribution and tumor localization of [125I]-323/A3-mGUS in OVCAR-
3 (human ovarian cancer) xenografted nude mice were determined. At ten days after
administration of the conjugate the tumor to blood ratio was >4. The tumor to tissue
ratios rose steadily for all organs indicating the specific retention of the conjugate into
the tumor and reached a maximum value of >5 at 7 days.
6.4.2 ADEPT
In an in vivo ADEPT experiment, mAb 323/A3-mGUS was given to nude mice bearing
ovarian cancer xenografts. After 7 days, 50, 100 or 250 mg/kg DAU-GA3 was given to
the mice. A delay in tumor growth was observed for the mice which had received 100
or 250 mg/kg prodrug. The tumor growth delay was more pronounced than that in
mice which were conventionally treated with daunorubicin. These first experiments
indicate the feasibility of ADEPT in a mouse model.
6.4.3 Monotherapy
Observations made by Connors et al. as early as 1966 [5] revealed that two types of
plasma cell tumors grown in BALB/c mice were highly sensitivity towards aniline
mustard 1 (scheme 6.1). In further experiments to investigate the surprisingly high
selective toxicity of aniline mustard 1 for these cancer cells, it was found that 1 is
hydroxylated in the liver to the highly toxic hydroxyaniline mustard 2 and then
detoxified by conversion to the b -D-glucuronide 3. Additionally, an increased
b -glucuronidase activity was found in the two plasma cell tumors and a direct
relationship was observed between the b -glucuronidase activity and the sensitivity to 1.
It was concluded that the highly toxic hydroxyaniline mustard 2 is selectively activated
in those tumors by the elevated levels of endogenous b -glucuronidase. It should be
noted that this high b -glucuronidase activity of various cancer tissues has already been
reported in 1947 [6].
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Scheme 6.1   Glucuronidation/deglucuronidation of aniline mustard 1.
In a more recent paper, Bosslet et al. [7 ]  (surprisingly not referring to the above-
mentioned findings of Connors and co-worker) have reported that high
b -glucuronidase activities were found especially in necrotic tumor areas where dying
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cells liberate their lysosomal b -glucuronidase. This was demonstrated for various
human bioptics viz. for breast cancer, lung cancer, gastrointestinal tract cancer and
melanomas. It was hypothesized that tumors with a diameter >3 mm develop necrosis
primarily due to poor vascularization. As a consequence, the cell contents of necrotic
cells, including lysosomal b -glucuronidase, is liberated in those areas. In this study of
Bosslet and co-workers it was stated that the released b -glucuronidase is much more
resistant toward proteases present in the plasma than other enzymes released by
defective cells and, consequently, high b -glucuronidase activities are present in necrotic
tumor areas. As already suggested by Connors et al. in 1966 [5], Bosslet and co-workers
suggested [7] that the b -glucuronidase activity in these necrotic tumor areas can be used
to activate a b -D-glucuronide containing prodrug to result in a more tumor selective
chemotherapy. In a recent study of Bosslet and co-workers in collaboration with other
groups [8], it was shown in a monotherapy experiment using a doxorubicin prodrug
(compound 10  chart 4.2) in a human lung tumor model that doxorubicin was
accumulated in the tumor cells. This was ascribed to the elevated b -glucuronidase
activity of the lung tumor which activated the prodrug.
In the context of these findings and suggestions, further experiments using DAU-GA3
and DOX-GA3 without the administration of a mAb-enzyme conjugate were under-
taken. Nude mice bearing human ovarian cancer xenografts (OVCAR-3) were used for
monotherapy experiments with DAU-GA3 and DOX-GA3. These tumors had a size
that necrosis could be expected and, therefore, will display an enhanced b -glucu-
ronidase activity.
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Figure 6.1   Monotherapy using prodrug DAU-GA3.
DAU-GA3 (2x 150 or 2x 200 mg/kg on day 0 and 7), was given to the mice; a second
group received 2x 8 mg/kg daunorubicin on day 0 and 7 and a third group received no
treatment (control group). Treatment of the mice with the prodrug DAU-GA3 showed
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a larger growth inhibition effect when compared with tumors treated with dauno-
rubicin alone, see figure 6.1 [9].
Monotherapy of the OVCAR-3 bearing nude mice with the doxorubicin prodrug DOX-
GA3 seemed to be even more promising than the monotherapy experiments with
DAU-GA3 outlined above. When compared with the DAU-GA3 monotherapy
experiment, a larger dose of DOX-GA3 was given to the mice because the MTD of
DOX-GA3 (2x 500 mg/kg) is higher than that of DAU-GA3 (2x 250 mg/kg). In these
experiments 2x 500 mg/kg DOX-GA3 was given also on day 0 and 7. The second group
received 2x 8 mg/kg doxorubicin (which is the MTD of doxorubicin) and the third
group was not treated (control group). In the group of mice treated with DOX-GA3 not
only a growth delay but even a decrease of the tumor volume was observed after
administration of the second dose of prodrug. The tumors of mice receiving
doxorubicin did not reduce in volume, only a growth delay was observed when
compared with the tumor-growth of in the control group. In conclusion, the effect of
doxorubicin prodrug DOX-GA3 in monotherapy experiments to treat human cancer
xenografts in mice is superior to the treatment of the mice with doxorubicin itself.
6.5 Outlook: Clinical trials in cancer patients
In two recent publications Bagshawe et al. [10] have reported the first clinical experience
with the use of an ADEPT system employing an aniline mustard prodrug in combi-
nation with a mAb-carboxypeptidase G2 conjugate (see section 1.4.3). A serious
limitation of this anti-cancer therapy, however, is the development of antibodies against
the bacterial carboxypeptidase G2 enzyme and immunosuppression using cyclosporin
was necessary. Despite this disadvantage of the use of the non-human enzyme,
Bagshawe and co-workers made a strong case for further development of the ADEPT
approach of treating cancer and a number of ADEPT systems have entered into the
clinic [11]. The major problems associated with ADEPT, however, originate from the
necessity for use of a mAb-enzyme conjugate (main problems are: development of host
antibodies, slow clearance from circulation after tumor-localization and low avail-
ability). Other prodrug activating systems have been devised to overcome the
limitations imposed by the mAb-enzyme conjugate. Among these are the use of a
fusion protein and the use of humanized catalytic antibodies (abzymes). For a more
comprehensive overview of tumor selective prodrug activating systems, see section 1.4.
The preclinical therapeutic efficacy of our anthracycline- b -D-glucuronide prodrug/
b -glucuronidase ADEPT system, simultaneously making use of the endogenous
b -glucuronidase activity of necrotic tumors to activate the prodrug, has been
demonstrated in mice. In this system, even without targeted b -glucuronidase activity,
the b -D-glucuronide containing prodrug  already possesses selective toxicity for the
tumor cells (monotherapy). Additional b -glucuronidase activity can then be targeted
(e.g. mAb-enzyme, fusion protein or abzyme) to enhance the efficacy of the
b -D-glucuronide containing prodrug. Finally, the use of prodrugs of anthracyclines in
ADEPT seem advantageous because of the lipophylicity of anthracyclines and their
potential to readily enter cells. Once an anthracycline is generated from the
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anthracycline-prodrug, leakage of the anthracycline into the surrounding healthy tissue
or into the circulation is therefore expected to be minimal.
For the elaboration of our ADEPT system and the monotherapy approach, promising in
vivo experiments have been performed using prodrugs DAU-GA3 and DOX-GA3 to
treat human tumor xenografted mice. From these, prodrug DOX-GA3 was chosen to be
further evaluated in phase 1 clinical experiments [12]. As a consequence, multiple gram
quantities of DOX-GA3 are required. Because the existing synthesis of DOX-GA3 does
not allow the preparation of large amounts, a modified method to prepare this
compound on a large scale is currently under investigation. The development of an
anti-cancer therapy using DOX-GA3 is financed by Pharmachemie BV Haarlem, the
Netherlands.
Simultaneous to the elaboration of the encouraging future prospects of DOX-GA3 as a
tumor selective anti-cancer agent, research is continued to prepare DOX-GA3 analogs
with improved properties (e.g. blood elimination rate, activation rate, cellular uptake,
cytotoxicity) for use in ADEPT and/or monotherapy. Moreover, research has started to
apply the successful spacer- b -D-glucuronyl carbamate pro-moieties in the design and
synthesis of prodrugs of other anti-tumor compounds (e.g. taxol).
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Summary
This thesis is devoted to the synthesis and biological evaluation of prodrugs of
anthracycline anti-tumor antibiotics designed for use in selective chemotherapy.
The severe side effects caused by conventional cancer chemotherapeutic agents arises
from the lack of distinction between tumor and normal cells. Most of the available
antitumor drugs are specifically toxic to proliferating cells and, therefore, tumor cells
are slightly more sensitive to cytostatic agents compared with normal cells.
Nevertheless, therapeutic indices of anticancer drugs are too low resulting in
unacceptable damage to healthy tissue upon chemo-treatment. This has stimulated the
development of a variety of approaches to improve the effectiveness and tumor cell
selectivity of anticancer agents.
In this thesis the synthesis of prodrugs which can be used in the Antibody Directed
Enzyme Prodrug Therapy (ADEPT) concept for selective cancer treatment is described.
A concise biological evaluation of the synthesized prodrugs for the ADEPT concept is
given at the end of each chapter.
In the ADEPT approach for treatment of cancer (see figure S.1.), an enzyme is
chemically coupled to a monoclonal antibody (mAb) which is selective for tumor
associated antigens. This conjugate is administered to a cancer patient and allowed to
localize selectively at the tumor site (step 1). After the mAb-enzyme conjugate is cleared
from plasma and other tissue, in the second step, a relatively non-toxic prodrug is
administered. This prodrug is converted to the parent cytotoxic drug by the action of
the targeted enzyme.
step 1
step 2
mAb
enzyme
enzyme
tumor
cell
tumor
cell
tumor
cell
tumor
cell
enzyme tumor
cell
tumor
cell
prodrug
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negative cell
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Figure S.1.   The concept of ADEPT.
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This ADEPT strategy has a number of advantages over conventional cancer chemo-
therapy which is outlined in more detail in chapter 1. In this introductory chapter, an
overview of the literature concerning prodrugs used in ADEPT is presented.
In chapter 2, an enzyme/prodrug combination which is most promising for use in
ADEPT is selected. In order to be able to select a suitable ADEPT system, polar
prodrugs from daunorubicin, employing phosphate-, sulfate-, b -glucuronide-,
b -glucoside- and b -galactoside groups were synthesized and subjected to a series of
cytotoxicity- and enzyme-hydrolysis assays. The prodrug containing a b -glucuronyl
carbamate group (DAU-GA1, scheme S.1.) was found to be the most promising
prodrug and further research was focussed on such b -glucuronyl carbamate containing
prodrugs.
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Scheme S.1.   The first b -glucuronyl carbamate containing prodrug.
As DAU-GA1 was activated to the parent drug daunorubicin at a rate which was
considered too slow for use in ADEPT, further research was devoted to the synthesis of
b -glucuronyl carbamate based prodrugs of anthracyclines containing a spacer moiety
between drug and b -glucuronyl specifier group (see figure S.2.). It is conceivable that
the use of a spacer facilitates enzymatic hydrolysis by decreasing steric hindrance of the
drug part to the enzyme action. The results of this approach are described in chapters 3
and 4.
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ENZYMATIC
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DRUG
SPONTANEOUS
DRUG
pro-moiety
1
2
Scheme S.2.   Spacer containing prodrugs.
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Chapter 3 deals with b -glucuronyl carbamate containing prodrugs 3 derived from
daunorubicin, (scheme S.3.) containing a spacer designed to immolate by a ring-closure
reaction after enzymatic hydrolysis of the specifier group. Unfortunately, after
hydrolysis of the glucuronyl specifier group, the spacer of drug-spacer molecules 4 did
not cycloeliminate and the free drug daunorubicin was not restored.
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Scheme S.3.   Prodrugs containing a cycloelimination-spacer.
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In chapter 4, b -glucuronyl carbamate containing prodrugs 6 (X, Y = -H, scheme S.4.) of
daunorubicin and other anthracyclines are described possessing a spacer designed to
immolate by a 1,6-elimination reaction after enzymatic hydrolysis of the specifier
group. The spacer of these prodrugs was substituted with electron-withdrawing groups
(X = -Cl, -Br) in order to facilitate enzymatic hydrolysis and serum protein binding. In
addition, a prodrug containing a lipophilic tail on the spacer in order to decrease the
rate of elimination from the circulation, compound 6 (X = -H, Y = -n-hexyl), is
described. Finally, the synthesis of b -glucosyl- and b -galactosyl analogs of prodrug 6 (X,
Y = -H)  are presented.  All  the synthesized  prodrugs
described in chapter 4 were converted into their
respective free drug upon contact with the matching
enzyme. The activation rate of the prodrugs
containing an electron-withdrawing group on the
spacer, however, was not significantly different from
that of the unsubstituted prodrug. The rates of
activation the b -glucosyl and b -galactosyl based
prodrugs were more than twice as low as that of the
b -glucuronyl analog and the n-hexyl substituted
prodrug was activated at an even slower rate. The
prodrug with the n-hexyl substituent on the spacer
and the prodrugs with an halogen atom did not have
improved pharmacokinetics compared to the
unsubstituted prodrug DAU-GA3 (chart S.1.). With
respect to these evaluation parameters, one prodrug
of daunorubicin and the corresponding analog of
doxorubicin, DAU-GA3 and DOX-GA3, respectively,
(see chart S.1.) were selected  from  all prodrugs to be
studied in greater detail in in vitro and in  vivo
biological  systems. From  these  prodrugs, DOX-GA3
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Chart S.1.
will be further evaluated in a phase 1 clinical trial in the near future.
In the key step of the synthesis of the prodrugs described in chapter 3 and 4, the
b -glucuronyl carbamate group was introduced by the addition reaction of the
glucuronyl donor 11 (or glucosyl or galactosyl donors in case of b -glucosyl- and
b -galactosyl carbamates) to a spacer isocyanate 10 (scheme S.5.). The isocyanate
addition reaction led to the respective glycosyl carbamates 12 in a very high b -dia-
stereoselective fashion. In chapter 5, this reaction is elaborated further. In general,
isocyanates 10 were synthesized from their respective spacer- carboxylic acids 8 by a
modified Curtius reaction, according to scheme S.5. In some individual cases isocya-
nates 10 were prepared from their respective amine hydrochlorides using phosgene or
diphosgene. After modification, pro-moieties 12 were coupled to an anthracycline,
resulting in protected prodrugs 13. Deprotection of compounds 13 led to prodrugs 14.
125
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
OOO
AcO
AcO
MeO2C
AcO
NH
HO O
N
C
O
OAcOAcO
MeO2C
AcO OH11
N3P
OPh
OPh
O
8
65 - 100 ° C
N3 O
9
SPA-
CER SPA-CER
SPA-
CER
SPA-
CER
OOO
AcO
AcO
MeO2C
AcO
NH
SPA-
CER
anthracycline-
3'-NH
OOO
HO
HO
NaO2C
HO
NH
SPA-
CER
anthracycline-
3'-NH
LiOHModification
of spacer
Coupling to 3'-NH2 
of anthracycline
10 12
13 14
Scheme S.5.   General synthetic scheme for the synthesis of prodrugs of chapter 3 and 4.
In chapter 6, a summary is given of the in vitro and in vivo experiments using the
prodrugs described in this thesis as obtained at the Department of Medical Oncology,
Vrije Universiteit of Amsterdam. Besides the application of the prodrugs in ADEPT also
the monotherapy approach is described. In this monotherapy, no mAb-enzyme
conjugate is used to activate a prodrug but the b -glucuronyl based prodrugs are
activated by endogeneous b -glucuronidase present in necrotic tumor areas. Some
results of monotherapy experiments using DAU-GA3 are presented.
Concluding Remarks
The research described in this thesis has led to the development of a number of general
synthetic pathways for spacer-containing b -glucuronide, b -glucoside or b -galactoside
based prodrugs of anthracyclines. The synthesized prodrugs were tested to evaluate
their applicability in ADEPT and monotherapy. Two prodrugs, DAU-GA3 and DOX-
GA3 (chart S.1.), were chosen for further studies. Of these compounds, DOX-GA3 was
found to be the most promising prodrug for further evaluation in ADEPT and
monotherapy for the treatment of cancer. This compound will be further evaluated for
application in a clinical trial in the near future.
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Samenvatting
In dit proefschrift wordt de synthese en de biologische evaluatie van prodrugs van
anthracycline anti-tumor antibiotica beschreven. Deze zijn ontworpen voor gebruik in
selectieve chemotherapie.
De ernstige bijwerkingen van conventionele anti-kanker medicijnen worden veroor-
zaakt door het gebrek aan verschil tussen kanker- en gezonde cellen. De meeste anti-
tumor middelen zijn giftig in het bijzonder voor snel delende cellen en daarom zijn
tumor-cellen iets gevoeliger voor deze middelen dan normale cellen. Ondanks dat is de
therapeutische index van anti-tumor middelen te laag en onaanvaardbare schade aan
gezond weefsel is een gevolg van een chemokuur. Deze problemen hebben onderzoek
gestimuleerd naar de ontwikkeling van meer selectieve anti-tumor middelen.
In dit proefschrift wordt de synthese van prodrugs beschreven die gebruikt kunnen
worden in het Antibody Directed Enzyme Prodrug Therapy (ADEPT) concept voor de
selectieve behandeling van kanker. Een beknopte biologische evaluatie van de gesyn-
thetiseerde prodrugs wordt gegeven aan het einde van elk hoofdstuk.
In het ADEPT concept voor de behandeling van kanker (zie figuur S.1.), wordt een
enzym covalent gebonden aan een monoklonaal antilichaam (mAb). Het gebruikte
mAb is selectief voor tumor-geassocieerde antigenen. Dit mAb-enzym conjugaat wordt
toegediend aan een kanker patient waarna het selectief aan tumor-cellen bindt (stap 1).
stap 1
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enzym
enzym
tumor
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tumor
cel
tumor
cel
tumor
cel
enzym tumor
cel
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Figuur S.1.   Het ADEPT concept.
Nadat het niet gebonden mAb-enzym conjugaat uit het bloed en uit ander weefsel is
verdwenen, wordt in stap 2 een relatief onschadelijke prodrug toegediend. Deze
prodrug wordt omgezet tot de oorspronkelijke anti-kanker drug door het, met behulp
van het antilichaam naar de tumor gebrachte enzym.
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Het ADEPT concept en de literatuur over prodrugs die voor ADEPT ontworpen en
gemaakt zijn, wordt in hoofdstuk 1 gehandeld.
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Schema S.1.   De eerste b -glucuronyl carbamaat-bevattende prodrug.
In hoofdstuk 2 wordt het meest veelbelovende enzym/prodrug systeem voor gebruik
in ADEPT gekozen. Om een keuze tussen verschillende ADEPT systemen te kunnen
maken, zijn er polaire prodrugs van daunorubicine gemaakt die met het overeen-
komstige enzymen geactiveerd kunnen worden. De prodrugs met fosfaat-, sulfaat-,
b -glucuronide-, b -glucoside- of b -galactoside groepen zijn gesynthetiseerd en getest op
cytotoxiciteit en enzym activerings-snelheid.
De prodrug met de b -glucuronyl carbamaat groep (DAU-GA1, schema S.1.) was het
meest veelbelovend, maar werd geactiveerd tot daunorubicine met een te lage snelheid
voor toepassing in ADEPT. Vervolg onderzoek werd geconcentreerd op de synthese
van b -glucuronyl carbamaat bevattende prodrugs van anthracyclines met een spacer
groep tussen drug en b -glucuronyl specifier (zie figuur S.2.). Er werd verwacht dat de
spacer de enzymatische hydrolyse van de prodrug zou vergemakkelijken door
vermindering van de sterische hindering dat het enzym van de drug ondervindt. Dit is
beschreven in hoofdstuk 3 en 4.
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Schema S.2.   Spacer bevattende prodrugs.
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Schema S.3.   Prodrugs met een cycloeliminatie-spacer.
In hoofdstuk 3 worden spacer- b -glucuronyl carbamaat bevattende prodrugs 3 (schema
S.3.) van daunorubicine beschreven. De spacer van deze prodrugs zou, na enzym-
atische hydrolyse van de specifier groep, van het resulterende drug-spacer molecuul 4
moeten elimineren via een ring-sluitings mechanisme. Dit gebeurde helaas niet, drug-
spacer molecuul 4 bleef intact na hydrolyse van de b -glucuronyl specifier groep en de
vrije drug werd niet verkregen.
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Schema S.4.   Prodrugs met een 1,6-eliminatie spacer.
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In hoofdstuk 4 worden prodrugs van daunorubicine en andere anthracyclines
beschreven die een b -glucuronyl carbamaat groep bevatten met een andere spacer, zie
prodrugs 6 in schema S.4. De prodrugs bevatten een spacer die, na enzymatische
hydrolyse van de specifier groep, af kan splitsen in een 1,6-eliminatie reactie. De spacer
van deze prodrugs is gesubstitueerd met electronenzuigende groepen (X = -Cl, -Br,
-NO2) bedoeld om de enzymatische hydrolyse te versnellen. Ook kunnen chloor- en
broomaromaten aan serum-eiwitten binden. Dit kan de uitscheidings-snelheid van de
prodrug verkleinen. Daarnaast is er een prodrug met een lipofiele staart gemaakt,
verbinding 6  (X = -H, Y = -n-hexyl). met het doel de uitscheidings-snelheid te
verkleinen.  Ten slotte zijn b -glucosyl- en b -galactosyl  analoga van prodrug 6  gemaakt.
Alle prodrugs beschreven in hoofdstuk 4 werden
geactiveerd tot de vrije drug door het bijbehorende
enzym. De activerings-snelheid van de prodrugs met
de electronenzuigende substituenten was echter niet
significant beter dan dat van de ongesubstitueerde
prodrug. De activerings-snelheid van de b -glucosyl en
b -galactosyl bevattende prodrugs was meer dan twee
keer zo laag als dat van het b -glucuronyl analogon. De
n-hexyl gesubstitueerde prodrug werd zelf nog lang-
zamer geactiveerd. De prodrug met de n-hexyl substi-
tuent en de prodrugs gesubstitueerd met een halo-
geen atoom, hadden geen verbeterde farmacokinetiek
vergeleken met de ongesubstitueerde prodrug DAU-
GA3  (chart S.1.). Beoordeeld naar deze karakter-
istieken, waren er twee prodrugs uitgekozen die in
meer detail bestudeerd zijn in in vitro en in vivo
biologische systemen. Dit zijn prodrugs van dauno-
rubicine (DAU-GA3) en doxorubicine (DOX-GA3).
Van deze prodrugs is DOX-GA3 gekozen om verder
geëvalueerd te worden  voor  toepassing in de kliniek.
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In de belangrijkste synthese-stap van de spacer-bevattende prodrugs, wordt de
b -glucuronyl carbamaat groep geïntroduceerd door middel van een additie reactie van
glucuronyl donor 11 aan spacer isocyanaten 10 (of de corresponderende glucosyl- of
galactosyl donoren in het geval van b -glucosyl en b -galactosyl carbamaten) zie schema
S.5. Deze additie reactie leidt tot de corresponderende b -glycosyl carbamaten 12 in een
zeer hoge b -diastereoselectiviteit. De reactie is uitgebreid beschreven in hoofdstuk 5.
Spacer-isocyanaten 10 werden in de meeste gevallen gesynthetiseerd uit spacer-
carbonzuren 8 door middel van een gemodificeerde Curtius reactie volgens schema S.5.
In sommige gevallen werd spacer-isocyanaat 10 gesynthetiseerd uit het corresponde-
rende amine hydrochloride waarbij gebruik werd gemaakt van fosgeen of difosgeen.
Pro-moieties 12 konden na modificatie gekoppeld worden aan een anthracycline,
leidende tot de beschermde prodrugs 13. Na ontscherming van 13 werden prodrugs 14
verkregen.
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Schema S.5.   Algemeen schema voor de synthese van prodrugs in hoofdstuk 3 en 4.
In hoofdstuk 6 wordt een samenvatting gegeven van de in vitro en in vivo experimenten
waarin de beste prodrugs van dit proefschrift gebruikt worden. Deze experimenten zijn
uitgevoerd op de afdeling Medische Oncologie aan de Vrije Universiteit van
Amsterdam. Naast de toepassing van de prodrugs in ADEPT, is de monotherapie
benadering in dit hoofdstuk beschreven. In de monotherapie benadering worden de
prodrugs geactiveerd door het endogene enzym b -glucuronidase, dat vrijkomt uit
necrotische gebieden in een tumor. Er behoeft dus in dit geval geen mAb-enzym
conjugaat toegediend te worden om de prodrug te activeren. Enige resultaten van
DAU-GA3 in monotherapie experimenten zijn beschreven.
Afsluitende opmerkingen
Het onderzoek beschreven in dit proefschrift heeft geleid tot de ontwikkeling van een
aantal algemene synthetische procedures voor de bereiding van spacer bevattende
b -glucuronide, b -glucoside en b -galactoside prodrugs van anthracyclines. De
gesynthetiseerde prodrugs zijn getest op hun bruikbaarheid in het ADEPT concept voor
de behandeling van kanker. Twee prodrugs, DAU-GA3 en DOX-GA3 (chart S.1.),
werden geselecteerd voor uitgebreide in vivo studies. Van deze prodrugs was DOX-
GA3 het meest veelbelovend om verder geëvalueerd te worden in ADEPT en in
monotherapy. Deze verbinding zal verder worden geëvalueerd voor toepassing in een
klinische fase 1 onderzoek.
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Samenvatting voor niet-chemici
Deze samenvatting is geschreven voor degenen die de rest van dit proefschrift zó
ondoorgrondelijk vinden dat ze, na het lezen van het voorwoord, al direct afhaken.
Anti-tumor middelen (= cytostatica) zijn giftig speciaal voor snel delende cellen. Omdat
tumor-cellen sneller groeien dan gezonde cellen, zijn tumor-cellen gevoeliger voor
cytostatica dan normale cellen. Dit verschil is echter klein en de behandeling van een
patiënt met een chemokuur gaat dan ook gepaard met ernstige bijwerkingen en een
grote schade aan gezond weefsel. Ernstige bijwerkingen zijn: haaruitval, misselijkheid,
beenmerg afbraak en vergiftiging van de hartspier. Omdat de conventionele cytostatica
zo giftig zijn, kan er maar een lage dosis aan een patiënt gegeven worden. Om toch
genoeg effect van de behandeling te hebben, worden er, gedurende een langere
periode, meerdere doses van een lage concentratie van het anti-tumor middel toege-
diend. Doordat de tumor-cellen op deze manier niet in een paar keer gedood kunnen
worden, is de kans groot dat tijdens zo'n lange chemokuur, tumor-cellen ontstaan die
resistent zijn geworden tegen de cytostatica. De resistente cellen zullen overleven en na
verloop van tijd bestaat de gehele tumor uit deze resistent cellen. De tumor is niet meer
te bestrijden met de gebruikte middelen en vaak ook niet meer met andere cytostatica
(= multi-drug resistentie).
Het onderzoek dat in dit proefschrift wordt beschreven, is gericht op het ontwikkelen
van een anti-kanker medicijn dat alléén tumorcellen dood en gewone cellen ongemoeid
laat. Het medicijn heeft dan minder bijwerkingen en kan in een hoge dosis aan de
patiënt gegeven worden. Hierdoor is de kans op het ontwikkelen van multi-drug
resistentie veel lager. In onderstaande figuur is het concept weergegeven waarmee
geprobeerd wordt bestaande anti-tumor middelen selectief werkzaam voor
tumorcellen te maken. In dit concept wordt een bestaand anti-tumor middel, bv
doxorubicine, chemisch geïnactiveerd door er een inactiverend molecuul aan te
koppelen. Het molecuul dat zo verkregen wordt is een zogenaamde pro-drug. Het
inactiverende molecuul wordt het pro- gedeelte genoemd en het cytostaticum is de
drug. Zo'n pro-drug is een niet-giftige variant van de drug en kan zonder (veel)
problemen gebruikt worden. Zo'n pro-drug moet dusdanig ontworpenzijn, dat het
door een van te voren geselecteerd enzym omgezet kan worden tot de oorspronkelijke
giftige drug. Het enzym knipt letterlijk de inactiverende groep (het pro- gedeelte) van
de pro-drug, zodat het oorspronkelijke cytostaticum weer is teruggevormd. Het
cytostaticum zal vervolgens de tumor-cel doden.
In stap 1 van de behandeling (zie plaatje) wordt het bewuste enzym, dat gekoppeld is
aan een een antilichaam (een "biologisch magneetje"), aan de patiënt toegediend. Het
antilichaam bindt selectief aan een tumor-cel en nergens anders aan en brengt zo het
enzym alleen naar de tumor-cel. Het enzym is dus alléén aanwezig bij de tumor en de
pro-drug kan dus alléén maar bij de tumor geactiveerd worden.
In stap 2 wordt de pro-drug in de bloedbaan van de patiënt gebracht. Zodra de pro-
drug in contact komt met het enzym, wordt het geactiveerd tot de giftige drug die
direct de tumor-cel binnen zal dringen en zal doden. Op deze manier worden alleen
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tumor-cellen blootgesteld aan de giftigheid van het anti-tumor middel. Deze strategie
wordt het "ADEPT" concept genoemd (Antibody Directed Enzyme Prodrug Therapy).
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Het "ADEPT" concept voor behandeling van kanker
Het onderzoek dat in dit proefschrift wordt beschreven, is gericht op de ontwikkeling
van een pro-drug die gebruikt kan worden in het ADEPT concept. Een goede pro-drug
moet aan een aantal voorwaarden voldoen. De belangrijkste zijn: i. De pro-drug moet
veel minder giftig zijn dan de oorspronkelijke drug, ii. de pro-drug moet door het
enzym met een goede snelheid omgezet kunnen worden tot de drug (om een giftige
hoeveelheid van de drug te kunnen genereren), en iii. de pro-drug moet gezonde cellen
niet binnen kunnen dringen. Als de pro-drug een gezonde cel binnen zou dringen, dan
zal hij niet meer bij de tumor-cel kunnen komen.
Tijdens het onderzoek is er gezocht naar een pro-drug die het beste voldoet aan
bovenstaande voorwaarden. Hiertoe is een aantal pro-drugs ontworpen en gemaakt (=
chemisch gesynthetiseerd). De pro-drugs zijn vervolgens getest op bovenstaande eigen-
schappen. Met behulp van deze testresultaten zijn nieuwe, verbeterde prodrugs
ontworpen en gemaakt, die op hun beurt weer getest zijn. Op deze manier is er in een
aantal stappen (ontwerpen-maken-testen, ontwerp bijstellen-maken-testen, etc.) een zo
optimaal mogelijke pro-drug ontwikkeld. Deze pro-drug zou de juiste eigenschappen
moeten beziten om tumor-cellen te doden, zonder dat dit gepaard gaat met ernstige
bijwerkingen voor de patiënt, en zonder dat drug-resistentie optreed (zie boven). De
meest veelbelovende pro-drug die uit het onderzoek naar voren is gekomen, zal in de
nabije toekomst getest worden op patiënten in een experimentele chemokuur.
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